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Affordability of medicines from the pharmaceutical system perspective
Abstract	 Aaltonen K. Affordability of medicines from the pharmaceutical system pers­
pective. Comparative analysis of Finland and New Zealand. Helsinki: The Social 
Insurance Institution of Finland, Studies in social security and health 146, 2017. 
189 pp. ISBN 978-952-284-019-6 (print), 978-952-284-020-2 (pdf). 
In this study, the access-related features – conditions, disincen­
tives, benefit level and universality – of the pharmaceutical sys­
tems in Finland and New Zealand were examined in conjunction 
to outcomes related to the distribution of out-of-pocket costs and 
cost-related access barriers. The studies were based on product 
and price listings, Household Budget Survey data, postal survey 
data and pharmacy sales registers. The systems had common fea­
tures related to universal coverage and conditions. Both countries 
used ceilings and mechanisms to protect high need or vulnerable 
groups, and restricted reimbursements. The main differences were 
related to disincentives and benefit level: The Finnish system pro­
vided a wider choice between reimbursed therapeutic options, and 
a faster availability of new innovative medicines, but the general 
level of co-payments was higher. The New Zealand system had a 
high overall control of the reimbursed range, which included fully 
reimbursed medicines for most health needs. However, the range 
of reimbursed medicines was skewed towards older medicines. In 
Finland, out-of-pocket costs had regressive effects. Cost-related 
access problems were associated with lower income and higher 
health needs, as has been described for New Zealand in the pre­
vious literature. Based on the assessment of high out-of-pocket 
costs among older people in New Zealand, the use of medicines 
not included in the fully reimbursed range seemed rare and unre­
lated to socioeconomic deprivation. However, despite their high­
er health needs, high costs were less frequent among indigenous 
Māori and they coincided with a lower overall level of medicine 
use. Both systems have strengths and weaknesses related to dif­
ferent dimensions of affordability. The protective mechanisms in 
neither country seemed sufficient to counterbalance the negative 
effects of user charges entirely. Further research is needed on the 
causes and consequences of socioeconomic and ethnic differences 
in medicine use. 
Key words: fees and charges, health care costs, cost sharing, phar­
maceutical preparations, reimbursement mechanisms, affordabil­
ity, health insurance, health services accessibility, health equity, 
Finland, New Zealand 
Affordability of medicines from the pharmaceutical system perspective
Tiivistelmä Aaltonen K. Lääkekorvausten riittävyys. Suomen ja Uuden-Seelannin lääkekor­
vausjärjestelmiä vertaileva analyysi. Helsinki: Kela, Sosiaali- ja terveysturvan tut­
kimuksia 146, 2017. 189 s. ISBN 978-952-284-019-6 (nid.), 978-952-284-020-2 
(pdf). 
Tutkimuksessa tarkasteltiin lääkekorvausjärjestelmien lääkkei­
den saatavuuteen vaikuttavia piirteitä, erityisesti korvattavuuden 
ehtoja, disinsentiivejä, korvattavaa valikoimaa ja universalismia, 
suhteessa lääkeomavastuiden jakautumiseen ja hoitojen käyt­
tämättä jättämiseen kustannussyistä. Aineistoina käytettiin tuote- 
ja hinnastotietoja, kulutustutkimusaineistoa, postikyselyaineistoa 
ja apteekkien ostorekistereitä. Yhtäläisyydet liittyivät universa­
lismiin ja korvattavuuden ehtoihin. Korvauksia kohdennettiin 
molemmissa maissa tarpeeseen liittyvillä mekanismeilla, oma­
vastuukaton avulla sekä korvattavuusrajoituksilla. Erot liittyivät 
valikoimaan ja disinsentiiveihin. Suomessa korvattiin enemmän 
hoidollisesti toisiaan lähellä olevia vaihtoehtoja ja uusien lääke­
innovaatioiden määrä markkinoilla oli laajempi, mutta omavas­
tuutaso korkeampi. Uudessa-Seelannissa kokonaan korvattavia 
lääkkeitä oli saatavissa useimpiin terveysongelmiin. Korvattava 
valikoima oli kuitenkin kontrolloidumpi ja sisälsi enemmän van­
hempia lääkkeitä. Suomessa omavastuilla oli regressiivisiä vaiku­
tuksia. Pienemmät tulot ja huonompi terveydentila olivat yhtey­
dessä palveluiden käyttämättä jättämiseen kustannussyistä, mikä 
vastasi aiemmassa kirjallisuudessa Uudesta-Seelannista julkais­
tuja tuloksia. Omavastuiden jakautumisen perusteella Uudessa-
Seelannissa ikääntyneet henkilöt käyttivät vain harvoin muita 
kuin kokonaan korvattavia lääkkeitä eivätkä korkeat omavastuut 
olleet yhteydessä potilaan sosioekonomiseen asemaan. Korkeam­
masta sairastavuudestaan huolimatta maoreilla (alkuperäiskansa) 
kuitenkin korkeat omavastuut olivat harvinaisempia, ja he myös 
ostivat vähemmän lääkkeitä eurooppalaistaustaisiin nähden. 
Kumpikin järjestelmä sisältää riittävyyteen liittyviä heikkouksia 
ja vahvuuksia eikä kumpikaan kykene täysin suojaamaan potilaita 
omavastuiden haitallisilta vaikutuksilta. Sosioekonomisten ja et­
nisten lääkkeiden käyttöön liittyvien erojen syiden ja seurausten 
selvittäminen vaatii vielä lisää tutkimusta. 
Avainsanat: lääkekorvaukset, lääkkeet, lääkehoito, kustannukset, 
kustannusten jako, omavastuu, korvausjärjestelmät, terveyspalve­
lut, lääkkeiden saatavuus, eriarvoisuus, Suomi, Uusi-Seelanti 
   
 
Affordability of medicines from the pharmaceutical system perspective
Sammandrag Aaltonen K. Tillräcklighet hos läkemedelsförmån. Komparativ analys av far­
maceutiska system i Finland och Nya Zeeland. Helsingfors: FPA, Social trygghet
och hälsa, undersökningar 146, 2017. 189 s. ISBN 978-952-284-019-6 (hft.), 
978-952-284-020-2 (pdf). 
I denna studie, undersöktes åtkomstrelaterade faktorer, – villkor, 
motincitament, förmånens omfattning och universalitet – hos 
läkemedelsförmåner i Finland och Nya Zeeland i samband med 
resultaten av fördelningen av självrisker och kostnadsrelaterade 
problem. Studierna baserades på produkt- och prislistor, kon­
sumtionsundersökning, postenkät och apotekens försäljning­
sregister. Gemensamma egenskaper var relaterade till villkor och 
universalitet. Båda länderna använder högkostnadskydd, mekan­
ismer baserad av behov och begränsade ersättningar. De största 
skillnaderna gällde motincitament och förmånens omfattning: 
det finska systemet gav ett större urval mellan ersätts terapeutiskt 
likvärdiga läkemedel, och en snabbare tillgång till nya innovativa 
läkemedel, men den allmänna nivån på självriskerna var högre. 
Det nyzeeländska systemet hade en hög kontroll över förmån­
ens omfattning, i vilken ingår läkemedel med full ersättning för 
de flesta hälsobehov. Emellertid var urvalen skeva mot äldre 
läkemedel. I Finland hade självriskerna hade regressiva effekter. 
Lägre inkomst och högre hälsobehov var associerade med högre 
frekvens av kostnadsrelaterade problem att få läkemedel och andra 
hälsovårdstjänster, som har beskrivits för Nya Zeeland i tidigare 
litteratur. Baserat på bedömningen av höga självrisker bland äldre 
personer i Nya Zeeland, var köp av läkemedel utan full ersättning 
ovanligt och inte associerat med socioekonomisk situation. Trots 
högre behov, var höga kostnader mindre frekventa bland Māori 
(urinvånare) och de sammanföll med en lägre total nivå av läke­
medelsanvändning. Båda systemen har styrkor och svagheter med 
olika dimensioner av tillräcklighet. I ingetdera landet var skydds­
mekanismerna tillräckliga för att motverka de negativa effekterna 
av självriskadelar helt. Ytterligare forskning behövs om orsaker 
till och konsekvenser av socioekonomiska och etniska skillnader i 
läkemedelsanvändning. 
Nyckelord: läkemedelsersättningar, läkemedel, medicinering, 
kostnader, kostnadsfördelning, läkemedelsförmån, ersättnings­
system, självrisk, hälsovårdstjänster, tillgång till läkemedel, ojäm­
likhet, Finland, Nya Zeeland 
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Terms, concepts and abbreviations
Terms are used as defined in Glossary by WHO CC for Pharmaceutical Pricing and 
Reimbursement Policies (2016). 
Affordability of medicines: “The extent to which health insurance covers the (phar­
maceutical) needs of patients in an adequate manner and at an afford­
able cost” (Kanavos et al. 2011, 55) 
ATC:	 A classification system where the active ingredients are divided into dif­
ferent groups according to the organ or system on which they act and 
their chemical, pharmacological and therapeutic properties. Medicines 
are divided into fourteen main groups (1st level, ATC 1 level), with 
pharmacological/therapeutic subgroups (2nd level – ATC 2 level). The 
3rd and 4th levels (ATC 3 and ATC 4 level) are chemical/pharmaco­
logical/therapeutic subgroups and the 5th level (ATC 5) is the chemical 
substance. (WHO CC for Drug Statistics Methodology 2008)
Cost-sharing: “A provision of health insurance or third-party payment that requires 
the individual who is covered to pay part of the cost of health care re­
ceived. This is distinct from the payment of a health insurance premi­
um, contribution or tax, which is paid whether health care is received 
or not.” (Rannan-Eliya and Lorenzoni 2010)
Country income grouping: Countries are grouped by, for example, the World Bank, 
to aggregate and compare key statistical data. The World Bank uses 
four income groups: low, lower-middle, upper-middle, and high, clas­
sified each year based on gross national income per capita. (The World 
Bank 2016) 
CWF IHPS:	 Commonwealth Fund International health policy surveys 
DDD (Defined daily dose): The assumed average maintenance dose per day for a 
drug used for its main indication in adults. (WHO CC for Drug Statis­
tics Methodology 2008)
De-commodification relates to the strength of the systems to provide social protec­
tion and to emancipate individuals from market dependence (Esping-
Andersen 1990) 
DHB: 	 District health board
EFPIA: 	 European Federation of Pharmaceutical Industries and Associations 
EMA: 	 the European Medicines Agency 
EU-SILC: 	 the EU Survey of Income and Living Conditions 
FDA: 	 The United States Food and Drug Administration 
Fimea: 	 The Finnish Medicines Agency (formerly: the National Agency for 
Medicines) 
FIP: 	 International Pharmaceutical Federation 
Health systems include “all the activities whose primary purpose is to promote, re­
store or maintain health”; vs. Health care systems, which include “the 
provision of, and investment in, health services”. (WHO 2000) 
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Inequalities vs. Inequities in health: “Health inequality is the generic term used to 
designate differences, variations, and disparities in the health achieve­
ments of individuals and groups – – Health inequity refers to those 
inequalities in health that are deemed to be unfair or stemming from 
some form of injustice.” (Kawachi et al. 2002) 
Kela: The Social Insurance Institution of Finland 
“Me-too” -product: New active ingredient with a comparable mode of action to an 
existing active ingredient (OECD 2008, 55) 
Medsafe:
MOH: 
MSAH:
NHI:
New Zealand Medicines and Medical Devices Safety Authority 
Ministry of Health 
Ministry of Social Affairs and Health 
National health insurance 
NHS: National health service 
OECD: Organisation for Economic Co-operation and Development 
PHARMAC: Pharmaceutical Management Agency of New Zealand 
PHO: Primary health organisation
Price elasticity is the change (percentage) in the consumption of a medicine related 
to one percentage change in the price or charge that patients pay for 
that medicine (Austvoll-Dahlgren et al. 2008) 
PPRI: Pharmaceutical Pricing and Reimbursement Information
Rational use of medicines: Patients receive medications appropriate to their clini­
cal needs, in doses that meet their own individual requirements, for an 
adequate period of time, and at the lowest cost to them and their com­
munity (WHO 1985) 
SHARE: Survey on Health, Ageing and Retirement in Europe 
WHO: World Health Organisation
WHO CC: World Health Organisation Collaborating Centre 
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 1 Introduction 
Inequalities in health have been explained by multifaceted mechanisms that include 
societal factors, material and social conditions, community-related and individual 
factors, as well as individuals’ position in the society and the cumulative effects of 
different risk factors throughout life (Dahlgren and Whitehead 1991, 11; Marmot 
2004; Wilkinson and Pickett 2010; WHO 2010a). Access to care is one determinant in 
this complex puzzle, and it can be further broken down into different dimensions, of 
which affordability is one (Penchansky and Thomas 1981; Whitehead and Dahlgren 
2006; WHO 2010a). Affordability, i.e. economic access, itself also contains multiple 
dimensions: insurance strategies affect the population covered, internal health care 
markets affect the range of available and covered benefits, and direct user charges af­
fect the utilisation (Dahlgren and Whitehead 1991, 36–38; OECD 2010a, 37; Reibling 
2010). 
Providing access to necessary care with affordable cost to patients and society is a 
key health policy goal globally (Declaration of Alma-Ata 1978; WHO 2005; Euro­
pean Commission 2010a; 2010b). Accordingly, most high-income countries have 
implemented health systems with financial protection on universal basis (OECD 
2013). However, these health systems differ by their characteristics and performance 
(WHO 2000; Commonwealth Fund 2010a; OECD 2010a). The need to understand 
the mechanisms and incentives within these systems, and to learn from others, has 
resulted in a large body of comparative health care research (OECD 1987; Moran 
1999; 2000; WHO 2000; OECD 2004; Wendt 2009; OECD 2010a). 
In terms of affordability, prescription medicines are of special interest. Medicine use 
is one of the most common and important health care interventions (Avorn 2010). 
Adherence to medicines is thus critical in terms of economics and health outcomes 
(Tamblyn et al. 2001; Haynes et al. 2002; Sabaté 2003; Dormuth et al. 2009). Cost is 
one of the barriers that affect adherence negatively (Sabaté 2003; Piette et al. 2006). 
Prescription medicines also represent a large part of the overall health care user 
charges in many countries (Jones et al. 2008; OECD 2008, 38; Corrieri et al. 2010; 
Bock et al. 2014; OECD 2015a). There is, however, limited comparable information 
on the extent to which the reimbursement systems in different countries cover pa­
tients’ pharmaceutical needs in terms of the adequacy of the covered benefits and 
affordable price (Kanavos et al. 2011). 
Finland and New Zealand are high-income OECD countries of similar geographi­
cal and population size. They share relatively similar public health problems, rela­
tively high health inequalities and have a similar level of health care spending per 
capita. Both countries have NHS (Beveridge) -type health care systems with universal 
coverage for prescription medicines (Klavus et al. 2012; Blank and Bureau 2014, 15; 
Lehto 2014). New Zealand has been able to keep the growth of public pharmaceutical 
spending at a lower level than many other high-income countries, and at the same 
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time, maintained low user charges (OECD 2011, 135, 155; Gleeson et al. 2013). Previ­
ous research has nevertheless revealed ethnic differences in cost-related barriers to 
prescription medicines (Jatrana et al. 2011). In Finland, high user charges have raised 
concerns over the equity in access to medicines (Mossialos and Srivastava 2008). In­
ternational comparisons have ranked New Zealand among the countries with the 
least new medicines launched and Finland among the countries with a relatively high 
number of launches (Danzon et al. 2005; Cheema et al. 2012). 
The purpose of this study was to evaluate and compare the features of the pharmaceu­
tical systems that affect access and on how these features translate into affordability­
related outcomes: distribution of out-of-pocket costs and cost-related access barriers. 
Finland and New Zealand were chosen for comparison because the two countries 
had several important differences in their pharmaceutical systems but similarities 
regarding the overall health care system, public health problems and market size. The 
results of this study provide a perspective through comparison to identify the relative 
strengths and weaknesses of each system. Further, the study provides methodological 
tools for the development of comparative pharmaceutical system analyses. 
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2 Review of the literature 
2.1 Social inequalities in health 
Social inequities in health are “systematic, socially produced (and therefore modifi­
able) and unfair” differences in health status between socioeconomic groups (White­
head and Dahlgren 2006, 2). Lower levels of income, education and social hierarchy, 
lower labour position and socioeconomic disadvantage have been associated with 
higher morbidity and lower life expectancy in numerous studies from many coun­
tries (e.g. Whitehead and Dahlgren 2006; Mackenbach et al. 2008; Tarkiainen et al. 
2013). 
The causes behind health inequalities have been explained by the different deter­
minants of health, conceptualised by e.g. Dahlgren and Whitehead (1991) and the 
WHO Commission on Social Determinants of Health (WHO 2010a). According to 
these models, health is linked to factors related to the socioeconomic and political 
context, to living and working conditions and to individual biological and behav­
ioural factors. A large body of research has evolved around the social gradient of 
health, the causes of causes, i.e. the role of income inequalities and social structures 
in explaining health inequalities (e.g. Marmot 2004; Wilkinson and Pickett 2010). In 
public policy, the wider perspective in health inequalities has led to the Health in All 
Policies (HiAP) -approach, i.e. taking health implications into account in policymak­
ing across sectors (WHO 2014). 
Accordingly, scholars in the fields of social policy and health research have examined 
to what extent general societal-level determinants explain differences in health and 
health inequalities between countries. Diverse results have been found in studies that 
have examined the associations between health and different types of regimes, i.e. 
ideological aspects of and political traditions in welfare provision (e.g. Bambra and 
Eikemo 2009; Bergqvist et al. 2013; Kangas and Blomgren 2014). The diversity of 
the results is likely to be influenced by differences in defining welfare state models, 
changes in time and the variance in the used health-related outcomes (Bergqvist et 
al. 2013). Studies with a focus on the association between health and institutional 
aspects, e.g. access to health care, family or unemployment benefits, have found that 
more generous benefits seem to be associated with better health outcomes. However, 
people with higher socioeconomic position seem to benefit disproportionately, which 
may lead to widening or stable inequalities in health. (Borrell et al. 2006; Korda et al. 
2007; Bergqvist et al. 2013.) Studies where the generosity of the system is measured 
as the level of public spending on health care and/or social services imply that higher 
spending is associated with better health and smaller health inequalities (Wu and 
Chiang 2007; Kangas 2010; Dahl and van der Wel 2012; Bergqvist et al. 2013; Kangas 
and Blomgren 2014). It seems likely, though, that after a certain level, the effect of 
higher spending on health levels off, as has been previously described between eco­
nomic growth and life expectancy (WHO 2000, 9; Kangas 2010). 
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2.2 Affordability and access as policy goals
Inequity in access to healthcare is one of the determinants of social inequality in 
health (Whitehead and Dahlgren 2006, 8; WHO 2010a). The principal idea of inequi­
table access is determined by the Inverse Care Law: “The availability of good medical 
care tends to vary inversely with the need for it in the population served” (Hart 1971). 
Various reasons may cause inequities in access and use. Penchansky and Thomas 
(1981) defined the concept of access to health care in five dimensions: affordability, 
availability, accessibility, accommodation, and acceptability. Existing frameworks of 
access to medicines, reviewed by Bigdeli et al. (2013), have focused on developing 
countries. Depending on the framework, the domains are affordability, availability, 
accessibility, acceptability, adoption, rational use, sustainable financing and reliable 
health and supply systems. Previous research has also identified health system -re­
lated, physician-related, patient-related, disease-related and therapy-related factors, 
that affect the accessibility of health services and adherence to prescribed medicines 
(Andersen 1968; 1995; Sabaté 2003; DiMatteo 2004; Kardas et al. 2013). 
Equitable access to health care is a key policy goal globally. According to WHO 
(2005), equity in access is achieved by universal coverage defined as “access to key 
promotive, preventive, curative and rehabilitative health interventions for all at an 
affordable cost”. Access to affordable, sustainable and high quality healthcare is also 
a focus area within the Europe 2020 strategy, to ensure equal opportunities and ulti­
mately to combat poverty (European Commission 2010a; 2010b). Social protection 
policies aim to increase the affordability of health care by facilitating financial access 
and by increasing the disposable income of poor households (Bambra 2005; Israel 
2016). 
Policy goals set the foundation for actual policies and for measuring their perfor­
mance (Blank and Burau 2014). However, broad rhetorical goals need to be distin­
guished from specific programmatic goals that set frames to the actual policies. Espe­
cially broader policy goals tend to be difficult to measure. Marmor and Wendt (2011; 
2012) presented a model of the ideas, interests and institutions that influence medical 
care arrangements and their performance (Figure 1, p. 19). This model can be used to 
conceptualise the processes that shape the ideas and broader policy goals of afford­
able medicines into actual policies and further to patient related outcomes. 
Measuring and monitoring any aspects of policy requires collecting and evaluating 
relevant and reliable data on both processes and outcomes (Mossialos et al. 2004). 
Inputs, outputs and regulation are processes. Regulation includes both the command­
and-control approach, i.e. “imposition of external constraints upon the behaviour of 
an individual or an organisation”, and the market approach, which relies on incen­
tives, i.e. “explicit or implicit rewards for performing a particular act” (Saltman 2002). 
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According to WHO (2000, 24), the fundamental, intrinsic objectives of health care 
are health, responsiveness and fair financing, of which the two latter are partly in­
strumental but also valuable on their own. Preferable outcomes are thus those related 
to patients, for example health status, quality of life, satisfaction and equity in access 
(Mossialos et al. 2004; Marmor and Wendt 2012). Using outputs (e.g. doctor visits, 
procedures, medicine use) as outcomes is common, although they do not necessarily 
correlate with health outcomes (OECD 2010a, 13). 
Figure 1. Ideas, interests and institutions that shape affordability of medicines and its patient-related 
outcomes.a 
Affordable medicines, equal 

access, quality, cost-containment, Ideas
 
competition, innovation
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a Adapted f rom the model of the ideas, interests, and institutions in healthcare by Marmor and Wendt (2012). 
Efforts to increase affordability often place pressure on other goals and ideas, especial­
ly cost-containment. Traulsen and Almarsdóttir (2005) have described the dynamic 
pharmaceutical policy process as evolution. Initially scientific or technical problems 
of ensuring quality, efficacy and safety result in sophisticated and costly medicines. 
Increasing use of these medicines leads to fiscal problems, and if used irrationally, to 
poor health outcomes and wasted resources. From the policy perspective, managing 
medicine use on the population level is referred to as the problem of rational use of 
medicines (Almarsdóttir and Traulsen 2005). WHO (1985) defined medicine use as 
being rational when “patients receive medications appropriate to their clinical needs, 
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in doses that meet their own individual requirements, for an adequate period of time, 
and at the lowest cost to them and their communities”. Affordability, to both the sys­
tem and the patient, is thus an essential part of rational use. 
2.3 Pharmaceutical policy setting 
Policy can be defined “as the conscious attempt of public officials or executives en­
trusted with public funds to achieve certain objectives through a set of laws, rules, 
procedures, and incentives” (Seiter 2010). The principles that guide policymaking, 
besides evidence, are based on values, ideology, and cultural, political, institutional 
and historical aspects (Immergut 1992; Traulsen and Almarsdóttir 2005; Seiter 2010; 
Leopold 2014, 10). Pharmaceutical policy, as defined by Almarsdóttir and Traulsen 
(2006), “deals with the principles guiding decision making in the field of pharma­
ceuticals. The goal of pharmaceutical policy is (similar to other social policy) to con­
tribute on the overall health, welfare and well-being of society. It includes any policy 
that attempts to improve or regulate registration, reimbursement, and distribution of 
pharmaceuticals.” 
Pharmaceutical policy differs, to some extent, from health care policy. The three core 
objectives of health policy are equity/access, cost-containment/efficiency and qual­
ity/safety (Papanicolas 2012; Blank and Burau 2014, 109). These objectives are partly 
competing. Pharmaceutical policy includes a fourth core objective, promoting in­
novation (Jacobzone 2000, 5; Seiter 2010; Kanavos et al. 2011; Paris and Belloni 2013, 
11). The most distinct difference is thus intertwinement with industrial policy, which 
derives from the importance of the pharmaceutical industry for the economies of 
many high-income countries (OECD 2008, 40–42; Kanavos et al. 2011, 19–21). The 
global pharmaceutical industry also has notable power in the national and interna­
tional pharmaceutical policy arena (Traulsen and Almarsdóttir 2005; Seiter 2010). 
While health care services typically have local markets, the market for pharmaceu­
ticals is increasingly global, with few companies accounting for a large part of total 
global sales (OECD 2008, 52). Supranational bodies (the European Union) also in­
fluence the market and policies, directly and indirectly, e.g. by the harmonisation of 
patent and marketing authorisation processes and by incentives that facilitate the 
market entry of orphan medicines (OECD 2008, 115, 125; Morgane and Mondher 
2012; Greer et al. 2013). The prices and consumption of pharmaceuticals neverthe­
less follow national patterns because of economic and political factors, national pric­
ing and reimbursement policies as well as differences in guidelines and treatment 
traditions (OECD 2008, 30–38; Kanavos et al. 2011, 19). Countries also differ in the 
mechanisms related to inpatient and outpatient medicines (Paris and Belloni 2013, 
20; Aho et al. 2017, 23). The industry therefore uses country-specific pricing and 
entry strategies to adapt to the differences and to avoid parallel trade (OECD 2008, 
65–66, 170–174; Kanavos et al. 2011, 37). However, national pricing decisions also 
affect prices in other countries via international price benchmarking. As a result, 
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confidential rebate, clawback and risk sharing agreements between the industry and 
public payers have become increasingly popular (Espin et al. 2011; Carone et al. 2012, 
29; Paris and Belloni 2013, 58; Vogler and Habimana 2014, 9). 
The pharmaceutical policy framework is highly dynamic. Evolving new issues and 
market adaptation require policies to be constantly monitored, changed and adjusted 
(Traulsen and Almarsdóttir 2005; Seiter 2010; Leopold 2014). In the 1980s and 1990s, 
a high number of new medicines (active ingredients) were introduced globally and 
the pharmaceutical expenditure in many high-income countries grew more rapidly 
than total health expenditure and GDP (OECD 2008, 29–30, 54). In the 2000s, sales 
slowed down in many countries, due to a slight decline in the number of new medi­
cines introduced and due to the increasing share of the generic market, spurred by 
the “patent cliff ” – the expiring patents of medicines that reached blockbuster sales 
during the previous decades (OECD 2008, 54, 59; Song and Han 2016). Whereas the 
growth in spending in the 1990s was driven by medicines used in primary care, in 
the 2000s the growth has been rapid for medicines used in specialised care. The mar­
ket has therefore concentrated and fewer very expensive medicines for small patient 
groups take up an increasing share of global sales. (OECD 2008, 59–60.) For example, 
between 2006 and 2015, the worldwide orphan medicine sales is estimated to have 
more than doubled and their share of total prescription medicine sales to have in­
creased from 9% to 16% (EvaluatePharma 2015). 
The unique and constantly changing mix of policies in each country is influenced by 
trade-offs between different policy objectives (Kanavos et al. 2011; Leopold 2014). 
However, although the mix is unique, similar policies are used by public payers and 
health insurance providers in different countries. Different sets of policies are used for 
different market segments, i.e. products with and without patent protection (Kanavos 
et al. 2011, 13–14; Carone et al. 2012, 33; Vogler and Habimana 2014, 6). Generic 
market policies include generic price links, internal reference pricing, generic pre­
scribing and tendering (Kanavos et al. 2011, 35; Vogler and Habimana 2014, 10–11). 
Policies used for patent protected medicines include international price referencing, 
health-technology assessment, price and expenditure control mechanisms (Kanavos 
et al. 2011, 35; Carone et al. 2012, 20; Vogler and Habimana 2014, 10–11). Measures 
targeted to high-cost medicines include managed entry and risk-sharing agreements 
(Carone et al. 2012, 32; Paris and Belloni 2013; Vogler and Habimana 2014, 3). 
Policy research methodology derives from political sciences, sociology and economics 
(Almarsdóttir and Traulsen 2006). Pharmaceutical policy analysis aims to study the 
performance and effects of implemented and changed policies on various outcomes, 
e.g. prices, expenditures, utilisation or health, and to predict the effects of future po­
lices (Traulsen and Almarsdóttir 2005; Leopold 2014). In practice, policy analyses 
aim to provide evidence to guide or influence national pharmaceutical policymaking. 
The interest in learning from international experiences and gathering information 
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on the mechanisms of pharmaceutical policy measures has resulted in scientific re­
search and in reports published by different organisations (e.g. OECD, WHO, Euro­
pean Commission, Commonwealth Fund) and networks (e.g. PPRI, Piperska Group, 
Matusewicz et al. 2015). Different stakeholders also conduct and fund policy research 
(e.g. EFPIA, FIP). The concurrent political debate and the interests of those who con­
duct and fund research influence topics chosen for policy research. 
Commonly studied pharmaceutical policy topics in high-income European countries 
are efficiency, cost-containment, pricing and reimbursement (Bloor and Freemantle 
1996; Bloor et al. 1996; Freemantle and Bloor 1996; Jacobzone 2000; Mossialos et al. 
2004; Kanavos et al. 2011; Paris and Belloni 2013; Kanavos 2014; Leopold 2014; Leo­
pold et al. 2014). Nevertheless, comprehensive and longitudinal studies of the impact 
of policies or policy mixes are still scarce (Carone et al. 2012, 47; Moreno-Serra 2013, 
20–21). The pharmaceutical industry has pressed the issues of availability of new 
medicines and the restricting effects of cost-containment policies on market entries, 
profitability and innovation (Garattini and Ghislandi 2007). In the US, the political 
debate over universal coverage for medicines has led to a large body of research con­
centrating on access and affordability of medicines (Poisal and Chulis 2000; Heisler 
et al. 2005; Gruber 2006; Briesacher et al. 2007; Schoen et al. 2010). However, rising 
health-care costs, together with the economic downturn, have led to increased cost­
sharing in many countries with extensive insurance coverage (Vogler et al. 2011; Leo­
pold et al. 2014; Vogler and Habimana 2014, 14, 17). These trends may have raised 
public interest in studying affordability. 
2.4 From policies to systems
The effects of policies are dependent on the joint effects of adopted policies rather 
than any one policy alone (e.g. Mossialos and Oliver 2005; OECD 2010a; Lehto et 
al. 2015). These complex entities of policies are referred to as systems, which, despite 
their uniqueness, represent variants or combinations of a limited number of types 
(Blank and Burau 2014, 13, 77). In policy research, the institutional context of differ­
ent systems has been conceptualised by using ideal models and typologies (Blank and 
Burau 2014, 13). These typologies aim to differentiate countries based on indicators 
that reflect specific sub-systems of the overall system (Table 1, p. 23). 
The main sub-systems used in comparative health policy research are funding, pro­
vision and governance (Blank and Burau 2014, 77). The OECD (1987) model used 
funding and provision as indicators to classify three types of health systems by the 
predominance of patient sovereignty (predominance of incentives) or social equity 
(predominance of control): the NHS-model (Beveridge), the social insurance -model 
(Bismarck) and the private-insurance-model (consumer sovereignty) (Table 1, p. 23). 
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Table 1. Health care system typologies/ideal models. 
Source 
Sub-systems & 
Indicators (ideal) models / typologies Examples 
OECD 
1987 
Funding,  
coverage,
ownership 
National Health Service (Beveridge) model: Universal cover­
age, national ownership or control of production and general 
taxation. 
the UK, Italy 
Social Insurance (Bismarck) model: Compulsory social security
financed by employer and individual contributions, non-profit
insurance funds, public/private ownership of production 
Germany, France 
Private Insurance (Consumer sovereignty) model: Employer­
based or individual private insurance, private ownership of
production. 
the US 
Moran 
1999; 
2000 
Governing the 
consumption, 
provision and 
production of
heath care 
Entrenched command and control states: Successful with 
resource scarcity: cost containment and equitable resource al­
locating. Weak at responding to increasing consumer demands. 
Scandinavia and 
the UK 
Supply state: Successful at developing and diffusing innovation, 
weak in equitable access and cost containment. 
the US 
Corporatist states: Successful at universal access to high-quality
care, weak at change due to rigid institutions. 
Germany
Insecure command and control states: Inadequately resourced, 
and have not achieved equity, high co-payments lessen their
universality
Greece, Portugal, 
Italy 
Wendt
2009 
Expenditures, 
financing, 
provision and 
access 
Health service provision oriented type: High level and impor­
tance of provision, smooth access, modest cost-sharing, no 
gatekeeping, high patient choice, fee for service remuneration, 
high incentive to increase level of services 
Austria, Belgium, 
France, Germany 
Universal coverage − controlled access type: Access to providers
strictly regulated, equity in access, low cost-sharing, capitation 
remuneration, low incentives for doctors to increase the level of
services 
Denmark, the UK, 
Sweden, Italy, 
Ireland 
Low budget − restricted access type: Low expenditure per
capita, restricted access, high cost-sharing which affects equity
in access, salary remuneration, low doctor autonomy 
Finland, Portugal, 
Spain 
Reibling 
2010 
Regulation 
of access: 
Conditions
(gatekeeping), 
disincentives
(cost-sharing), 
benefit
level (supply) 
Financial incentive state: Mainly regulate access by cost-sharing Austria, Belgium, 
Sweden, France, 
Switzerland 
Strong gatekeeping and low supply: No/low cost-sharing, exten­
sive regulation and gatekeeping, low number of providers 
Denmark, the 
Netherlands, 
Poland, Spain, 
the UK 
Weak regulation and high supply: Low/no gatekeeping and cost­
sharing, high number of providers 
Germany, Greece, 
Czech Republic 
Mixed regulation: Gatekeeping and cost-sharing Finland, Italy, 
Portugal 
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In the assessment of access and affordability, the key dimensions in the different ty­
pologies and models are those related to regulating the demand for, and supply of, 
services. Moran (1999; 2000) examined the different roles of the state by examining 
the governance of consumption, provision and technology, and the relative weak­
nesses and strengths of different types of health-care states (Table 1, p. 23). Wendt 
et al. (2009) formed 27 ideal types by assessing relations between financing agents, 
providers and beneficiaries by the mixes of state, societal and private elements within 
the dimensions of regulation, financing and provision. By using data on health care 
expenditures, financing, provision and access from 15 European countries, Wendt 
(2009) used cluster analysis to construct three types of health care systems, 1) health 
service provision oriented, 2) universal coverage − controlled access and 3) low 
budget – restricted access. Reibling (2010) also used cluster analysis to type health 
care systems by the patient access dimension, by using gatekeeping, cost-sharing and 
supply as indicators (see Chapter 2.7). 
Comparing and assessing the performance of health systems across countries and 
over time is a widely studied area of research (e.g. WHO 2000; OECD 2004; OECD 
2010a; OECD 2011a). However, there is a large variation in the used outcomes and 
system indicators. 
As population health is the defining health system goal, a common setting has been 
to assess system characteristics in relation to the level and/or distribution of health 
(WHO 2000; OECD 2010a). However, health and its equitable distribution are in­
fluenced by several other factors besides the health care system (see Chapter 2.1). 
Different measures used to measure overall population health include life-expectance 
at different ages, infant mortality, disability-adjusted life-expectancy (DALE), health­
adjusted life-expectancy (HALE), amenable mortality and premature mortality as 
potential years of life lost (PYLL) (WHO 2000, 28; OECD 2004, 20–24; OECD 2010a, 
13–26). 
Besides health, other health system goals used in performance assessments include 
responsiveness, quality and fair financing (WHO 2000; OECD 2004; OECD 2010a). 
Responsiveness is an indicator of quality and has been measured by surveys assessing 
patient experiences and satisfaction, more specifically e.g. patient choice, involve­
ment and autonomy, confidentiality, waiting times, satisfaction and unmet needs 
(WHO 2000; Garratt et al. 2008; Schoen et al. 2010; OECD 2015b, 119–162). Fairness 
in financing implies that individuals and households contribute according to their 
ability to pay instead of need, do not face the risk of impoverishment and are not 
forced to go without necessary treatments due to the costs (WHO 2000; de Looper 
and Lafortune 2009). Measurements of fair financing are reviewed in more detail in 
Chapter 2.6. 
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Comparative studies have ranked or compared individual countries based on meas­
ures, indices or several measures of performance (e.g. WHO 2000; van Doorslaer et 
al. 2004; Schoen et al. 2010; OECD 2015b). In the WHO (2000) World health report, 
countries were assessed based on attainments, i.e. outcomes achieved, and relative 
performance, i.e. how well they could perform with the same resources. 
The OECD (2010a) study combined system characteristics with performance out­
comes to assess strengths and weaknesses of different types of systems. A set of 20 
policy and institutional indicators were used to cluster the health care systems in 29 
OECD countries into six groups. Within groups, the countries were benchmarked 
against each other, based on outcomes related to system efficiency and quality. Over­
all, efficiency varied more within groups than across them and therefore no specific 
type seemed to be preferential. Instead, well and poorly performing countries were 
identified in most institutional groups. The policy lessons from the benchmark were 
that similar reform approaches are unlikely to be efficient across systems, instead the 
areas for improvement were system-specific. Some countries could profit from rein­
forcing gatekeeping, others from increasing price signals for users. The reasons for 
inequalities in health also seemed to vary by country, and therefore it would be use­
ful to examine whether inequities in access result from high out-of-pocket payments, 
from reliance on over-the-basic coverage or both. 
Performance comparisons can also focus on a specific sub-sector (e.g. in-patient care, 
outpatient care, pharmaceuticals). Focusing has the advantage of examining similar 
activities thus enabling researchers to draw sector-specific policy recommendations. 
However, finding outcomes that only relate to one sub-sector may be challenging 
(OECD 2010a). 
2.5 Pharmaceutical reimbursement systems
The reimbursement system refers to the institutional arrangements related to evalu­
ating and deciding reimbursement status, mechanisms of funding as well as the eli­
gibilities and conditions that define the circumstances under which reimbursements 
are paid (Seiter 2010, 4; Paris and Belloni 2013, 21–23). The features related to reim­
bursement eligibilities and schemes are described in more detail in Chapter 2.7. 
Reimbursement systems may be public or private, compulsory or voluntary (Austvoll-
Dahlgren et al. 2008). In high-income countries, the most common funding models 
are tax-funded systems (National Health Service, NHS or National Health Insurance, 
NHI) and social insurance, funded through insurance contributions by employers 
and employees as well as state subsidies. The role of private insurance varies by coun­
try, but it is typically supplemental or substitutive. (Kanavos et al. 2011; Paris and 
Belloni 2013, 17; WHO CC for Pharmaceutical Pricing and Reimbursement Policies 
2016.) Conversely, in the US, health care is regulated, delivered and financed through 
various public and private institutions and programs, and there is wide variation in 
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coverage for prescription medicines. Also in Canada, the coverage for prescription 
medicines varies by province. (Commonwealth Fund 2010a; Paris and Belloni 2013, 
17.) 
In Europe, regulation regarding reimbursements usually falls under health and social 
legislation (Vogler 2008, 78; Seiter 2010, 4). The authorities responsible for reim­
bursement decisions in most European countries are the Ministries of Health or So­
cial Affairs, Social Insurance Institutions, Medicines Agencies or specific institutions 
(Vogler 2008, 78). In several countries, the assessment of therapeutic value and/or 
price is conducted separately, based on which recommendations are given to deci­
sion makers (Paris and Belloni 2013, 22–23). The decision on price can be made in 
conjunction to the reimbursement decision, or separately, by a different body (Paris 
and Belloni 2013, 22–23). 
Published pharmaceutical system comparisons have described in detail or classified 
different pharmaceutical systems by their sub-systems with or without macro-level 
indicators (e.g. Mossialos and Oliver 2005; Hutton et al. 2006; Garattini et al. 2007; 
Vogler 2008; Tele and Groot 2009; Paris and Belloni 2013). Comparisons have also 
focused on a single implemented policy, e.g. the reference-price system (Danzon and 
Kelcham 2004). A common measure of performance is comparing prices of medi­
cines (Danzon and Chao 2000; Martikainen et al. 2005; Kanavos and Vandoros 2011). 
Kanavos (2014) compared the performance of generic markets by using several indi­
cators. Few studies have studied countries as clusters in terms of e.g. by being more 
or less market-based (Matthews and Glass 2013), by economic stability (Leopold et 
al. 2014) or by WHO region (Cameron et al. 2009). 
2.6 Dimensions of affordability 
De-commodification has previously been used to address the protective strength of 
health insurance, both in terms of cash benefits and services provided (Kangas 1994; 
Moran 1999; Bambra 2005). Originally, de-commodification relates to the strength 
of social protection, i.e. “the extent to which individuals and families can maintain a 
normal and socially acceptable standard of living regardless of their market perfor­
mance” (Esping-Andersen 1987, 86). Reibling (2010) operationalised four indicators 
of de-commodification to categorise dimensions of access to health care into: 1) Con­
ditions, under which benefits may be received, which relate to eligibility criteria such 
as means or needs tests (e.g. gatekeeping); 2) Disincentives are measures that aim 
to reduce the take-up of benefits, i.e. to address moral hazards (e.g. cost-sharing); 
3) Benefit level in health care, relates to the benefit package covered by the health sys­
tem; 4) Universality, which is the degree of coverage of the system for the population. 
Reibling (2010) did not include the fourth indicator, universality, in the cluster analy­
ses, since most high-income countries have universal coverage of health care services 
and the degree of coverage was thus not useful for differentiating system types. 
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Dimensions of access have also been used to compare pharmaceutical systems, but 
no standard methodology was identified in the literature (Cohen et al. 2007; Vogler 
2008; Kanavos et al. 2011). The dimensions used for health insurance largely apply 
to pharmaceutical reimbursement systems, but also distinct differences exist, main­
ly because the focus of reimbursement systems is on products rather than services 
(Jacobzone 2000; Traulsen and Almarsdóttir 2005; Cohen et al. 2007; OECD 2010a, 
27). The indicators of access to health care, operationalised by Reibling (2010) are 
thus examined below from the perspective of pharmaceutical systems. 
Conditions: Pharmaceutical reimbursement systems typically include different lev­
els of coverage, based on eligibility and exemption policies. The conditions, under 
which these policies apply, differ between systems. The Glossary by WHO CC for 
Pharmaceutical Pricing and Reimbursement Policies (2016), and respectively, also 
Vogler (2008) distinguish between four main types of reimbursement schemes re­
garding eligibility: disease-specific, product-specific, consumption-based and popu­
lation group-specific. The most commonly used scheme in the EU is product-spe­
cific, where eligibility is considered based on an evaluation of different aspects of 
the pharmaceutical product (Vogler 2008). Disease-specific eligibility is linked to the 
treated condition and a certain pharmaceutical may be reimbursed at different rates 
for different conditions. Under population group-specific eligibility, specific groups, 
such as children, older persons or persons with low income are eligible while others 
are not. Finally, under the consumption-based eligibility scheme, the level of reim­
bursement depends on the patients’ cumulative expenditure during a defined period. 
The reimbursement schemes can also be mixed with elements from several eligibili­
ties. (Vogler 2008; WHO CC for Pharmaceutical Pricing and Reimbursement Poli­
cies 2016.) Another form of exemption within pharmaceutical systems is prior au­
thorisation or restricted reimbursement, which limits the use of a product to specific 
(named) patients or circumstances (Austvoll-Dahlgren et al. 2008). 
Disincentives: Cost-sharing is the most commonly used cost containment policy tar­
geted at patients (Freemantle and Bloor 1996, Kanavos et al. 2011). Cost-sharing is 
used to reduce third-party payer expenditures but also as an incentive for the patient 
to deter overuse, use of ineffective and inappropriate medicines and thus limit the 
danger of moral hazard (Robinson 2002). Different forms of cost-sharing and patient 
payments are described in more detail in Chapter 2.4.1. 
Benefit level: Assessments of benefit packages in the field of pharmaceuticals relates to 
the range of reimbursed products. Most European countries, as well as Australia and 
New Zealand, define reimbursable products on the national level by positive lists, i.e. 
lists of medicines that may be prescribed at the expense of a third party payer (Vogler 
2008; Paris and Belloni 2013, 17). There is, however, some variation in whether the 
benefits are similar across different insurance schemes or regions and in whether the 
patients have a choice over the benefit packages (Cohen et al 2007; Paris and Belloni 
Affordability of medicines from the pharmaceutical system perspective 28 
  
2013, 17). In the UK covered medicines are decided on a county level and in Canada 
by public or private drug plans. In Germany and the Netherlands insurance providers 
may decide on coverage of different brands and include benefits above the national 
positive list (Paris and Belloni 2013, 17). One country may also have several positive 
lists with different reimbursement rates (Vogler 2008). Comparisons of the range of 
medicines available or reimbursed are reviewed in more detail in Chapter 2.4.2. 
Universality: Most health systems in high-income countries are characterised by uni­
versal coverage for pharmaceuticals, with the exception of Northern America (Com­
monwealth Fund 2010a; Kanavos et al. 2011). 
2.6.1 Cost-sharing for medicines 
Different forms of patient payments for medicines have been determined and clas­
sified in the OECD Glossary of Statistical Terms (OECD 2001), in the Glossary of 
WHO CC for Pharmaceutical Pricing and Reimbursement Policies (2016), by Ran­
nan-Eliya and Lorenzoni (2010), by Austvoll-Dahlgren et al. (2008) and by Rubin and 
Mendelson (1995). Patient payments include direct payments (also “out-of-pocket 
payments”), that are paid by private households directly to the provider, without the 
benefit of insurance (Figure 2, p. 29). Indirect payments, conversely, are paid irre­
spective of service use, and they may include insurance premiums and taxes, depend­
ing on the system. 
Direct payments are classified into cost-sharing and other payments (Figure 2). Cost­
sharing is the part of the cost that the health insurance or third party payer requires 
the covered individual to pay for received care. Rubin and Mendelson (1995) dis­
tinguish between direct and indirect cost-sharing. The former includes e.g. co-pay­
ments, coinsurances and deductibles, and the latter e.g. non-reimbursed/non-formu­
lary medicines, tier payments and reference premiums. Non-reimbursed prescription 
medicines may also be regarded as self-medication, together with over-the-counter 
medicines and informal payments to medical care providers (OECD 2001). 
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Figure 2. Forms of patient payments.  
Direct
patient 
payments 
Self­
medication / 
other forms 
of direct 
payments 
Informal payments to 
providers 
Cost­
sharing 
Indirect 
patient 
payments 
Insurance
premiums 
(taxes) 
Patient 
payments 
OTC-medicines 
Non-reimbursed / non­
formulary medicines 
Indirect 
cost-sharing 
Tier co-payments 
Reference premiums 
Direct
cost-sharing 
Cap 
Ceiling 
(fixed) copayment = 
prescription charge = 
consumer charge = 
prescription fee = 
patient fee = 
cost-sharing 
Coinsurance = 
percentage copayment 
Deductible 
Red background = paid irrespective of ser vice use, white background = paid for care received. 
Abbreviation: OTC = Over-the-counter. 
Cost-sharing can have negative effects on health, equity and efficiency (Remler and 
Greene 2009; WHO 2010; Hurley 2013; Smith 2013). Cost-sharing may deter people 
from using services, cause financial distress to those who use services and encourage 
overuse of services among those who can pay (WHO 2010b). The effects of cost­
sharing policies on the (rational) use of medicines have been reviewed by Lexchin 
and Grootendorst (2004), Goldman et al. (2007), Austvoll-Dahlgren et al. (2008), 
Gemmill et al. (2008), Martikainen (2012) and Kiil et al. (2014). These systematic 
reviews show that the implementation of or increases in cost-sharing are associated 
with decreased use, especially in vulnerable populations. The decreases identified in 
the studies were not limited to discretionary and less necessary medicines and did 
not always lead to rational use. Previous research has also shown that increased cost­
sharing can lead to an increased rate of adverse events, e.g. hospitalisation, nursing 
home admission and mortality (Tamblyn et al. 2001; Dormuth et al. 2009). In ad­
dition, self-reported non-adherence due to costs has been associated with adverse 
health outcomes (Mojtabai and Olfson 2003; Jatrana et al. 2015). 
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  2.6.2 Range of reimbursed medicines
The priorities and resources available in each country define which therapies are re­
imbursed, and to what extent. However, the range of reimbursed medicines is also 
dependent on the range of medicines in the market. Availability is affected by phar­
maceutical policies, together with market size, market structure, cultural and his­
toric factors (Taylor 1992; Folino-Gallo et al. 2001; Cohen et al. 2007; Vogler 2008; 
Kanavos et al. 2011). According to several studies regarding price controls and entry 
strategies, launches of new medicines occur more often and with less delay in coun­
tries with higher expected price and volume and/or less price controls (e.g. Danzon 
et al. 2005; Kyle 2007; Danzon and Epstein 2008; Varol et al. 2010). Differences in 
prescribing patterns, in the role of industry promotion and in the use of generics or 
“me-too” products can influence the available range (Taylor 1992; Folino-Gallo et 
al. 2001). National policies can also affect availability in other countries, via external 
price referencing, parallel trade and global shortages, e.g. due to low profitability of 
older generic medicines and active ingredients (Kyle 2007; Kanavos et al. 2011; Link 
et al. 2012). 
Examinations and comparisons of the overall range of medicines available or reim­
bursed across countries or systems are scarce and challenged by the complexity of 
such comparisons (Table 2, p. 32). Lack of uniform, standardised and comparable 
data has been a key methodological difficulty (Folino-Gallo et al. 2001; Vogler 2008; 
Ballem and Krause 2011). Identified challenges include e.g. incomplete or lacking 
national listings of products, and if listings have been available, differences in what 
products are included and excluded; differences in defining which products are med­
icines and lacking or variable assignment of ATC-codes. 
Nevertheless, all identified comparisons have showed notable differences between 
countries. Differences have been found in the number and range of medicines availa­
ble and reimbursed, the share of reimbursed products, the availability and reimburse­
ment of newer and innovative products and in the active ingredients and suitable 
product formulations available and reimbursed for paediatric use (Folino-Gallo et al. 
2001; Vogler 2008; Ragupathy et al. 2010; 2012). Comparisons focused on a certain 
illness or type of product found further differences across countries in e.g. author­
ised and reimbursed indications, distribution procedures (specialised centres only, 
second physician approval) and payer requirements (Blankart et al. 2011; Cheema et 
al. 2012). 
In the most exhaustive of identified comparisons, conducted in 14 EU countries, only 
7% of medicines (active ingredients) were available in all 14 countries and each coun­
try had exclusively available active ingredients. The most medicines were available 
in Germany and the least in Denmark. (Folino-Gallo et al. 2001.) In a comparison 
of four countries or systems – the UK, the US VANF (Veterans Affairs National For­
mulary), Australia and New Zealand – the UK had the most and New Zealand the 
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least available and reimbursed medicines as well as therapeutic groups with available 
or reimbursed medicines. The US had most innovative medicines available, and the 
US and UK had similar average age of available medicines. However, the UK had on 
average the newest reimbursed medicines and the highest number of reimbursed in­
novative medicines. New Zealand had fewer and older active ingredients and fewer 
innovative medicines available and reimbursed than the US VANF, UK and Australia 
(Ragupathy et al. 2012). 
Due to the large number and variety of products available in different markets, sev­
eral studies have focused on a basket of products. Based on a comparison of the 100 
top selling medicines, France, the Netherlands, and the UK had approved fewer med­
icines than the US (Cohen et al. 2007). Of the medicines approved in all four coun­
tries, similar share was reimbursed in all countries. The Netherlands had the lowest 
cost-sharing but the most conditions on reimbursement, the USA had the highest 
cost-sharing and most variation in coverage across the population, but also the most 
choice over benefit schemes. In a comparison of five major therapeutic groups in 
three countries using therapeutic reference pricing – Germany, the Netherlands and 
New Zealand – Germany had the most and New Zealand the least active ingredients 
available (Danzon and Kelcham 2004). The difference between New Zealand and the 
other two countries was largest among active ingredients that were newest by global 
age.
Affordability is especially an issue in the case of new and expensive medicines. Ac­
cordingly, several studies have compared differences in access to expensive oncology 
medicines or orphan medicines. Ballem and Krause (2011) found provincial differ­
ences in the Canada in availability, coverage and cost-sharing of new oncology medi­
cines. Wilson and Cohen (2011) observed a trade-off in access between the US Medi­
care and Australia: whereas the US Medicare covered a wider range of products, the 
cost-sharing and prices were notably higher. In neither system did all patients who 
could have benefited from new oncology medicines have access to them. Cheema et 
al. (2012) found large variation in the number of reimbursed indications for oncol­
ogy medicines across 13 countries, regions or systems. Differences were influenced 
by e.g. the stringency of cost-effectiveness assessment and submissions. Blankart et 
al. (2011) compared access to orphan medicines in 11 countries and found differ­
ences in approved and reimbursed indications, prices and cost-sharing. In the US and 
Canada, patient co-payments were substantial. Matthews and Glass (2013) compared 
the adoption of orphan medicines in more and less market-based systems and found 
that less market-based systems may provide more efficient delivery of orphan medi­
cines to patients. According to the authors, these results suggest that reimbursement 
mechanisms may be the primary factor affecting orphan medicine adoption. 
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From the public health perspective, new medicines can bring therapeutic innovation 
and thus improve health outcomes and system efficiency. However, not all medicines 
have equal therapeutic value (Paris and Belloni 2013). Taking opportunity costs in 
account, non-rational use of medicines may also lead to inefficient use of scarce re­
sources. As a consequence, assessments of therapeutic value have been developed 
academically and for regulatory purposes (Ahlqvist-Rastad et al. 2004; Motola et al. 
2005; 2006; Prescrire editorial 2012; Vitry et al. 2013; Baird et al. 2014). Accordingly, 
comparison studies have focused on innovative medicines (e.g. Roughead et al. 2007, 
in price comparison). Westerling et al. (2014) retrospectively analysed the introduc­
tion and diffusion of pharmaceutical innovations first registered in the 1970−1980s 
and found that the between-country differences in introduction became shorter with 
innovations that are more recent. Further, time of registration was not always in line 
with time of start of diffusion.  
2.7 Measuring affordability
The indicators of inequities used to measure health care access and use are share 
of population covered, out-of-pocket expenditure, health care utilisation and unmet 
care needs/forgone care (de Looper and Lafortune 2009; Allin and Masseria 2009a). 
Although all countries struggle with questions of affordability, the specific challenges, 
and the policies adopted in response to these challenges, are different for countries 
with different income levels (Seiter 2010). In general, medicines are more affordable 
in high-income countries than in low-income countries, when adjusted for national 
or individual income level (Machado et al. 2011). In many low and middle-income 
countries, treatments for acute and chronic illness are largely unaffordable, especially 
in the private health care sector, and they may be unavailable in the public sector 
(McIntyre et al. 2006; Cameron et al. 2009; van Mourik et al. 2010; Force 2012). 
Wagstaff and Doorslaer (2001; 2003) have assessed affordability of health care by 
impoverishment (the proportion of population who drop below a defined poverty 
line due to costs for care) and catastrophic spending (proportion of population who 
spend more than a defined proportion of their income on care). These methods have 
been used prospectively, to quantify the proportion of people who would fall below 
or exceed the specified threshold due to the price of a specific service, or retrospec­
tively, to quantify the proportion of people who in reality did exceed or fall below the 
threshold due to costs for care (Xu et al. 2003; Niëns and Brouwer 2013). However, 
the large variation in methods and used thresholds influences the comparability of 
results across studies (O’Donnell and Wagstaff 2008; Luczak and Garcia-Gomez 2012; 
Niëns and Brouwer 2013). The assessment of impoverishment is also not sensitive to 
the proportion of the population that already is below the poverty line and to whom 
the services are unaffordable at any price. Conversely, the cost is rated as affordable, 
however large it may be, for people who do not fall below poverty line. The method 
of assessing catastrophic spending does not take into account that the affordable level 
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might not be same for people with very low and very high incomes. (O’Donnell and 
Wagstaff 2008; Moreno-Serra et al. 2012; Niëns and Brouwer 2013.) 
Facing catastrophic health expenses (e.g. over 40% of disposable income) is relatively 
rare in most high-income countries, due to exemptions and ceilings placed on patient 
payments (Xu et al. 2003). Nevertheless, the economic burden from cost-sharing is 
associated with the risk of delaying or forgoing needed medical care, also among 
insured populations (de Looper and Lafortune 2009; Schoen et al. 2010). The level 
and distribution of out-of-pocket costs for health care have been commonly used as 
indicators in evaluating reforms in the health care sector. National average estimates 
of out-of-pocket health expenditures are routinely reported in National Health Ac­
counts (NHA) in many countries. Information on the share of household income or 
consumption spent on health care, i.e. burden of out-of-pocket spending, is regularly 
collected through household expenditure surveys (e.g. Household Budget Surveys, 
Living Standard Measurement Surveys, Income and Expenditure Surveys). However, 
the validity and comparability of these surveys varies between countries, and also 
within countries across measurement points. (Heijink et al. 2011.) 
Purely considering costs of care does not provide a complete picture of affordability. 
Low realised out-of-pocket costs for poorer households may indicate a progressive 
financing mechanism or it may be the result of low access to and use of services 
(McIntyre et al. 2006; O’Donnell and Wagstaff 2008; Moreno-Serra et al. 2012). In 
low-income country settings, this has been address by Pradhan and Prescott (2002) 
by measuring catastrophic risk rather than realised payments. In high-income coun­
tries, commonly used indicators of unequal access are unmet need for care and ser­
vice utilisation between low and high income groups (de Looper and Lafortune 2009; 
Hernández-Quevedo and Papanicolas 2012; Moreno-Serra et al. 2012). 
Self-reported unmet medical needs or forgone care are a feature of a number of na­
tional and cross-national surveys, including the European Union Statistics in Income 
and Living Conditions Survey (EU-SILC), where individuals are asked whether they, 
during the previous 12 months, did not receive medical examination or treatment 
they thought they needed due various reasons e.g. cost, waiting time or availabil­
ity (Allin and Masseria 2009a; de Looper and Lafortune 2009; OECD 2015b). The 
international health policy surveys conducted by The Commonwealth Fund have 
surveyed e.g. forgone care and medicines, out-of-pocket cost burden and insurance 
coverage in several countries, including the US, Australia, New Zealand, Canada and 
the EU countries (Schoen et al. 2007b; 2009a; 2009b; 2010; 2011; 2013; Osborn et al. 
2014; Commonwealth Fund 2016). Unmet need and access barriers are examined in 
more detail in Chapter 2.5.2. 
In health economics, inequity is assessed based on the interpretation of the principle 
of horizontal equity, which implies that individuals with similar needs have simi­
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lar treatments. Empirically, horizontal inequity is measured by the degree of utilisa­
tion related to income, after adjusting for indicators of need (Bago d’Uva et al. 2009; 
Hernández-Quevedo and Papanicolas 2012). Generally, high-income countries tend 
to have rather equitable distribution of primary care service use but a “pro-rich” bias 
exists in the use of specialist care, especially when private health care options are 
available (van Doorslaer et al. 2004; 2006). 
Assessing equity in utilisation is complicated by the multiple factors that affect use. 
A commonly used theoretical framework is Andersen’s Behavioral Model, according 
to which health service use is a function of enabling and impeding factors, predispo­
sition to use services and need for care (Andersen 1968; 1995). Within this model, 
access is equitable when demographic (e.g. age and gender) and need variables ac­
count for most of the variance in use, and inequitable when social structure (e.g., eth­
nicity, education, occupation), health beliefs, and enabling resources (e.g., income, 
insurance, waiting times) become dominant factors explaining differences. There is, 
however, wide variation in the operationalisation of the model (Babitsch et al. 2012). 
The abovementioned methods used in measuring inequities in access to health care
have also been applied to medicines. Catastrophic pharmaceutical out-of-pocket 
spending has been measured using various thresholds (e.g. McLeod et al. 2011; Luc­
zak and Garcia-Gomez 2012). Cost-related non-adherence and equal use have been 
used as indicators of equal access to pharmaceuticals (Gemmill et al. 2008; Schoen 
et al. 2010; Mayer and Österle 2014). For low-income country settings, WHO and 
Health Action International (HAI) have developed a method where the prices of the 
medicines for selected chronic conditions are compared in relation to the wage of 
the lowest paid unskilled government worker in each country (WHO and HAI 2003; 
Gelders et al. 2006). This method is simple and straightforward, and requires only 
limited data. However, the method does not provide population-level information or 
take into account the overall range of medicines actually used. (Niëns and Brouwer 
2013). 
2.7.1 Distribution of out-of-pocket costs for medicines 
A system-level approach of addressing patient payments is to examine the private 
components of spending on pharmaceuticals from national and international statis­
tics (e.g. Kemp et al. 2011; Zare and Anderson 2013). However, this method disre­
gards how the costs are distributed within the population. Overall, the distribution 
of costs for health care and pharmaceuticals is strongly skewed (Steinberg et al. 2000; 
Berk and Monheit 2001; Goulding 2005; Zuvekas and Cohen 2007; Saastamoinen and 
Verho 2013). Depending on the level and allocation of reimbursements, the skewed 
distribution may persist in patient payments and thus burden population subgroups 
inequitably (Poisal et al. 1999; Sambamoorthi et al. 2005; Corrieri et al. 2010; Bock 
et al. 2014). Nevertheless, since most countries have implemented mechanisms to 
protect patients from high burden of costs, the observed levels of private expenditure 
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are often lower than could be predicted from reimbursement arrangements (Paris et 
al. 2010). 
An earlier systematic review of health care out-of-pocket payments found that among 
older people, low-income individuals paid most in relation to their income. Prescrip­
tion medicines accounted for the largest share of health care payments. A lower level 
of education and female gender were associated with higher out-of-pocket payments 
and less comprehensive insurance coverage. (Corrieri et al. 2010.) However, the re­
viewed 29 studies included all types of health services (e.g. mammography) and, ex­
cept from one study from Australia, derived from the US. 
Using search methodology adapted from Corrieri et al. (2010), a comprehensive 
literature search was performed to examine income, ethnicity/race, education and 
gender-related inequalities in out-of-pocket payments for medicines in high-income 
countries. The search resulted in 25 research articles with data from 1995 onwards 
(Table 3, p. 40). Most studies (18) came from the US, where universal coverage for 
medicines has been a subject of political debate for decades (e.g. Poisal et al. 1999) 
but there is currently none. Evidence from other countries was relatively recent in 
comparison to the US. In 16 studies, the population was limited to older adults, typi­
cally individuals aged 65 and older. 
The identified studies used a large variety of variables to assess out-of-pocket costs 
and cost burden (Table 3, p. 40). Absolute out-of-pocket costs for medicines were 
most commonly reported on annual level, but also per 3 months (Bock et al. 2014), 
monthly (Mojtabai and Olfson 2003; Safran et al. 2005; 2009; Neuman et al. 2007; 
Sanwald and Theurl 2014) and weekly (Jones et al. 2008; Searles et al. 2013). Relative 
costs were calculated with person-level income (Sambamoorthi et al. 2003; 2005; Wei 
et al. 2006; Bock et al. 2014), family income (Xu 2003) or total household budget/ 
consumption (Jones et al. 2008; McLeod et al. 2011) as denominator. Sambamoorthi 
et al. 2003, 2005 and McLeod et al. 2011 used a threshold to define high/catastrophic 
out-of-pocket cost burden (> 10% of income). Two studies addressed primarily cost­
related experiences: self-reported financial burden – from nil to extreme – (Searles et 
al. 2013) or categorised expenditures (Safran et al. 2005; 2009; Neuman et al. 2007). 
Two studies (Chen et al. 2010; Chen 2013) reported neither absolute nor relative 
costs, but the proportion of total costs paid out-of-pocket. Three studies assessed 
out-of-pocket costs for health care as the main outcome and only limited results re­
garding medicines were presented (Jones et al. 2008; Bock et al. 2014; Sanmartin et 
al. 2014). 
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In the USA, decreasing income was associated with increasing absolute out-of-pock­
et spending on medicines, presumably due to high-income people having a more ex­
tensive insurance coverage, together with lower need (Table 4, p. 45). However, at the 
other end of the spectrum, the poorest people also tended to have had lower absolute 
out-of-pocket spending despite higher use, due to a high proportion of people being 
eligible for public programs. (Poisal et al. 1999; Mojtabai and Olfson 2003; Xu 2003; 
Goulding 2005; Safran et al. 2005.) Wide variation was described between different 
insurance schemes, with Medicaid providing the most extensive coverage, followed 
by employer sponsored insurance (Poisal et al. 1999). Insured people were more likely 
than non-insured to purchase any medicines and they incurred higher costs and paid 
lower out-of-pocket payments (Poisal et al. 1999; Poisal and Chulis 2000; Safran et 
al. 2005). In Canada, the highest spending was reported in the second-lowest income 
quintile and in another analysis, in senior households. Lower spending was reported 
in the lowest income quintile and among social assistance households. (McLeod et 
al. 2011; Sanmartin et al. 2014.) In Australia, Germany and Italy lower income was 
associated with lower out-of-pocket spending on medicines and in Austria income 
had no independent and significant effect on out-of-pocket costs (Jones et al. 2008; 
Searles et al. 2013; Bock et al. 2014; Sanwald and Theurl 2014; Terraneo et al. 2014). 
Cost-sharing is known to have regressive effects, i.e. individuals with a lower income 
face a higher burden than individuals with a higher income, even when the absolute 
payments are lower (Corrieri et al. 2010, Valtorta and Hanratty 2013). The largest 
regressive effects were described in the US: among the older population,18−26% of 
the individuals with the lowest and 2−3% of the individuals with the highest income 
spent over 10% of their income on prescription medicines (Sambamoorthi et al. 
2005); and the average spending (as the share of family income) among the individu­
als with the lowest vs. the highest income individuals was 8% vs. 0.2% within the 
working-age population and 14% vs. 0.8% within the older population (Xu 2003). 
In Canada, 0.3% of general households, 1.1% of social assistance households and 
2.5% of senior households spent over 10% of their household budget on medicines 
(McLeod et al. 2011). 
  
  
 
  
 
 
  
  
   
  
 
  
  
    
 
 
 
  
  
 
    
 
 
 
 
 
 
45 Affordability of medicines from the pharmaceutical system perspective
Table 4. Results related to the effects of income on out-of-pocket costs. 
Study Key findings (multivariate findings in italics) 
Confounders controlled for
in multivariate analyses 
Bock et al. 2014 Average OOP burden (all health care) 3% of disposable income. 
Pharmaceuticals accounted for 21% of OOP costs. Higher
income → higher OOP in total and for pharmaceuticals. The
wealthiest quintile → smaller OOP cost to income ratio than 
the poorest for total health care. 
Gender, age, education, 
health, marital status, 
insurance, CIRS-G 
Goulding 2005 The lowest vs. the highest income → higher N of Rx but lower
Rx OOP. No significant difference in total Rx costs. Among the 
lowest income people, insured individuals had higher N of Rx, 
higher total Rx costs but lower OOP costs than uninsured. 
None 
Jones et al. 
2008 
Low income → lower OOP costs for Rx and OTC, but higher
share of total consumption. Among low-income households, 
expenditure share on Rx is higher for concession cardholders
than non-holders. Lower co-payments seem to be offset by
higher utilisation. 
Age, area 
McLeod et al. 
2011 
Social assistance vs. general households → lower median 
OOP, similar median budget share (0.1% vs. 0.1%), higher OOP
costs and OOP share at 95th percentile (5.4% vs. 2.6%), higher
frequency of households with high Rx OOP burden i.e. ≥ 10% of
household budget (1.1 vs. 0.3). Senior households’ median Rx
OOP share 1.1% and 2.5% of households with high burden. 
None 
Mojtabai and 
Olfson 2003 
No significant differences in the likelihood to have any Rx. 
The lowest income → the lowest OOP costs (descriptive). Low 
income together with high OOP costs increased the frequency
of cost-related poor adherence (descriptive).  
Poor adherence associated with adverse health outcomes. 
Age, gender, race/ethnicity, 
education, income, insur­
ance, OOP costs, access to 
health services: office visits, 
preventive services, illness­
specific factors (e.g. diet for
hypertension outcomes) 
Neuman et al. 
2007 
High-income people → less likely to have Part D and more 
likely to have employer sponsored Rx coverage. Low-income →
more likely to have Part D or no Rx coverage. 
No coverage vs. Part D and Part D vs. employer sponsored →
higher odds to spend > $100/$300 OOP and to not fill/delay
filling Rx. 
Age, gender, urbanity, race/ 
ethnicity, education, poverty
level, N of chronic condi­
tions, N of prescriptions. 
Poisal and 
Chulis 2000 
People without Rx coverage vs. with coverage → lower use, 
lower total costs, higher OOP costs across income groups. 
None 
Poisal et al. 
1999 
Low-income people with income just above Medicaid limits
(second-lowest income groups) → the lowest share with Rx cov­
erage (60% vs. 63% in the lowest income, 72% in the highest
income) and the highest OOP costs. Insured people were more 
likely to incur any costs and incur high total costs.
None 
Table 4 continues. 
  
  
 
 
  
  
 
 
 
  
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
46 Affordability of medicines from the pharmaceutical system perspective
Table 4 continued. 
Study Key findings (multivariate findings in italics) 
Confounders controlled for
in multivariate analyses 
Safran et al. 
2005 
Low income was associated with higher than average N of Rx
but no significant difference in the distribution of OOP costs
(8% of all and 9% of low-income beneficiaries spent > $300 / 
month on Rx). Medicaid covered 33% of poor, 7% of near-poor
and 1% of non-poor. Employer sponsored insurance covered 
7% of poor, 20% of near-poor and 38% of non-poor. Without Rx
coverage: 34% of poor, 33% of near-poor and 23% of non-poor. 
Low income, no Rx coverage and high disease burden signifi­
cantly associated with higher cost-related non-adherence. 
Sociodemographic and 
health characteristics (not
specified in detail). 
Safran et al. 
2009 
Part D (2006) advantageous to people previously (2003) 
without coverage/ with individually purchased coverage →
decreased OOP costs, increased N of Rx, decreased non­
adherence. They were also likely to have low income (& low 
education & minority ethnicity/race). People who transitioned 
from employer sponsored insurance (2003) to Part D (2006) 
→ Increased OOP costs, increased non-adherence. People
who retained employer-sponsored insurance (2003&2006) →
Increased OOP costs but the lowest non-adherence before and 
after Part D. Those who retained employer-sponsored insur­
ance were disproportionately high income (& high education & 
white). 
Age, race/ethnicity, poverty, 
number of Rx, change in N 
of Rx, specific chronic condi­
tions, change in Rx coverage. 
Sambamoorthi 
et al. 2003 
Mean Rx OOP burden was 3% of income; 8% of people spent
> 10% of income. 
Low income → lower odds (OR 0.71) to use any Rx, lower total 
and OOP costs, higher odds for high (≥ 10% of income) OOP
burden (OR 6.3). 
Gender, age, race, educa­
tion, marital status, poverty
(≤ 200% / > 200% FPL), 
education, insurance, urban­
ity, area, self-rated health, 
ADL&IADL, N of chronic
conditions. 
Sambamoorthi 
et al. 2005 
Low income → lower OOP Rx costs, slower OOP Rx growth 
1992−2000 but more frequent high OOP cost burden. Among 
poorest, 18−26% spent ≥ 10% of income on Rx, among the 
highest income, 2−3%. Poorest had significantly lower OOP
costs than higher income individuals. 
Gender, race/ethnicity
(white/African American/ 
Hispanic/other), age, marital 
status, education, urbanity, 
insurance, self-rated health, 
year. Poverty included in 
other analyses except OOP
cost burden. 
Sanmartin et al. 
2014 
The highest Rx OOP costs in the second lowest income quintile 
all years. The lowest Rx OOP costs in the lowest income quintile 
all years, except in 2009 in the highest quintile. The largest
increase in OOP Rx costs between 1997−2006 in the lowest
income quintile (64%), the smallest in the highest (21%). 
None 
Table 4 continues. 
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Table 4 continued. 
Study Key findings (multivariate findings in italics) 
Confounders controlled for
in multivariate analyses 
Sanwald and 
Theurl 2014 
Higher income → higher odds for OTC spending. No significant
effect of income on OTC/Rx OOP expenditure or odds for Rx
spending. 
Household structure, urban­
ity, age, education, income, 
insurance, gender (of house­
holder), early retirement
status, doctoral visits 
Searles et al. 
2013 
31% with the lowest income vs. 19% with the highest income 
reported moderate to extreme burden with Rx OOP costs (p = 
0.03). No significant difference in reporting moderate to ex­
treme burden between concession card-holders vs. general pa­
tients. Patients who reported high financial burden spent more 
OOP and were more likely to report cost-saving behaviours. 
None 
Terraneo et al. 
2014 
Higher income → higher expenditure on medicines and 
consumption more elastic in response to changes in cost shar­
ing. For the poorest families, OOP spending remained at fairly
constant. Just above the poorest (deciles II−III) cut their spend­
ing most in response to increased cost sharing. Poor families
(consumption below 60% of the median equivalised expendi­
ture) vs. higher income families → Lower absolute spending 
but larger share (approximately 1% more) of overall spending. 
Year, region, gender, age, 
presence of family members
aged ≥ 75 years or ≤ 6 years, 
family size. 
Xu 2003 Decreasing income coincided with increasing OOP Rx costs and 
burden except among the older population, the poorest had 
the lowest OOP costs but the highest OOP burden. 
None 
Abbreviations: OOP = out-of-pocket, R x = prescription, OTC = over-the-counter, FPL = Federal povert y level, LIS = low income sup­
por t, VA = Veterans Af fairs, (I)ADL = (Instrumental) activities of daily living, CIRS-G = Cumulative Illness Rating Scale for Geriatrics. 
Smaller scale regressive effects also existed among universally insured populations. 
The likely explanations were that the exemptions and reduced co-payment policies 
were not generous enough to entirely compensate for the regressive effects, or com­
prehensive enough to reach all people in need, or that all necessary medicines were 
not adequately covered. In Australia, 31% of people with the lowest income vs. 19% of 
those with the highest income reported a moderate to extreme burden from out-of­
pocket costs, while patients with concession cards reported a high burden at a similar 
rate to the general patients (Searles et al. 2013). Low-income cardholders had higher 
relative costs than low-income non-cardholders, which was likely to be due to low­
ered co-payments being off-set by higher utilisation (Jones et al. 2008). In Italy, when 
compared with other families, low-income families spent approximately 1% more of 
their total spending on medicines (Terraneo et al. 2014). In Germany, no information 
was available for medicines but the mean out-of-pocket cost to income ratio was 3% 
for overall health care in the older population. The lowest income quintile experi­
enced a higher burden than the highest income quintile, despite the presence of an 
income-dependent annual ceiling (Bock et al. 2014). 
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Terraneo et al. (2014) found that the spending on medicines of high-income fami­
lies was more elastic in response to changes in cost-sharing. For the families with 
the lowest income (the lowest decile), spending remained at a fairly constant level 
in 2001−2010, apparently due to exemption policies. However, those just above the 
lowest income level (deciles 2−3) cut their spending most in response to increased 
cost-sharing. These results suggest that low-income people who are just above the ex­
emption thresholds may end up bearing the highest burden and are, therefore, most 
vulnerable to the negative effects of cost-sharing. On the other hand, these effects 
may be due to the higher-income groups limiting the use of discretionary or less nec­
essary medicines. Also in Canada, Sanmartin et al. (2014) suggested that the second­
lowest income quintile was at the highest risk, as a result of the highest out-of-pocket 
costs, and possibly not being eligible for public insurance programs. 
Only studies from the US explored ethnic/racial disparities in costs and medicine 
use (Table 5, p.  49). Several studies reported significant discrepancies in terms of 
at least one indicator of medicine use or costs, when racial/ethnic/immigrant mi­
norities were compared to their Caucasian/white/US-born counterparts (Poisal et al. 
1999; Briesacher et al. 2003; Sambamoorthi et al. 2003; 2005; Xu and Borders 2007; 
Chen et al. 2010; Chen 2013; Mahmoudi and Jensen 2014). Since ethnic/racial/im­
migrated population groups also differed from their counterparts and each other by 
most characteristics (e.g. age, income, education, health status, insurance), several 
studies, with various methods, assessed the effect of these underlying factors on the 
observed disparities (Briesacher et al. 2003; Gaskin et al. 2006; Neuman et al. 2007; 
Xu and Borders 2007; Chen et al. 2010; Chen 2013). Four studies (Gaskin et al. 2006; 
Chen et al. 2010; Chen 2013; Mahmoudi and Jensen 2014) were based on Andersen’s 
Behavioral Model, according to which health service use is a function of enabling and 
impeding factors, predisposition to use services and need for care (Andersen 1968; 
1995, see also chapter 2.5). Decomposition (Oaxaca-Blinder) techniques were used 
to determine the extent to which the disparities were attributed to the unobserved 
factors associated with race/ethnicity/immigration (Gaskin et al. 2006; Chen et al. 
2010 Chen 2013). One study assessed underlying differences in health, insurance 
generosity and utilisation patterns (Xu and Borders 2007). 
Observed predisposing, enabling and health related factors did not seem to fully ex­
plain the higher use or total costs for medicines among Caucasian/white/US-born 
individuals (Briesacher et al. 2003; Gaskin et al. 2006; Chen et al. 2010; Chen 2013; 
Mahmoudi and Jensen 2014) (Table 5). One study suggested that the higher spend­
ing observed among white in contrast to African Americans could be even larger if 
population characteristics were the same (Gaskin et al. 2006). The observed factors 
seemed, however, to explain the majority of ethnic/racial disparities in out-of-pocket 
costs and share (Gaskin et al. 2006), and in out-of-pocket cost burden (Sambamoor­
thi et al. 2003; 2005). Accordingly, further controlling for insurance generosity and 
prescription medicine use eliminated significant disparities in out-of-pocket costs 
and share (Xu and Borders 2007). 
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Table 5. Results related to the effects of ethnicity/race on out-of-pocket costs. 
Study Key findings (multivariate findings in italics) 
Confounders controlled 
for in multivariate 
analyses 
Briesacher
et al. 2003 
African American/Hispanic vs. white → more often public Rx cover­
age (e.g. Medicaid) and less often employer sponsored Rx coverage. 
African American vs. white with similar types of coverage: No consist­
ent significant differences in OOP costs, except among diabetics with 
no Rx coverage → lower OOP costs. Lower odds to use antidiabetic
medicines with any type of or no Rx coverage. Otherwise few signifi­
cant differences in overall use or total costs. Hispanic vs. white with 
similar types of coverage: Mostly lower OOP, especially with Medic­
aid together with any condition and heart disease together with any
type of Rx coverage. Mostly no significant differences in odds to use
condition-specific medications, although tendency for lower overall 
medicine use and total costs. 
Age, gender, income, 
self-rated health, 
number of comorbidities. 
Stratified by Rx insurance 
coverage type 
Chen 2013 Citizenship: Non-US citizens with ≤ 10 yrs of residence vs. US-born 
→ lower odds to use any Rx. Other immigrants no significant differ­
ence vs. US-born in odds to use any Rx. All immigrants vs. US-born 
→ lower total costs. Non-citizens vs. US-born → higher OOP share. 
Ethnicity: African American/Hispanic/Asian vs. whites → lower odds 
to use any Rx (the lowest Asians OR 0.6) and lower total costs if any
use. No significant difference in OOP share.  
Major significant factors affecting disparities in total costs between 
US-born and immigrants: Ethnicity and English language, for natu­
ralised citizens and non-US citizens with ≤ 10 yrs of residence also 
age and health status, for non-US citizens with > 10yrs of residence
also education ; in OOP share: US-born vs. naturalised US-citizens
→ no significant difference; US-born vs. non-citizens → insurance
and having usual source of care. Medicaid negatively associated 
(disparities would be larger without Medicaid). 
Age, gender, marital 
status, Ethnicity/race, 
citizenship, self-rated 
health & mental health, 
SF-12 PCS&MCS, exist­
ence of 7 pre-defined 
illnesses (e.g. diabetes, 
hypertension, depres­
sion), education, income, 
having usual source of
care (USC), insurance 
type, employment status, 
English language, urban­
ity, region, year. 
Chen et al. 
2010 
All Latino subgroups vs. whites → less likely to use any Rx and lower
total costs (except Cubans no significant difference vs. whites in total 
costs). Mexicans or other Latinos vs. whites → higher OOP share, 
Cubans and Central or South American vs. whites → No significant
difference in OOP share, Puerto Ricans vs. whites → lower OOP
share.  
Major significant factors affecting disparities in medicine use: All 
subgroups except Puerto Ricans: access to health care, English profi­
ciency, insurance. Puerto Ricans, insurance and having USC; in total 
costs: All Latino subgroups: Age, citizenship, having USC (except
Puerto Ricans); and in OOP share: Puerto Ricans lower predicted 
share vs. whites, other Latino subgroups higher predicted share vs. 
whites.  
Differences also found in the tendency to use generic medicines
(Mexicans the highest share).  
Age, gender, marital 
status, citizenship, edu­
cation, family income, 
employment status, self­
rated health, IADL&ADL, 
insurance, having usual 
source of care (USC), lan­
guage, area, study year. 
Table 5 continues. 
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Table 5 continued. 
Study Key findings (multivariate findings in italics) 
Confounders controlled 
for in multivariate 
analyses 
Gaskin et al. 
2006 
White vs. African American → higher total costs, no difference in 
OOP, higher N of Rx. White vs. Hispanic → higher total and OOP
costs, higher N of Rx. Most of the observed disparities in use not
explained by population characteristics, however a substantial 
proportion of OOP cost disparities was explained. 
Ethnicity, age, gender, 
marital status, insur­
ance, poverty, education, 
urbanity, area, self­
assessed health, N of
ADL&IADL, N of chronic
conditions. 
Goulding 2005 African Americans vs. white: higher N of Rx, lower OOP Rx costs, no 
significant difference in total Rx costs. 
None 
Mahmoudi and 
Jensen 2014 
Overall: Before and after Part D, in both age groups, African Ameri­
can/Hispanic individuals vs. white were less likely to fill any Rx, 
filled fewer Rx, had lower total and OOP costs. ≥ 65 + yr-old African 
American/Hispanic had lower OOP share than white; 55–64 yr-old 
African American/Hispanic had higher OOP share than white. 
After Part D (2006–2009) vs. before (2002–2005): Use increased, 
OOP costs and OOP share decreased for all ≥ 65 + year-olds, but
effects on disparities were mixed: African American vs. white → net 
disparity in total costs increased, no significant change in disparity
in other measures. Hispanic vs. white → disparities decreased in 
total and OOP costs (nearly significant in N or Rx). No significant
effect on disparities in other utilisation and spending measures.  
Age, gender, marital sta­
tus, education, income, 
insurance, area, lan­
guage, self-rated health 
and mental health,  
SF-12 PCS&MCS, exist­
ence of 5 pre-specific
chronic illnesses (e.g. 
asthma, arthritis, dia­
betes), N of functional 
limitations. 
Mojtabai and 
Olfson 2003 
No significant differences in the likelihood of taking Rx medicines. 
White vs. African American vs. Hispanic → higher OOP Rx spending 
if any (descriptive). 
None 
Neuman et al. 
2007 
African American and Hispanics vs. white → more likely to have 
Part D but less likely to have employer sponsored Rx coverage. 
None 
Poisal et al. 
1999 
African American/other vs. white → more likely to have Rx coverage 
(59%/75% vs. 64%) due to higher share with Medicaid. White: The 
highest total Rx costs and OOP Rx costs; African American: The sec­
ond highest total Rx costs, the lowest Rx OOP costs and OOP share; 
Other ethnicity: The lowest total Rx costs, the highest OOP share. 
None 
Sambamoorthi 
et al. 2003 
African American/other vs. white → no significant difference in odds
to use any Rx, lower total and OOP Rx costs, no significant difference
in odds for high (≥ 10% of income) OOP burden. 
Gender, age, race, 
education, marital 
status, income (≤ 200% 
/ > 200% FPL), educa­
tion, insurance, urbanity, 
area, self-rated health, 
ADL&IADL, N of chronic
conditions. 
Table 5 continues. 
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Table 5 continued. 
Study Key findings (multivariate findings in italics) 
Confounders controlled 
for in multivariate 
analyses 
Sambamoorthi 
et al. 2005 
Between 1992 and 2000: White had the highest OOP Rx costs, 
African Americans the second highest OOP Rx costs and the fastest
growth in OOP Rx costs, Hispanic/other had the lowest OOP costs, 
the slowest growth in OOP Rx costs. High (> 10% of income) OOP
burden affected annually 7−11% of white, 7−13% of African Ameri­
can, 6−16%  of Hispanic and 4–10% of other individuals. 
Hispanic vs. white → significantly lower OOP costs and higher
odds of high OOP burden, no significant difference between African 
American and white. 
Gender, race/ethnicity
(white/African American/ 
Hispanic/other), age, 
marital status, educa­
tion, urbanity, insurance, 
self-rated health, year. 
Poverty included in other
analyses except OOP
cost burden. 
Xu and Borders
2007 
Ethnic minorities less likely than white to use Rx but when they
did, they had lower OOP share. Hispanics had significantly lower
OOP costs than white, between African Americans and white no 
significant difference.  
Need- or utilisation-adjusted models: After controlling for health 
status, health care utilisation, insurance generosity for other health 
care and/or prescription medicine utilisation, no significant differ­
ences in OOP costs or share were found between African American/ 
Hispanic vs. white. Variables that had greatest effect in the models
were insurance-related. 
Control variables: 
Ethnicity/race, area, age, 
gender, education, in­
come, insurance, health 
care total costs and OOP
costs excl. Rx.
Need-adjusted model: 
Control variables and 
specific chronic condi­
tions, SF-12 PCS&MCS. 
Utilisation-adjusted 
model: Control variables
and N of medicines, 
average N of refills / Rx, 
average quantity / Rx. 
Abbreviations: OOP = out-of-pocket, R x = prescription, OTC = over-the-counter, F PL = Federal pover t y level, LIS = low income sup­
por t, (I)ADL = (Instrumental) activities of daily living, SF-12 = 12-Item Short Form Health Sur vey, PCS&MCS = Correlated physical 
health and mental health. 
The effects of ethnicity/race and immigration status were interrelated, e.g. the lack 
of insurance coverage and language barriers affected especially non-US citizens, of 
whom the majority were Hispanic (Chen 2013) (Table 5, p. 49). In part, associated 
factors were also offsetting (e.g. lower share of minority populations with (private) 
insurance but higher share with Medicaid), which diluted overall effects (Poisal et al. 
1999; Briesacher et al. 2003; Gaskin et al. 2006; Neuman et al. 2007; Chen et al. 2010). 
The findings also varied between studied ethnic/racial groups and subgroups (Poisal 
et al. 1999; Sambamoorthi et al. 2005; Chen et al. 2010; Chen 2013). Increased insur­
ance coverage did not necessarily lead to decreasing disparities between ethnic/ra­
cial groups. Implementation of prescription coverage to older population (Medicare 
Part D) increased spending and use for all, but the increases were larger for whites 
than for African Americans, which resulted in increasing disparities (Mahmoudi and 
Jensen 2014) (Table 5). Similar results have been found for health care services (Bor­
rell et al. 2006; Korda et al. 2007). 
  52 
 
 
  
 
   
 
 
   
 
 
 
 
   
  
 
 
 
 
  
 
  
 
  
 
 
Affordability of medicines from the pharmaceutical system perspective
Table 6. Results related to the effects of gender on out-of-pocket costs. 
Study Key findings (multivariate findings in italics) 
Confounders controlled for in 
multivariate analyses 
Bock et al. 
2014 
No independent significant effect between education and 
OOP costs for medicines or total health care, or between 
education and OOP costs to income -ratio. 
Gender, age, education, health, 
marital status, insurance, CIRS-G 
Goulding 
2005 
Females significantly higher use, total costs and OOP
costs. 
None 
Mojtabai and 
Olfson 2003 
Females significantly higher proportion with any Rx. Also 
higher OOP if any use (descriptive). 
None 
Poisal et al. 
1999 
Females vs. males → slightly lower share with Rx cover­
age (64% vs. 66%), higher total Rx costs, higher OOP
costs.
None 
Sambamoorthi
et al. 2003 
Females vs males → higher odds to use any Rx (OR 1.7), 
higher total and OOP Rx costs, higher odds for high 
(≥ 10% of income) OOP burden (OR 1.7). 
Gender, age, race, education, marital 
status, income (≤ 200% / > 200% 
FPL), education, insurance, urbanity, 
area, self-rated health, ADL&IADL, 
N of chronic conditions. 
Sambamoorthi
et al. 2005 
Females vs. males → higher OOP Rx costs and higher
odds for high (≥ 10% of income) OOP burden. High 
burden affected annually 8−12% of women and 6−9% 
of men. 
Gender, race/ethnicity (white/African 
American/Hispanic/other), age, 
marital status, education, urbanity, 
insurance, self-rated health, year. 
Poverty included in other analyses
except OOP cost burden. 
Sanwald and 
Theurl 2014 
Female householder increased the odds of OTC pur­
chases, no effect on odds of Rx purchases or on OOP Rx/ 
OTC costs. 
Household structure, urbanity, 
age, education, income, insurance, 
gender (of householder), early retire­
ment status, doctoral visits 
Searles et al. 
2013 
No significant gender differences in reporting moderate 
to extreme financial burden with OOP Rx costs. 
None 
Steinberg  
et al. 2000 
Female vs. male → higher proportion with any Rx/OOP
Rx costs, higher Rx and OOP Rx costs. Similar findings
across the cost distribution, except among top 1% 
spenders men had higher total expenditures. 
None 
Wei et al. 
2006 
Female vs. male → higher N of prescriptions (22 vs. 18 
/ yr) → 20% higher OOP Rx costs and higher burden 
(4.4% vs. 3.2% of income). Direction and significance of
impacts of explanatory variables on OOP Rx costs and 
burden similar for both genders. According to model 2, 
the increase in OOP cost per additional Rx was lower
for women but the increase in OOP burden was higher. 
Major factors explaining gender gap in OOP costs were
higher Rx use and chronic conditions; and in OOP bur­
den also poverty, whereas Medicaid narrowed the gap. 
Stratified by gender. Adjusted by
race/ethnicity, age, marital status, 
education, urbanity, poverty, insur­
ance, IADL&ADL, self-rated health,  
N of chronic conditions, year. Model 
2 also N of Rx / yr. 
Abbreviations: OOP = out-of-pocket, R x = prescription, OTC = over-the-counter, FPL = Federal povert y level, LIS = low income sup­
por t, (I)ADL = (Instrumental) activities of daily living, SF-12 = 12-Item Shor t Form Health Sur vey, PCS&MCS = Correlated physical 
health and mental health, CIRS-G = Cumulative Illness Rating Scale for Geriatrics. 
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Table 7. Results related to the effects of education on out-of-pocket costs. 
Study Key findings (multivariate findings in italics) 
Confounders controlled for in 
multivariate analyses 
Bock et al. 2014 No independent significant effect between gender
and OOP costs for medicines or total health care, 
or between gender and OOP costs to income -ratio. 
Gender, age, education, health, 
marital status, insurance, CIRS-G 
Mojtabai and Olfson 
2003 
Lower education → lower OOP costs if any
(descriptive). No significant differences in the 
proportion with any Rx use. 
None 
Sambamoorthi et al. 
2003 
More years of education → increased odds to buy
any Rx, higher total and OOP Rx costs.No inde­
pendent effect on odds for high OOP burden after
adjusting for income. 
Gender, age, race, education, 
marital status, income (≤ 200% / 
> 200% FPL), education, insurance, 
urbanity, area, self-rated health, 
ADL&IADL, N of chronic conditions. 
Sambamoorthi et al. 
2005 
Higher education → higher OOP Rx costs but lower
odds for high (≥10% of income) OOP burden. 
Gender, race/ethnicity (white/Afri­
can American/Hispanic/other), age, 
marital status, education, urbanity, 
insurance, self-rated health, year. 
Poverty included in other analyses
except OOP cost burden. 
Sanwald and Theurl 
2014 
Higher education → higher odds of OTC purchases. 
No independent effect on OOP OTC/Rx costs or odds
of Rx purchases. 
Household structure, urbanity, 
age, education, income, insurance, 
gender (of householder), early retire­
ment status, doctoral visits 
Abbreviations: OOP = out-of-pocket, R x = prescription, OTC = over-the-counter, FPL = Federal povert y level, LIS = low income sup­
por t, (I)ADL = (Instrumental) activities of daily living, SF-12 = 12-Item Shor t Form Health Sur vey, PC S&MCS = Correlated physical 
health and mental health, CIRS-G = Cumulative Illness Rating Scale for Geriatrics. 
Female gender was associated with higher medicine use in the US and Austria (Stein­
berg et al. 2000; Sambamoorthi et al. 2003; 2005; Wei et al. 2006; Sanwald and Theurl 
2014) (Table 6, p. 52). This is in line with the known association of female gender and 
higher use of health-services (e.g. Mustard et al. 1998; Bertakis et al. 2000; Redondo-
Sendino et al. 2006). However, higher use seemed to lead to higher out-of-pocket 
costs and/or cost burden only in the US (Sambamoorthi et al. 2003; 2005; Wei et al. 
2006). The major factor contributing to the difference in out-of-pocket cost burden 
between genders in the US was poverty (Wei et al. 2006). No significant gender dif­
ference in out-of-pocket costs for medicines was observed in Germany or Austria 
(Bock et al. 2014; Sanwald and Theurl 2014) or in burden from out-of-pocket costs in 
Australia (Searles et al. 2013). 
Only five studies included relevant results regarding education and cost-sharing 
(Table 7). In Austria, higher education had an independent increasing effect on the 
probability of using OTC-medicines but no independent effect on out-of-pocket 
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costs or on the probability of using prescription medicines, which was similar to the 
findings from Germany (Bock et al. 2014; Sanwald and Theurl 2014). In the US, a 
higher number of years of education was associated with higher odds of using any 
prescription medicines and higher total costs among older people, even after adjust­
ing for income (Sambamoorthi et al. 2003; 2005). The effect of education on high 
out-of-pocket cost burden, however, did not seem to be independent from the effects 
of income (Sambamoorthi et al. 2003). 
In summary, most published literature regarding the distribution of out-of-pocket 
costs derived from the US and was focused on older individuals. Varied methods and 
outcomes limited the comparability of results across studies. The overall patterns ob­
served in different studies were, however largely consistent. In studies where relative 
costs were assessed, user charges seemed to have regressive effects even among in­
sured populations, and despite concession mechanisms. More than one of the studies 
from different systems identified those just above the thresholds for low-income sup­
port systems as most vulnerable for the negative effects of cost-sharing. Nevertheless, 
the income-related differences were much larger in the US and Canada, where only 
the part of the population are eligible to public programmes, than in countries with 
universal coverage. Further, gender or education related differences in cost burden 
were only observed in studies from the USA. Ethnic differences were only studied 
in the US, where ethnicity-related differences in out-of-pocket costs were associated 
with insurance generosity and differences in use patterns. However, the differences 
in use were not fully explained by the observed predisposing, enabling and health 
related factors. 
2.7.2 Access barriers, foregone care and unmet needs 
Forgone care and unmet health needs are commonly used measures of health care 
access in national and cross-national health surveys (de Looper and Lafortune 2009; 
Moreno-Serra et al. 2012). Depending on the survey, the questions may include un­
met needs for any reason, or address reasons for unmet needs by a follow-up question 
or focus specifically on e.g. cost-related or availability related unmet needs. Cross-na­
tional continuously collected surveys with questions related to unmet needs include 
the Survey on Health, Ageing and Retirement in Europe (SHARE), the EU Survey 
of Income and Living Conditions (EU-SILC) and the Commonwealth Fund Inter­
national Health Policy Surveys (CWF IHPS). SHARE includes a question on cost 
and availability-related access barriers during the past 12 months, and distinguishes 
the types of care e.g. physician, medicine, dental (Allin and Masseria 2009b; SHARE 
2016). 
EU-SILC assesses unmet need for medical examination or treatment during the past 
12 months due to multiple causes including cost, availability and fear (Hernández-
Quevedo and Papanicolas 2012). CWF IHPS focus on experiences with health care 
systems, especially accessing and affording care (Schoen et al. 2010; Hernández­
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Quevedo and Papanicolas 2012). Recently, a module on the social determinants of 
health was included in the European Social Survey (ESS) Round 7 collected in 2014. 
This module contained questions on unmet need for medical consultation or treat­
ment for multiple reasons including cost, availability, waiting-list, and inability to 
take time off work. (Eikemo et al. 2016; ESS 2016.) 
EU-SILC aims to collect cross-sectional and longitudinal data on income, poverty, 
social exclusion and living conditions. The first survey in 2003 included six EU mem­
ber states and the 2011 survey included all EU27-countries, Croatia, Iceland, Turkey, 
Norway and Switzerland (Eurostat 2016a). According to EU-SILC 2013, the lowest 
shares of unmet needs for medical examination due to cost, being too far to travel 
or waiting list were reported in the Netherlands, Austria and Spain (Eurostat 2016b; 
Figure 3). Countries with the lowest share of cost-related unmet needs were the UK, 
the Netherlands, Norway, Denmark and Finland. Finland, the UK and Estonia stood 
out for relatively low share of cost-related unmet needs in comparison to unmet 
needs for other causes. The variation between countries was large but unmet needs 
were consistently more common among low- than high-income respondents (OECD 
2015b). 
Figure 3. Self-reported unmet need for medical examination due to cost (grey bar) or due to cost, waiting 
list or travel distance (red bar) based on EU-SILC 2013.a 
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a Results for respondents in the first quintile of equivalised income (QI) are included above the respective bars. Countries with 

complete data for 2013 are included. 

Source: Authors representation based on EU-SILC 2013 online data (Eurostat 2016b).
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The Commonwealth Fund and its partners have conducted international surveys of 
health care system performance since 1998, first in five English-speaking countries: 
Australia, Canada, New Zealand, the UK and the US. Germany was included in 2005, 
the Netherlands in 2006, France in 2008, Norway, Sweden and Italy (not included in 
later years) in 2009 and Switzerland in 2010. Surveys included a general sample of 
adults in 1998, 2001, 2004, 2007, 2010, 2013; a sample of older adults in 1999 and 
2014 and a sample of adults with health problems/high health needs in 2002, 2005, 
2008 and 2011. Surveys targeted to physicians were conducted in 2000, 2006, 2009, 
2012 and 2015, and to hospital executives in 2003. (Commonwealth Fund 2016.) 
According to The Commonwealth Fund surveys to the general adult population in 
2007, 2010 and 2013, cost-related barriers were consistently more frequent in the US 
and less frequent in the UK than in the other surveyed countries (Figure 4). Sweden 
and Norway had low rates of cost-related barriers, together with the Netherlands 
with the exception of the 2013 survey, presumably due to increases in cost-sharing 
(Schoen et al. 2013). Australia, Canada and New Zealand tended to fall between the 
US and European countries. In New Zealand, access barriers seem to decrease over 
time, especially when compared to earlier studies conducted in 2001 and 2004, which 
is likely to be due to primary care payment reforms (Schoen et al. 2010). 
Figure 4. Self-reported cost-related access problems based on the Commonwealth Fund (CWF) 2007, 2011 
and 2013 International Health Policy Surveys of the general adult population and 2011 International 
Health Policy Survey of Sicker Adults. 
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Did not fill/skipped Rx, did not visit doctor Did not fill/skipped Rx because of cost
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Abbreviation: R x = Prescription.
 
Source: Authors representation based on published results of the Commonwealth Fund sur vey (Schoen and Osborn 2011; Schoen 

et al. 2007a; 2007b; 2013; Commonwealth Fund 2010b). 
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Based on the Commonwealth Fund surveys, respondents from countries with 
low cost-sharing tended to report lower frequencies of cost-related access barriers 
(Schoen et al. 2007b; 2010; 2011; 2013). Respondents from the US were most likely 
to report spending over $1,000 during the past year out-of-pocket on medical care, 
whereas respondents from Sweden, the UK, France, the Netherlands and New Zea­
land were least likely to report spendings that high (Schoen et al. 2013). Switzer­
land and Australia had lower rates of cost-related barriers despite high out-of-pocket 
costs. This is presumably due to ceilings and exemption policies (Schoen et al. 2010; 
2013). These findings largely persisted in surveys targeted to older adults and “sicker” 
adults (Schoen et al. 2009a; 2011; Osborn et al. 2014) and when questions of afford­
ability were targeted to general practitioners (Schoen et al. 2009b; 2012). 
The systems in different countries seemed to vary in how they protected patients 
with high needs and/or low incomes. In France, Germany, the Netherlands, Norway, 
New Zealand and the UK, respondents with a chronical illness (asthma or chronic 
lung problems, cancer, diabetes or heart disease) were not significantly more likely 
to report access problems than people without these conditions, whereas in Aus­
tralia, Canada, Sweden, Switzerland and the US, access barriers were significantly 
more common among chronically ill patients than other adults (Schoen et al. 2013). 
In surveys targeted to “sicker” adults, the lowest out-of-pocket expenditures were 
reported in the UK, Sweden and France, and the lowest frequency of access barriers 
in the UK, Sweden and Norway (Schoen et al. 2011). In comparisons adjusted by age 
and health status, below-average income respondents were more likely to report ac­
cess barriers than above-average income respondents in all countries except the UK 
(Schoen et al. 2010). 
Generally, people who report unmet need or forgone care tend to have worse health 
and a lower income or socioeconomic position. Other factors that have been associ­
ated with unmet needs are female gender, lack of insurance coverage and belonging 
to an ethnic/racial minority or immigrant group. (Mielck et al. 2007; 2009; Allin and 
Masseria 2009a; 2009b; Allin et al. 2010; Bryant et al. 2009; de Looper and Lafortune 
2009; Litwin and Sapir 2009; Israel 2016.) However, unmet needs derive from a va­
riety of reasons with different impacts on equity and utilisation. Overall, in Europe, 
individuals with unmet needs due to any cause have been found to use more services 
and spend more out-of-pocket than expected based on observed need-related factors 
(Allin and Masseria 2009a; 2009b). More specifically, based on a Canadian study, 
unmet needs related to waiting times have been associated with higher health care 
service use, and higher education, whereas unmet needs due to barriers (e.g. costs) 
have been associated with lower service use and lower income. Also unmet needs for 
personal reasons (e.g. dislike, personal choice, too busy) seem to coincide with low 
service use. (Allin et al. 2010.) 
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Factors that increase the tendency to seek care, specifically education and labour 
force participation, can also influence the extent to which unmet needs are perceived 
and unperceived (Allin et al. 2010; van Doorslaer et al. 2004). These variables are 
especially of interest in explaining unmet needs with a structural-critical approach, 
where the focus is on the distribution of economic and social resources and how they 
shape the opportunities provided by society. Other approaches include social capital 
and social support approaches, with focus on coping and opportunities shaped by 
community and individual factors, and a more narrow lifestyle approach, with focus 
on personal factors and choices (Bryant et al. 2009). Social and cultural differences 
may also exist across countries in reporting unmet needs, e.g. due to differences in 
expectations and experiences (Allin and Masseria 2009b). Across-country differenc­
es in the level of unmet needs may be influenced by differences in income level and 
inequalities (Mielck et al. 2007). 
Suggested factors that influence cost-related underuse of medicines include sys­
tem-related factors (e.g. barriers to refilling prescriptions or applying for benefits, 
prescriber incentives), financial pressures (e.g. income, insurance), patient charac­
teristics (e.g. sociocultural, health, perceived treatment benefits, health literacy), cli­
nician-related factors (e.g. knowledge of costs, understanding and discussion about 
prescription costs and adherence), treatment related factors (e.g. regimen complex­
ity, adverse effects, perceived need) and diagnosis-related factors (e.g.quality of life 
and life expectancy). (Piette et al. 2006.) Robust risk factors for cost-related non­
adherence identified in the literature mainly deriving from the US include low in­
come, lack of or inadequate insurance coverage, high cost-sharing, disease burden 
and poor health (mental or physical or poor health habits) and younger age. Mixed 
results have been found for gender, education and race/ethnicity, after controlling 
for income and insurance. Some evidence was found to support the association of 
perceived risks or benefits of treatment and good physician-patient relationship on 
protecting from cost-related non-adherence. No evidence was found on the associa­
tion of polypharmacy and no clear patterns were observed in regards essential and 
non-essential medicines. (Briesacher et al. 2007.) 
Patients vary in their response to cost-sharing for medicines. Besides restricting use 
(stop taking, split pills, delay refills, skip doses, avoid prescription), patients may use 
other coping strategies to manage costs, e.g. seek the best price or free samples, re­
quest generics, increase debt, import or cut back on basic needs. (Piette et al. 2006; 
Briesacher et al. 2007.) In the US, female gender, older age and minority race/ethnic­
ity were associated with the likelihood to cut back necessities as a coping strategy, 
minority race/ethnicity also with the likelihood of increasing debt. Low income, old­
est age and high out-of-pocket costs were associated with all assessed coping strate­
gies: cutting necessities, increasing debt and restricting use. No independent associa­
tions were found for education and number of medicines used. (Heisler et al. 2005.) 
Of note, socioeconomic disadvantage has also been associated with poor adherence 
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and primary non-adherence (due to any cause) to medicines (e.g. DiMatteo 2004; 
Wamala et al. 2007; Kardas et al. 2013). 
In a comparative analysis of the US, Canada, Germany, the UK, the Netherlands, 
Australia and New Zealand, medicine underuse due to cost was most frequent in the 
countries with higher out-of-pocket costs and least frequent in countries with low 
out-of-pocket costs. The US (median out-of-pocket costs $300) and Australia ($140) 
had the highest proportion of non-adherence while the Netherlands ($0) and the 
UK ($0) had the lowest. High out-of-pocket costs and low income were significantly 
associated with non-adherence in all countries except Germany. Also in the Neth­
erlands the association was not consistent. The results from Germany may be influ­
enced by the income-based annual ceiling. Higher education increased the odds for 
non-adherence in Germany but the effect of education was not significant in other 
countries. Insurance was only assessed in the US and Canada, where public insurance 
only or no insurance increased odds for non-adherence. Female gender was associat­
ed with higher odds for non-adherence only in the US. Ethnic minorities had higher 
odds for non-adherence in Australia, Canada, the Netherlands and New Zealand but 
not in the US (not assessed in Germany and the UK). Younger age (18−64 vs. 65 +) 
was associated with higher odds in all countries except Germany and the Nether­
lands. Diagnosed depression increased the odds significantly in all countries except 
Australia and the UK, other diagnosed chronic conditions only in the Netherlands. 
Poor health status increased the odds in Australia, Canada and the US. Involvement 
with treatment decisions decreased odds in all countries except the Netherlands and 
New Zealand. (Kemp et al. 2010.) 
In summary, cost-related barriers to care and medicines were reported in all coun­
tries, and they were nearly always more frequent among individuals with lower in­
comes. Countries differed in how the experiences of patients with high health needs 
differed from the experiences of the general population. Worse health and lower 
income were robust risk factors for cost-related access-barriers. Depending on the 
system, other important associated factors were insurance coverage and high out-of­
pocket costs. Mixed results were found for age, female gender and ethnicity/race, as 
well as factors related to prescriber and attitudes towards the treatment. 
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3 Aims of the study 
The overall purpose of this study was to examine and compare the features of phar­
maceutical systems in Finland and New Zealand and assess how they translate into 
affordability-related outcomes: distribution of out-of-pocket costs and cost-related 
access-barriers. The system features of interest in this study are those related to ac­
cess, operationalised by using adapted indicators of de-commodification: conditions, 
disincentives, benefit level and universality. The comparative analysis is based on lit­
erature, international statistics and four sub-studies presented in this thesis. The aims 
of the sub-studies were to shed light on specific dimensions of affordability of which 
limited information was available in the published literature. 
The comparative method, especially when a case-oriented approach is taken, aims 
to investigate situations as wholes, by determining a combination of conditions as­
sociated with specific outcomes or processes, and by examining similarities and dif­
ferences (Ragin 1987, 14−16; Kangas 1994). In the case-oriented approach, the fo­
cus is on understanding the dynamics of a few cases, which are selected because of 
their significance to the research question. Case-oriented studies benefit from using 
methodological triangulation and typically the data is derived from various sources. 
(Cacace et al. 2013.) When directly comparable data is not available from different 
countries, country-level associations can be compared to identify similarities and dif­
ferences in the patterns observed in countries with different systems (Kangas and 
Hussain 2014). 
Methodologically, the purpose was to examine the usability of different data sources 
in measuring dimensions of availability and affordability of medicines. 
The more specific aims of the sub-studies were as follows: 
a) Examine the distribution of out-of-pocket costs by income in Finland (Study I) 
b) Examine the distribution of out-of-pocket costs by socioeconomic deprivation 
and ethnicity in New Zealand (Study II). 
c) Assess cost-related access barriers to prescription medicines and health care in 
Finland (Study III). 
d) Compare the range of medicines available and reimbursed in Finland and New 
Zealand (Study IV). 
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4 Materials and methods 
The present thesis comprises four sub-studies summarised in Table 8. 
Table 8. Design and methods of publications (studies I−IV refers to original publications) presented in this
doctoral thesis. 
Study Countries Aims Design Data Time Population 
I Finland To examine out-of­
pocket costs for medi­
cines in Finland 
Cross-sectional 
time series
Household 
Budget
Survey 
1985, 1990, 
1995, 2001, 
2006 
Finnish house­
hold population 
II New 
Zealand 
To explore out-of-pock­
et costs for medicines
among older people in 
New Zealand 
Cross-sectional 
register
Community
pharmacy
dispensing 
data 
2005−2006 65 years and 
older population 
with prescription 
purchases in Te 
Tairāwhiti region 
III Finland To examine cost-related 
barriers to using health 
services and prescrip­
tion medicines in 
Finland 
Cross-sectional 
postal survey 
Population 
based postal 
survey 
2010 Community
dwelling Finnish 
citizens aged 
18−74 
IV Finland 
and New 
Zealand 
To compare the range 
of available and 
reimbursed medicines
in Finland and New 
Zealand 
Cross-sectional 
observational 
Product
information 
sources
2007 Product level 
examination 
4.1 Settings 
4.1.1 Finland and New Zealand – population and population health 
Finland and New Zealand are high-income OECD countries (Appendix). They are 
similar in geographical and population size and in population density. The popula­
tion of New Zealand is slightly younger and ethnically more diverse than Finnish 
population. Between 2002−2009 the GDP per capita in Finland was higher, and in 
New Zealand lower, than the average of the European Union or high-income OECD 
countries. Between 2010−2014, the GDP per capita in New Zealand exceeded the av­
erage of EU or OECD high-income countries, due to more rapid growth (The World 
Bank 2016). Income inequality and poverty rates are slightly higher in New Zealand 
than in Finland. 
In Finland and New Zealand, life expectancy at birth was approximately 81 years in 
2013, and both countries rate above the OECD average (80.5 years) (OECD 2015b). 
Finland has one of the lowest infant and maternal mortality rates in the OECD, to­
gether with other Nordic countries and Japan. New Zealand, ranks at the higher end, 
together with Eastern European countries and the United States. By potential life 
Affordability of medicines from the pharmaceutical system perspective 62 
 
years lost (PYLL) due to any cause of death, both Finland and New Zealand are close 
to the OECD average (Appendix). New Zealanders have more potential years of life 
lost due to neoplasms, endocrine, nutritional and metabolic diseases and diseases of 
respiratory system, whereas Finns have more potential years of life lost due to mental 
and behavioural diseases and diseases of the circulatory system. Smoking rates have 
decreased below the OECD average between 2000 and 2012 in both countries (17% 
in both countries vs. 21% OECD average) while obesity rates have increased. Among 
the 16 OECD countries with measured data, the mean obesity rate was 22.7%. Fin­
land ranked the 13th highest with 20.2% obesity rate and New Zealand the 4th high­
est with 28.4% obesity rate (OECD 2014a; 2014b). 
Both countries are characterised by relatively high health inequalities. In New Zea­
land, indigenous Māori (15% of the population) have a lower life expectancy, higher 
mortality and poorer health outcomes than New Zealanders of European descent 
(Bramley et al. 2005; Elley et al. 2008; Kenealy et al. 2008; Robinson et al. 2016). In 
Finland, studies have shown an increasing trend in relative excess mortality among 
the lowest income groups (Tarkiainen et al. 2013). 
By self-reported health status, Finland and New Zealand have notable response pat­
tern differences. In New Zealand, 94% of the highest income adults and 87% of the 
lowest income adults reported being in good or very good health in 2013. In Finland, 
the respective shares were 77% and 49%. (OECD 2015b.) 
4.1.2 Health care systems in Finland and New Zealand 
The institutional setting of the health care systems in Finland and New Zealand bring 
them closest to the National Health Service (Beveridge) model, although both sys­
tems have traces of other models (Häkkinen and Lehto 2005; Blank and Bureau 2014, 
97). Finland and New Zealand also have similarities in their health political culture, 
both are traditionally characterised by egalitarianism rather than communitarianism 
or individualism (Blank and Burau 2014, 50–54). Both countries are characterised 
by universal coverage and the main source of health care funding is general taxation 
(Häkkinen and Lehto 2005; Blank and Bureau 2014, 97). The majority of services 
are also publicly provided, although in New Zealand, the primary care services have 
traditionally been provided by private practitioners and, until recently, these services 
been subject to particularly high patient payments (Hefford et al. 2005; Häkkinen 
and Lehto 2005; Cumming et al. 2014, 117). The Finnish system has a Bismarckian 
element: a small part of services, including reimbursement for medicines, are funded 
via National Health Insurance (Häkkinen and Lehto 2005). The development of the 
Finnish system has been gradual and characterised by layering and institutional path 
dependency whereas the system in New Zealand has gone through several larger 
structural reforms (French et al. 2001, 105; Häkkinen and Lehto 2005; Mattila 2011, 
342). 
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Development 
A national department of health was set up in New Zealand in 1900, and in 1938, New 
Zealand became the first country to introduce tax-funded National Health Service 
(NHS) with universal coverage (WHO 2000, 12; French et al. 2001, 23). By the end 
of 1940s, most services were provided free of charge, including hospital services and 
medicines. Practitioners remained independent, and were remunerated on fee-for­
service basis, although they also had the right to charge fees from patients. (French et 
al. 2001, 23.) The centrally funded and managed system was gradually decentralised 
during the 1970s and 1980s, first by increasing the autonomy of Hospital Boards and 
later by introduction of regional authorities (14 Area Health Boards). The changes 
resulted from attempts to strengthen the integration of health services and improve 
equitable access, compromised by the increasing patient charges that remunerations 
were not able to compensate. (French et al. 2001, 25; Cumming et al. 2014, 21, 153.) 
In Finland, the legislative basis for primary and secondary health care was set in 
the 1940s, including municipal GPs, mainly financed by patient payments with 
small state subsidies, and universal rights to maternal and child health care services 
(Vuorenkoski et al. 2008, 21–22; Mattila 2011, 67; Niemelä and Saarinen 2015, 14). 
The time period from 1960s to 1980s was characterised by the expansion of the wel­
fare state, which in health care meant fast development and improvements in access 
to and quality of health care services (Niemelä and Saarinen 2015, 16). The National 
Health Insurance was introduced in 1960s, to shift focus from inpatient to outpatient 
care and to improve affordability of care. (Järvelin 2002, 13; Vuorenkoski et al. 2008, 
22; Mattila 2011, 83). The NHI covered part of the costs for medicines and outpa­
tient health services (Häkkinen and Lehto 2005; Vuorenkoski et al. 2008, 21–22). 
The initial level of reimbursement for medicines was 50%, after a fixed deductible, 
but medicines for certain serious and long-term illnesses were reimbursed in full 
(Niemelä 2014, 111). In the beginning of the 1970s, publicly provided local health 
centers were positioned as the main providers of primary care services in Finland 
(Häkkinen and Lehto, 2005; Vuorenkoski et al. 2008, 22; Niemelä and Saarinen 2015, 
17). In 1979, employers were obliged to arrange occupational preventive health care 
services, which were later extended to curative services through labour market agree­
ments (Vuorenkoski et al. 2008, 22; Niemelä and Saarinen 2015, 18). 
In the 1980s and 1990s, health care systems worldwide were faced with sustainability 
issues, influenced by the global economic circumstances together with technological 
development, rising expectations and population ageing. At the same time, an ide­
ological shift towards neo-liberalism shaped the political atmosphere and changed 
political foci from access and quality to productivity, cost containment and consum­
erism. Reforms influenced by the New Public Management (NPM) -approach aimed 
to increase efficiency by applying private sector management models to public sector. 
(Häkkinen and Lehto, 2005; Vuorenkoski et al. 2008, 123; Blank and Burau 2014, 117; 
Lehto et al. 2015; Niemelä and Saarinen 2015, 21.) The development of health tech­
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nologies and pharmaceutical treatments facilitated deinstitutionalisation, i.e. shifting 
focus from inpatient and institutional care to outpatient services (Vuorenkoski et al. 
2008, 123; Lehto et al. 2015). 
In Finland, the deregulation and decentralisation reforms were implemented in the 
1990s, at the same time when Finland was impacted by a deep economic recession 
(Häkkinen and Lehto 2005; Vuorenkoski et al. 2008, 25; Niemelä and Saarinen 2015, 
19). The state subsidy reform (1993), which strengthened the responsibility and au­
tonomy of the municipalities in organising and funding health care, coincided with 
deinstitutionalisation and several cuts and cost-shifting measures: re-introduction of 
user charges to municipal health care services, abolishing health-related tax refunds 
and raising patient co-payments for medicines, dental care and long-term care. The 
state subsidies were previously paid to providers based on delivered care but after 
1993, the subsidies were calculated based on population need and paid directly to 
municipalities. Municipalities were also permitted to purchase services from private 
providers. (Martikainen et al. 1999; Järvelin 2002, 14; Lehto et al. 2015; Niemelä and 
Saarinen 2015, 19; Ruskoaho 2016, 27.) The Act on Specialised Medical Care in 1991 
led to the introduction of current hospital districts, owned by municipalities or feder­
ations of municipalities (Vuorenkoski et al. 2008, 25). In 1994, Finland joined the Eu­
ropean Union (EU) and signed the Agreement on European Economic Area (EEA). 
The reforms in New Zealand in the 1990s aimed to further improve access to health 
care, and to improve system efficiency (French et al. 2001, 26). The 1993 reform in­
troduced a quasi-market model (referred to as purchase/provider split), where own­
ership, purchasing and provision were separated (French et al. 2001, 26). The Crown 
remained the owner, but financing was decentralised to four regional authorities. 
These authorities were given a budget to purchase services for their residents from 
public and private providers. (French et al. 2001, 27; Cumming et al. 2014, 23.) The 
14 Area Health Boards were transformed into 23 Crown Health Enterprises, which 
were expected to run hospital and health care services as commercial units, and to 
make a surplus (Cumming et al. 2014, 23). The experiment was highly unpopular 
among health professionals and the public, and the dissatisfaction, together with fail­
ure to reach the original objectives of the reform soon led to a series of readjustments. 
(Blank and Burau 2014, 54; Cumming et al. 2014, 160–164.) Between 1996 and 1999 
the four regional authorities were replaced by one purchasing agency, the Health 
Funding Authority, and the Crown Health Enterprises became Hospital and Health 
Services, which continued to operate hospitals and other services but were no longer 
expected to make profit (Cumming et al. 2014, 165). A shift back towards a non-com­
mercial model of health care begun in 1999, which led to another structural reform of 
the health care sector implemented in the 2000s (Cumming et al. 2014, 166). 
The establishment of the Pharmaceutical Management Agency (PHARMAC) has 
been seen as one of the advantages of the 1990s reforms (Cumming et al. 2014, 23). 
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PHARMAC was first established in 1993 to develop new strategies to control phar­
maceutical expenditure. In the following reforms, PHARMAC first became a non­
profit company and later in 2000, a separate Crown agency (French et al. 2001, 98). 
PHARMACs strategies are reviewed in more detail in Chapter 4.1.3. 
In the 2000s, emphasis has been placed on health care performance through integra­
tion, increasing the role of primary care, system responsiveness and inequalities in 
health. In Finland, responsiveness has been addressed mainly by increasing freedom 
of choice and in New Zealand, by the more active involvement of communities and 
consumers. Both countries have also attempted to shorten waiting times. (Cumming 
et al. 2014, 166, 167, 187, 179; Niemelä and Saarinen 2015, 22–25.) Nevertheless, 
efficiency and cost containment continue to be on the agenda in both countries, es­
pecially since the beginning of the global financial crisis in 2008 (Ministry of Social 
Affairs and Health 2012; Cumming et al. 2014, 7, 176). Both countries have also in­
creased national coordination and steering and addressed inefficiencies related to 
decentralisation by attempts to reduce the number of local administrations (Blank 
and Burau 2014, 97; Cumming et al. 2014, 24, 166, 177; Lehto et al. 2015; Niemelä 
and Saarinen 2015, 14). 
In the beginning on 2000s, New Zealand ended the purchaser/provider spilt and re­
turned to regional governance by establishing 21 District Health Boards (DHBs) (20 
since 2010) that became responsible for purchasing and providing primary, second­
ary and tertiary health services, as well as aged care services, with population-based 
funding (French et al. 2001, 31; Cumming et al. 2014, 153, 167). In 2001, a new strat­
egy for primary care was released based on rising concerns over access to primary 
health care, inequalities in health and pressures on inpatient care (Cumming et al. 
2014, 183). At the time, primary care services were mainly funded by co-payments 
(60%), which, together with strong gatekeeping, were thought to increase inequal­
ities in access and health. Government subsidies for primary care, which in most 
cases covered less than half of the costs, were limited to children, certain beneficiar­
ies, individuals with low-income and high users of health care. (Hefford et al. 2005.) 
Since 2002, local non-profit structures, Primary Health Organisations (PHO), have 
been funded by DHBs to coordinate health care services (Cumming et al. 2014, 36). 
Membership of a Primary Health Organisation (PHO) was voluntary for both prac­
titioners and patients but it meant switching to more generous capitation-based gov­
ernment funding (Hefford et al. 2005). In 2004, PHOs covered approximately three 
quarters of the population and in 2009, 95% (Commonwealth Fund 2010a; Cum­
ming et al. 2014, 36). However, GPs continued to have the right to set co-payments 
for patients, although the fees are reviewed by DHBs. PHO enrolees also had reduced 
co-payments for reimbursed prescription medicines (from NZ$15 to NZ$3) since 
2004. In 2008 lowered co-payment (NZ$3) were extended to most prescriptions, and 
in 2013, this standard co-payment was raised to NZ$5. (Hefford et al. 2005; Cum­
ming et al. 2014, 66, 70, 170.) 
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In 2008, attempts to increase coordination and integration led to the establishment 
of the National Health Board (NHB), with responsibility for funding and planning 
national health services, and the Shared Service Agency, to reduce duplication and 
the administrative work of the DHBs by offering support services. Merges of PHOs 
and DHBs are encouraged, to improve system efficiency (Blank and Burau 2014, 97; 
Cumming et al. 2014, 153). 
In Finland, no major health care reforms have been implemented in the 2000s, al­
though the planning of a major structural reform of health care and social services 
has been ongoing for most of the time period (Vuorenkoski et al. 2008, 123; Lehto 
et al. 2015; Niemelä and Saarinen 2015, 22–26). Since 2005, the municipalities have 
been encouraged to merge and form larger units, to increase productivity, coordi­
nation and freedom of choice (Mattila 2011, 241; Niemelä and Saarinen 2015, 22). 
Smaller legislative changes included a statutory care guarantee, implemented in 2005, 
to shorten waiting times and increase equity. Since 2009, municipalities have had the 
possibility to offer vouchers for patients, to purchase services from private provides, 
and in 2011, patients’ rights to choose between public service providers were extend­
ed. (Mattila 2011, 230–241, 245; Niemelä and Saarinen 2015, 22–23). Reimburse­
ments for medicines, as well as other benefits under the National Health Insurance 
have been subject to continuous savings measures (Ministry of Social Affairs and 
Health 2011; Ruskoaho 2016, 27–29). Cost containment measures in the pharmaceu­
tical sector were focused on both the supply and demand side, and included imple­
mentations of mandatory generic substitution by pharmacists in 2003 and an internal 
generic reference price system in 2009. Savings were sought in 2006 and 2013 by 
statutory price cuts for reimbursable products and by adjustments and increases to 
patients’ share of costs in 2003, 2006 and 2013. (Ruskoaho 2016, 27–29). 
Organisation 
In Finland, the main responsibility for ensuring basic health services lies with the 
municipalities. Municipalities have elected councils and a right to collect taxes (Vuo­
renkoski et al. 2008). Municipalities also receive state subsidies based on the charac­
teristics of the residing population. The government steers the health care system at a 
general level, by legislation and financing. Health care policy is mainly the field of the 
Ministry of Social Affairs and Health. Primary health care services are delivered from 
health centres provided by individual municipalities or joint municipal boards. Mu­
nicipalities may also purchase health care services from other municipalities, non­
governmental organisations or the private sector. Municipalities fund and manage 
secondary care services, through federations of municipalities, i.e. hospital districts. 
All hospital districts have a central hospital, some of which are university-level teach­
ing hospitals. (Vuorenkoski et al. 2008; Peura et al. 2011.) 
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Part of the health care services, e.g. reimbursements for outpatient medicines, sick­
ness allowances and reimbursements for rehabilitation services, are financed through 
the statutory National Health Insurance (NHI). The NHI is administered by the So­
cial Insurance Institution (Kela), operating directly under the Parliament. The NHI 
is financed by statutory contributions from the insured, employers, and with funding 
from the state (Kela 2015). The NHI also reimburses part of the cost of private health 
care services, including specialist visits, to patients. Alongside municipal health care, 
the occupational health service system covers the majority of the working popula­
tion. Occupational health care is financed by employers, employees and the state. 
(Vuorenkoski et al. 2008; Peura et al. 2011.) 
In New Zealand, the Ministry of Health (MOH) has the overall responsibility for the 
health care system. Public health care is mainly financed by general taxation with the 
Accident Compensation Corporation (ACC) as the second largest source of govern­
ment funding. The ACC is an insurance scheme arranged by the state and funded 
through employer, employee and car-licensing levies. District Health Boards (DHB) 
are responsible for planning and funding health care services in their geographical 
area. DHBs are crown agents governed by DHB boards with both elected and MOH 
appointed members. DHBs are funded by the MOH based on a population-based 
formula. Primary health care is coordinated through Primary Health Organisations 
(PHO) with capitation (population needs) based funding from the DHBs. PHOs are 
non-profit-organisations that contract general practitioners (GP) and other for-profit 
or non-profit providers. Patients are free to choose their GPs. Specialist care is pro­
vided in public or private clinics and hospital outpatient departments. Public inpa­
tient and outpatient hospital services are provided by public hospitals that can be 
owned or funded by the DHBs. Primary health care and health promotion services 
are also offered by Māori and Pacific health providers. (Cumming et al. 2014.) 
Health expenditure and health care utilisation 
The total per capita health expenditure in New Zealand was almost the same as that 
in Finland in 2013, and both countries ranked just below the OECD average (USD 
PPP 3,453) (Appendix). In the previous years, growth was faster in New Zealand 
during 2005−2009 and in Finland during 2009−2013. The public per capita spend­
ing on health was higher in New Zealand than in Finland, and in both countries, it 
was higher than on average among OECD countries. The public share of health care 
financing is higher and the private out-of-pocket share lower in New Zealand than in 
Finland. In New Zealand, health expenditure made up 22% of the total government 
expenditure in 2013, which was the highest share among OECD countries. In Fin­
land, the respective share was 11%. (OECD 2015b.) Private insurance accounted for 
2% of total health care financing in Finland and 5% in New Zealand. 
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On average, New Zealanders consult doctors more often than Finns, but both coun­
tries rank in the lower end in the number of doctor consultations among OECD 
countries (OECD 2015b) (Appendix). According to international comparisons, Fin­
land has slightly larger income-related inequities in visits to doctor (OECD 2011a, 
138–139). By hospital discharge rate, New Zealand ranks below average and Finland 
above average. By the average length of stay (ALOS) and waiting times for elective 
surgery, New Zealand performs slightly better. However, waiting times for revascu­
larisation procedures were shorter in Finland. (Appendix.) 
Pharmaceutical expenditure 
No recent directly comparable data of total pharmaceutical expenditure is publicly 
available for New Zealand. The latest OECD data of spending on medical goods is 
from 2007 (Appendix). At that time, the per capita total and out-of-pocket spending 
for prescription medicines and OTC medicines were lower in New Zealand than in 
Finland. More recent figures are only available for pharmaceutical sales, however the 
Finnish and New Zealand data are not comparable (OECD 2015c). The data from 
New Zealand (ex-manufacturer prices) exclude the share of costs paid by the patients 
as well as hospital medicines and non-reimbursed prescription medicines. The Finn­
ish data (wholesale prices) include all pharmaceuticals used in hospitals as well as 
reimbursed and non-reimbursed prescription medicines and OTC-medicines. Nev­
ertheless, growth seems slower in New Zealand, as between 2000 and 2013 the per 
capita total pharmaceutical sales increased 1.8-fold in Finland and 1.5-fold in New 
Zealand. The generic share of the pharmaceutical market, both in value and volume, 
seems notably larger in New Zealand. 
Household spending on health 
Although national Household Economic/Budget Survey results are not directly 
comparable, they support the assumption of lower out-of-pocket contributions in 
New Zealand, for both health care and pharmaceuticals (Table 9, p.  69). Calculated 
from weekly expenditures, New Zealand households used 0.6% of their household 
total spending on pharmaceutical products and 2.4−2.5% on health in 2007−2013 
(Statistics New Zealand 2016). In Finland, calculated from annual expenditures in 
2006−2012, households used on average 1.4−1.2% of their total spending on pharma­
ceutical products and 3.5−3.2% on health (Statistics Finland 2016c). Pharmaceutical 
products accounted for 25% of total household health spending in New Zealand and 
39−40% in Finland. According to OECD Health data 2015, the out-of-pocket medi­
cal spending as a share of final household consumption in 2013 (or nearest year) was 
2.9% in Finland, 2.2% in New Zealand and 2.8% on average in the OECD countries 
(OECD 2015b). 
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Table 9. Household expenditures for health and pharmaceuticals according to national Household Bud­
get/Economic Survey results in Finland and New Zealand. 
Country Household expenditure (annual/weekly) 
FI 2006/ 
NZ 2007 2010 
FI 2012/ 
NZ 2013 Source 
Finland 
Euros per year 
Total, euros 30,275 35,770 HBSa 
Health, euros 1,053 1,130 HBS 
Health, % of total 3.5% 3.2% * 
Pharmaceutical products, euros 418 442 HBS 
Pharmaceutical products, % of total 1.4% 1.2 % * 
Pharmaceutical products, % of health 39.7% 39.1 % * 
New Zealand 
NZD per week 
Total, NZD 966.1 1,021.3 1,110.1 HESb 
Health, NZD 23.9 24.4 27.2 HES 
Health, % of total 2.5% 2.4% 2.5% * 
Pharmaceutical products, NZD 5.9 6.1 6.9 HES 
Pharmaceutical products, % of total 0.6% 0.6% 0.6% * 
Pharmaceutical products, % of health 24.7% 25.0% 25.4% * 
a HBS: Household Budget Sur vey (Statistics Finland 2016c); b HE S: Household Economic Sur vey (Statistics New Zealand 2016). 
* Calculated by the author. 
4.1.3 Pharmaceutical systems in Finland and New Zealand 
Both Finland and New Zealand have centralised pharmaceutical systems, with Min­
istry of Social Affairs and Health (MSAH, in Finland) and Ministry of Health (MOH, 
in New Zealand) holding the overall responsibility. Both countries have separate in­
stitutions in charge of regulation, marketing authorisations and vigilance: the Finn­
ish Medical Agency (Fimea, formerly: National Agency for Medicines) and the New 
Zealand Medicines and Medical Devices Safety Authority (Medsafe). (Peura et al. 
2011; Cumming et al. 2014.) In Finland, pharmaceuticals brought to the market can 
be authorised by Fimea, though national, mutual recognition or decentralised proce­
dures, or by the European Medicinal Agency (EMA), through centralised procedure 
(Directive 2001/83/EC; Peura et al. 2011). In New Zealand, a national pre-marketing 
approval from Medsafe is required for all pharmaceuticals (Cumming et al. 2014). 
In 2006, the number of pharmaceutical companies operating in Finland was 64 and 
pharmaceutical industry employed approximately 6,700 persons. (Peura et al. 2011). 
Most pharmaceutical products are imported into New Zealand, with a small amount 
of local production (Cumming et al. 2014). 
Product reimbursement status and price are assessed and decided on the national 
level in both countries: In Finland, by the Pharmaceutical Pricing Board (PPB), op­
erating under the MSAH, and in New Zealand, by the Pharmaceutical Management 
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Agency (PHARMAC), a separate Crown Agency (Grocott 2009; Peura et al. 2011; 
Babar 2015). In Finland, reimbursements for medicines are benefits administered 
under the National Health Insurance. The NHI medical care insurance component 
is funded by contributions from employees and the state. (Health Insurance Act 
1224/2004.) In New Zealand, PHARMAC manages the capped national pharmaceu­
tical budget on behalf of the DHBs and acts as a monopsony purchaser of reimbursed 
medicines (Cumming et al. 2014, 28; Babar 2015). PHARMAC also negotiates the 
purchase of medicines directly with the companies (Grocott 2009; Cumming et al. 
2014, 28; Babar 2015). The reimbursement process is generally initiated by an appli­
cation from the holder of the marketing authorisation in both countries, but in New 
Zealand also e.g. doctors, patients or interest groups can make applications (Health 
Insurance Act 1224/2004; PHARMAC 2015, 10). 
In Finland, the diseases attached to higher reimbursements are regulated by govern­
ment decree. The PPB makes product-level decisions on the level and conditions of 
reimbursements and Kela makes patient-level decisions on eligibilities to disease­
based and restricted reimbursements. Restricted reimbursement by prior authorisa­
tion (needs-test) applies to particularly expensive treatments. (Health Insurance Act 
1224/2004.) In New Zealand, the PHARMAC Board makes decisions on the listing of 
products on the positive list called the Pharmaceutical Schedule, the reimbursement 
levels, prescribing guidelines and conditions (Cumming et al. 2014, 28; PHARMAC 
2015, 16). PHARMAC also makes patient-level decisions on eligibility to restricted 
reimbursements and based on exceptional circumstances. Restricted reimbursement, 
under Special Authority scheme, by prior authorisation (needs-test) applies to many 
second- or third-line treatments, especially newer and more expensive treatment al­
ternatives. (PHARMAC 2004−2010.) 
The criteria for price and reimbursement assessment derive in Finland from the 
Health Insurance Act (1224/2004), based on which products that are indicated for 
treatment or relieving of an illness or its symptoms are reimbursable. Price evaluation 
criteria include therapeutic value, comparison to other treatments, sales estimate, 
cost-effectiveness and prices in other EEA-countries. PHARMAC decision criteria 
include the health needs of all eligible people within New Zealand and the particular 
needs of Māori and Pacific people, other available therapeutic options, clinical ben­
efits and risks, cost-effectiveness, budgetary impact, costs to users and the Govern­
ment’s priorities. (PHARMAC 2004−2010; PHARMAC 2015, 15). Proposals undergo 
a cost-utility analysis, usually conducted by PHARMAC, and the focus is strongly on 
relative cost-effectiveness. Any funding decision is weighted against other possible 
reimbursable medicines or extending reimbursements to new patient groups. Pro­
gramme Budgeting Marginal Analysis is used to maximise health gains with consid­
eration of the opportunity costs. (Braae et al. 1999; Grocott 2009; Babar 2015.) 
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In both countries, price regulation applies to reimbursed products only, and non­
reimbursed products are under free pricing. Finnish pharmacies are remunerated 
via a statutory regressive mark-up scheme based on the approved wholesale price or 
pharmacy purchase price. Pharmaceutical cost-containment policies include manda­
tory generic substitution by pharmacists and generic reference pricing. (Peura et al. 
2011.) In New Zealand, the manufacturers are able to set their own prices to phar­
macies. When this price exceeds PHARMAC reimbursement, the difference – called 
Manufacturer’s surcharge − is paid in full by the patient. The reimbursement is paid 
to pharmacies, supplemented with a dispensing and distribution service fee. PHAR­
MAC aims to fully reimburse at least one pharmaceutical in each therapeutic group 
(PHARMAC 2004−2010). PHARMAC uses several strategies to influence prices, 
including generic and therapeutic reference pricing, tendering (with sole supplier 
agreements), risk-sharing agreements (e.g. rebates) and multiproduct agreements 
(PHARMAC 2006; Grocott 2009; Ragupathy et al. 2012). Due to the complex ar­
rangements between PHARMAC and pharmaceutical companies, as well as rebates, 
the actual prices paid for pharmaceutical products are not publicly available. (PHAR­
MAC 2004−2010; OECD 2015c.) 
In both Finland and New Zealand, all residents are eligible for reimbursed medicines 
(Health Insurance Act 1224/2004; Ragupathy et al. 2012). In Finland, reimbursement 
eligibility is disease-specific, i.e. the reimbursements for medicines are differentiated 
by disease severity and one pharmaceutical may be reimbursed at different rates for 
different medical conditions (Peura et al. 2011). No population group-specific eligi­
bilities were applied to medicines, e.g. based on age or income, before 2016. Munici­
pal social assistance acts as a means-tested last resort minimum income assistance 
resource (Vuorenkoski et al. 2008). In New Zealand, reimbursement eligibility is 
product-specific, i.e. eligibility is considered based on an evaluation of different as­
pects of the pharmaceutical product and is population group-specific, i.e. children are 
eligible to exemptions and reductions in payments. (PHARMAC 2004−2010.) In Fin­
land, cost-sharing for medicines is a mix of deductibles, fixed co-payments and co­
insurances, the level of which are regulated by the Health Insurance Act (1224/2004). 
In New Zealand cost-sharing applies to most purchased medicines and prescription 
charges are regulated by the government (Norris et al. 2011a; PHARMAC 2017). 
4.1.4 Reimbursement schemes for pharmaceuticals at the time of Studies I–IV
(2005−2010) in Finland and New Zealand 
In Finland, prior 2006, three reimbursement rates applied: 100% for vital medicines, 
75% for chronic and severe conditions and 50% for other medicines on the posi­
tive list. A deductible applied to each purchase (€5−10 in total for all items) but no 
co-payments applied after exceeding the annual ceiling. In 2006, deductibles were 
abolished, and instead, fixed co-payments were implemented to 100% reimbursed 
medicines (€3/item/purchase, max 3 months) and to medicines purchased after ex­
ceeding the annual ceiling (€1.50/item/purchase, max 3 months). At the same time, 
Affordability of medicines from the pharmaceutical system perspective 72 
 
 
  
 
  
reimbursement rates were decreased from 75% to 72% and from 50% to 42%. (Kela 
2014.) The annual ceiling was based on individual patient’s cumulative co-payment 
expenditure for reimbursed medicines. The level of the annual ceiling is index-linked 
(€616.72 in 2006). 
In New Zealand, the level of prescription charge depended on the prescriber, phar­
macy, patient’s age and concession mechanisms. For fully reimbursed products, pa­
tients paid a fixed prescription charge. For partly reimbursed products, patients paid 
the applicable prescription charge plus the manufacturer’s surcharge. The annual ceil­
ing is based on the number of prescription items for the family, and after 20 prescrip­
tion items per year, the prescription charge is lowered (to $2) or waived. In 2005, the 
maximum prescription charge for adults not enrolled to a low-cost PHO and without 
concession cards was $15 per three month’s course, $10 to children aged 6−17 and 
$0 to children under the age of 6. However, a $3 prescription charge applied to low­
cost PHO enrolees, high-need Care-plus -patients, and people with certain types of 
concession cards (Community Services Card, High Use Health Card). (PHARMAC 
2004−2010.) In September 2008, the $3 co-payment was extended to all people eli­
gible to publicly funded health care and to most prescriptions, e.g. all prescriptions 
from prescribers (incl. specialists, dentists, midwives) employed by a public hospital 
or with a District Health Board (DHB) or a PHO contract (PHARMAC 2004−2010). 
4.2 Studies I−IV 
4.2.1 Trends and income related differences in out-of-pocket costs for medicines in 
Finland (I) 
Out-of-pocket costs for medicines in Finland were assessed by using Household 
Budget Survey (HBS) data. HBS is an EU-harmonised survey, conducted in all EU 
member states with the primary aim to calculate weights for the Consumer Price 
Index. HBS is also used in determining the consumption of the household sector in 
the National Accounts and the official statistics on Household’s Consumption are
composed based on HBS data (Statistics Finland 2014b; 2016a). In Finland, Statistics 
Finland has conducted HBSs periodically since 1966. Eurostat, the Statistical Office 
of the European Communities, provides guidelines to achieve better international 
comparability. The concepts, definitions and classifications are harmonised but the 
methodologies for e.g. data collection may vary by country. (Statistics Finland 2009; 
2014a; 2016a; Eurostat 2016c.) 
Sampling unit: The target population of Statistic Finland’s HBS was the Finnish house­
hold population, which comprised private households permanently resident in Fin­
land, excluding institutionalised persons (e.g. in care institutions, prisons and hospi­
tals). The basic sampling frame for HBS was the population database. Stratified (by 
area of residence) probability sampling was used with community dwelling Finnish 
residents aged 15 years or older as the sampling unit. Dwelling-unit members were 
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linked to the selected persons based on registers. The household was further defined 
at the beginning of the interview as consisting of persons who shared meals, lived 
together and used their income together. (Statistics Finland 2009; 2014a; 2016b.) In 
this study, cross-sectional, comparable HBS data from 1985, 1990, 1995 (combined 
from 1994, 1995, 1996), 2001 and 2006 were used (Table 10). 
Table 10. Sampling in Statistics Finland’s Household Budget Surveys used in Study I. 
1985 1990 1995a 2001 2006 
Gross sample, N 12,174 12,053 10,608 8,960 7,852 
Ineligibleb, N 398 297 237 167 194 
Net sample, N (%) 11,776 (100%) 11,756 (100%) 10,371 (100%) 8,793 (100%) 7,658 (100%) 
Total non-response, N (%) 3,756 (30.4%) 3,498 (29.8%) 3,628 (35.0%) 3,298 (37.5%) 3,651 (47.7%) 
Final sample, N (%, 
response rate) 8,200 (69.6%) 8,258 (70.2%) 6,743 (65.0%) 5,495 (62.5%) 4,007 (52.3%) 
a Combined from data collected in 1994, 1995 and 1996, b Due to e.g. death, becoming institutionalised or emigration. 
Source: Statistics F inland 2009. 
Measurements: The household’s background data, e.g. on ownership and purchasing 
of durable goods, and residential costs, were collected with interviews (face-to-face 
or telephone). After the interview, the households kept a diary about their consump­
tion expenditure and retained receipts on their purchases for two weeks. Annual con­
sumption expenditures were based on aggregated consumption data from the two­
week collection periods, distributed throughout the year. Consumption was divided 
in approximately 900 categories based on the Classification of Individual Consump­
tion According to Purpose (COICOP-HBS) nomenclature. Further background data 
were retrieved from administrative registers, e.g. the population register, tax register, 
social security registers. (Statistics Finland 2009; 2014a; 2016a.) 
The main explanatory variable in the analyses was annual out-of-pocket costs for 
medicines. The classification of medicine expenditure in the Finnish HBSs was more 
detailed than in the original COICOP-HBS by Eurostat. In this study, two expendi­
ture variables were used to calculate total out-of-pocket costs: prescription medicines 
(Statistic Finland code A0611101, COICOP-HBS code 06.1.1.) and OTC medicines 
(Statistic Finland code A0611102, COICOP-HBS code 06.1.1.). Excluded were costs 
for preparations with vitamins and trace elements (Statistic Finland code A0611103), 
as well as natural and herbal products (Statistic Finland code A0611104). All prices 
were adjusted for inflation to 2006 currency value using the Cost of Living Index 
(Statistics Finland 2006). 
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Independent variables in the analyses were total annual disposable household income 
and household actual total consumption. the age of the reference person was used as 
a covariate. The reference person was the person with the highest personal income. 
The total annual disposable household income consisted of total income (employee 
or self-employment income + capital income + current transfers received) after de­
duction of current transfers paid, as defined by the Expert group on Household In­
come Statistics (2011). In the Finnish context, current transfers paid consisted of, e.g. 
direct taxes, social security contributions, compulsory pension, and unemployment 
insurance premiums. Current transfers received consisted of, e.g. pensions, social se­
curity benefits and social allowance (Statistics Finland 2012). To standardise the size 
and age differences of households, incomes were divided by the number of consump­
tion units – i.e. household equivalents – in the household. The equivalence scale used 
was the modified OECD scale: 
m = 1 + a (A−1) + b C 
in which A is the number of adults and C the number of children in the household. 
The parameter a has a weight of 0.5 and the parameter b a weight of 0.3 (OECD 
2011b). For the current study, the households were divided into five income quintiles 
based on household total annual disposable income. Each income quintile contained 
an equal number of household equivalents. 
Household actual total consumption, according to European System of Accounts 
1995 framework definition ESA 95, 3.82, consists of “Goods and services for individ­
ual consumption (‘individual goods and services’) that are acquired by a household 
and used to satisfy the needs and wants of members of that household. Individual 
goods and services have the following characteristics: a) It must be possible to ob­
serve and record the acquisition of the good or services by an individual household 
or member thereof and also the time at which it took place; b) the household must 
have agreed to the provision of the good or service and take whatever action is nec­
essary to make it possible, for example by attending a school or clinic; c) the goods 
or service must be such that its acquisition by one household or person, or possibly 
by a small, restricted group of persons, precludes its acquisition by other households 
or persons.” Thus, services for collective consumption (such as national defence, the 
usage of public infrastructures or public broadcasting) are excluded. (Eurostat 2003.) 
Statistical analyses: Mean out-of-pocket costs for medicines and their share of to­
tal consumption were calculated for each study year. Separate analysis of covariance 
(ANCOVA) with general linear model (GLM) procedure was conducted for each 
year and for different types of medicines, in order to examine the variation of out-of­
pocket costs and their share of total consumption between income quintiles with the 
age of the reference person as a covariate. Age-adjusted marginal means estimates 
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for household out-of-pocket costs by income quintile for medicines were derived in 
total, for prescription medicines and for over-the-counter medicines. Test of main 
effect of income quintile was used, and differences at p < 0.05 level were considered 
as statistically significant. The interaction effect between age and income group was 
significant only for prescription medicines and all medicines in 1990 and therefore it 
was excluded from the main analyses. All statistical analyses were performed using 
Predictive Analytics Software (PASW) version 18. 
Aggregating the consumption data to annual level, as well as weighting and calibra­
tion as means to correct for non-response and sampling errors were conducted previ­
ously by Statistics Finland (2009). 
4.2.2 Distribution of out-of-pocket costs for medicines among community dwelling older
people in New Zealand (II) 
The distribution of out-of-pocket costs for medicines among community dwelling 
older people was assessed by using data from a previously collected dataset for a larg­
er study project – The Equity in Prescription Medicine Use Study (EIPMU) (Hors­
burgh et al. 2010; Norris et al. 2011a; 2011b; 2014). For the EIPMU-study, pharmacy 
dispensing data were collected in the Te Tairāwhiti region of New Zealand (1% of the 
New Zealand population). 
The EIPMU-study was granted an ethical approval by a New Zealand Ministry of 
Health accredited ethics committee (Ethics approval NTX/06/09/111). 
EIPMU-dataset: In the EIPMU-study, electronic records were collected from all eight 
community pharmacies in Gisborne for the period from 1 October 2005 to 30 Sep­
tember 2006 (Horsburgh et al. 2010). Records of outpatient dispensings were also 
obtained from the hospital pharmacy. The pharmacy records included information 
on patient demographics (name, date of birth, gender, address and health system 
identifier), the dispensed medicine (brand and generic name, quantity, strength, 
product specific pharmacode) and costs (patient payment, reimbursement, fees as­
sociated with the dispensing, concessions applied). For each purchase with sufficient 
information, Anatomical Therapeutic Chemical (ATC, WHO CC for Drug Statistics 
Methodology 2008) codes were linked and the dispensed quantity was calculated in 
Defined Daily Doses (DDDs). Probabilistic matching methods, using an individual’s 
full name, date of birth, gender and health identifier (if recorded), were used to link 
records belonging to the same individual across pharmacies. Information of indi­
vidual’s age and gender were primarily obtained from the pharmacy records and if 
they were not present, from the central repository. Information on ethnicity derived 
solely from the central repository. Socioeconomic deprivation was derived from pa­
tient address in the database, which had been matched with an area measure of rela­
tive socio-economic deprivation, NZDep2006. (Horsburgh et al. 2010.) NZDep2006 
is a widely used, previously validated small area measure of material socioeconomic 
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deprivation, which combines variables from the New Zealand Census into a single 
measure of deprivation. (Salmond et al. 2002; 2007). 
Population: For the present study, records for individuals aged 65 years or older 
(N = 5,217) were extracted from the previously created EIPMU-dataset described 
above. The dataset encompassed nearly all residents of the area, since in Census 2006, 
the total ≥ 65 year-old population count (end of year) in the Te Tairāwhiti region was 
5,346 (Statistics New Zealand 2006). In the study population, 23% (N = 1,155) were 
Māori and 77% (N = 3,864) were non-Māori. Māori were on average younger than 
non-Māori (mean age 73 vs. 76 years) and they were more likely to be living in non­
urban (36% vs. 11%) and the most deprived (77% vs. 42%) areas. 
Variables: The main explanatory variable was out-of-pocket costs. These were defined 
as the total amount paid by the patients for all their prescription items, including fees 
(e.g. for safety cap [pharmacists are required to use safety caps with specific medi­
cines, and these are also reimbursed], after hours, phone and fax, dose packs) and 
adjustments. High out-of-pocket costs were defined as costs exceeding the 90th per­
centile of the annual out-of-pocket costs in the study population (NZ$217.50). Other 
explanatory variables were reimbursements and medicine use. Reimbursements were 
calculated from the pharmacy dispensing database excluding purchases extracted 
from pharmacy software Galen, which did not contain reimbursement information 
(0.3% of all purchases). Medicine use was defined as the number of distinct medi­
cines, i.e. distinct ATCs at level 5, used per person per year and as the quantity of 
purchased medicines, i.e. the number of dispensed DDDs per person per year. 
The main independent variable was ethnicity (indigenous Māori/non-Māori). Other 
independent variables used were age, gender, area of residence and socioeconomic 
deprivation by NZDep2006. Area of residence was classified as urban or non-urban 
(including rural or mixed area). 
Statistical analyses: Distribution of costs, reimbursements and medicine use were as­
sessed using descriptive statistics and by comparing the top 1%, 5%, 10%, 25%, 50% 
and bottom 50% spenders ranked by their total annual out-of-pocket costs. Further 
examination was conducted by ethnicity, while adjusting for differences in age struc­
tures by direct standardisation. 
Multivariate logistic regression was used to compute odds ratios (ORs) and 95% con­
fidence intervals (CIs) for characteristics associated with high out-of-pocket costs. 
Logistic regression was used, since out-of-pocket costs have a strongly right-skewed 
distribution, with a multitude of observations for a specific value. The first model 
included sociodemographic covariates (age, gender, deprivation index and area of 
residence), and in the second model the number of used medicines (distinct ATCs) 
was added. The chi-squared test was used for the bivariate associations. Differences at 
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p < 0.05 level were considered as statistically significant. All statistical analyses were 
performed using SAS software version 9.2 (SAS Institute Inc., Cary, North Carolina). 
All prices are in New Zealand dollars (NZ$), 2006 currency value. In relation to $US, 
the $NZ exchange rate in 2006 was 0.6132 (Mid-rate 31 March 2006, Reserve Bank 
of New Zealand). 
4.2.3 Cost-related barriers to prescription medicines and health care in Finland (III) 
Cost-related access barriers to medicines and health care were assessed by using na­
tional cross-sectional postal survey data, previously conducted in 2010 by the Social 
Insurance Institution of Finland. The original purpose of the survey was to assess 
adults’ experiences of and opinions about the social security system. People’s eco­
nomic problems and the solutions they found, their health, social relations and wel­
fare deficiencies were among the topics investigated in the study. (Airio 2013.) 
Data: A total of 5,000 community dwelling Finnish- or Swedish-speaking Finnish 
citizens aged 18−74 years were randomly selected from the national population reg­
ister. The sampling frame included 3,633,643 individuals. The questionnaire was ad­
ministered in Finnish and in Swedish. The final response rate was 35% (n = 1,770) 
after three reminders. All information was derived from the survey and was based on 
self-report. 
Participants were asked whether they encountered cost-related access barriers by the 
following questions, each with five response options (i) No, ii) Once, iii) A few times, 
iv) Often, v) Repeatedly): “In the past year, have you or a member of your household 
experienced any of the following situations? a) You did not go to a hospital visit be­
cause you didn’t have the money; b) You did not fill a prescription due to cost; c) You 
also went without a treatment that was recommended by a doctor because you didn’t 
have the money.”
Receipt of social assistance and other social benefits was measured by a multiple re­
sponse question: “In the past year, have you or a member of your household received 
any of the following benefits? (Select all appropriate options)”. Social assistance was 
listed among 19 other options. Applying for social assistance was investigated us­
ing the follow-up question: “How have you tried to solve the financial problems you 
indicated in the previous question? (If you did not indicate any financial problems, 
please move to the next question)”. Applying for social assistance was listed among 
12 other pre-defined coping strategies with four options (i) No, ii) Once, iii) A few 
times, iv) Repeatedly). 
Variables: The main explanatory variables were cost-related barriers to access to 
hospital, medicines or other treatments. For the bivariate and multivariate analyses, 
the responses were dichotomised into once or more vs. not at all. A dichotomous 
composite variable of having encountered at least one of the aforementioned access 
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barriers vs. none was also formed. Applying for and receiving social assistance were 
used as secondary outcome variables, to explore financial coping strategies among 
respondents who reported encountering access barriers. 
The main independent variable was household members’ total monthly net income 
categorised into tertiles (low/mid/high) according to the sample distribution. Other 
independent variables were family structure, area of residence (urban/rural), re­
spondent’s state of health, age, gender and education. Family structure was catego­
rised into four categories (i) couple with children (0–17 years), (ii) couple only, (iii) 
single parent with children (0–17 years) and (iv) others (including adults living with 
parents). State of health was based on self-assessment (How would you rate your cur­
rent health status? (i) very good, (ii) good, (iii) average, (iv) fair and (v) poor) and by 
presence of a diagnosed disabling illness or impairment (Have you been diagnosed 
with a permanent or long-term illness or impairment that decreases your ability to 
work or function?). The primary unit of analysis in the survey was household. How­
ever, certain background information – age, gender, education, state of health – used 
in the analyses related to the respondent (reference person). the adults in a family 
were assumed to belong to the same wide age group and to have a similar level of 
education and thus these variables were used as proxies for the entire household. The 
explanatory role of gender, however, is of limited importance for couples and fami­
lies. Therefore, gender was mainly used as a covariate. 
Statistical analyses: The frequency of and the characteristics associated with cost­
related access barriers to prescription medicines and health services by population 
group were assessed by bivariate analyses and multivariate logistic regression. The 
bivariate associations were tested for statistically significant differences by a Chi­
squared-test. 
Based on bivariate associations (significant at a p < 0.05 level), education, income and 
health status were included in the multivariate models. Both health predictors gave 
similar results, but only one was included in the model since these variables were 
highly correlated. Self-assessed health was selected for the model over permanent or 
long-term illness or impairment, since it covered a wider range of health problems, 
and is commonly used in other studies (Mackenbach et al. 2008; Jatrana et al. 2011). 
Relevant covariates (age, gender and family structure) were also included in the mul­
tivariate model. The interaction effect between education and income was excluded 
from the main analysis, since it did not reach statistical significance. 
The extent to which the experiences of encountering access barriers differed by in­
come were examined by comparing the results of above average income and below 
average income respondents, after adjusting for age and health by weighting (w2, see 
below). Applying for and receipt of social assistance were assessed among people who 
experienced barriers and compared with the results from all respondents. 
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To account for non-respondents, the results were weighted (w) using post-stratifica­
tion by respondent age, gender, education (primary/secondary/tertiary) and working 
status (employed/unemployed/pensioner) to represent the studied population. For 
multiple variables (age group, gender, education and working status), the post-strat­
ification was conducted using an SAS raking algorithm. The weighting process has 
been described in more detail elsewhere (Miettinen 2013). Weights (w) were used in 
all analyses, except for the comparison between above and below average income. For 
this comparison, adjusting was conducted by creating two subsets (above average = 
above median/ below average = median or below) and applying a post-stratification 
weighting procedure to stratify the differences in age and health status between the 
two subsets (w2). The post-stratification for multiple variables was conducted using a 
SAS raking algorithm (Izrael et al. 2000). 
The population used in the age- and health adjusted comparison by income con­
sisted of 1,609 people and in the regression analysis of 1,412 people, of whom com­
plete information on all of the variables under analysis was available. Differences at 
p < 0.05 level were considered as statistically significant. All statistical analyses were 
performed using SAS software version 9.2 (SAS Institute Inc., Cary, North Carolina). 
4.2.4 Range of available and reimbursed medicines in Finland and in New Zealand (IV) 
A four-dimensional approach was used to compare the available and reimbursed 
medicines in Finland and New Zealand in terms of the following: (i) the total num­
bers and overlap of medicines (unique ATC-codes); (ii) differences by therapeutic 
group; (iii) differences in reimbursing old and new medicines; and (iv) numbers of 
innovative medicines licensed and brought to market. The time point of comparison 
was June 1st 2007. The unit of examination was medicine, defined as a unique ATC­
level 5 code, i.e. products within the same ATC level 5 class (active ingredient) were 
treated as one medicine. 
Data: To form an equally representative, comparable dataset of available products on 
the market, a method published earlier by Chui et al. (2004; 2005) was used. In this 
method, available medicines are determined based on being listed in the published 
national physician’s desk reference. 
The products from New Zealand were manually entered from the published desk 
reference, MIMS – Monthly Index of Medical Specialities – New Ethicals 2007 Issue 6 
(January–June), with information on product name, active ingredients, formulation 
(Donohoo 2007). The reimbursement status for each product was sought from the 
published version of the New Zealand Pharmaceutical Schedule June 2007 version 
(PHARMAC 2007). An ATC-code was assigned to each product primarily based 
ATC Index 2007, or secondarily based on the 2008 index (WHO CC for Drug Statis­
tics Methodology 2008). If the ATC-group was available in the ATC-code system but 
the active ingredient was not, the International Non-proprietary Name (INN) was 
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used (Sweetman 2008). Where several classes were suitable, classification and nam­
ing was conducted similarly to the Finnish listing. 
The Finnish products were imported from an electronic file received for research pur­
poses from the Association of Finnish Pharmacies, where such price and product lists 
were composed regularly, to update pharmacy dispensing software systems. From 
the original list, products listed on the published version of Pharmaca Fennica 2007 
(Lääketietokeskus 2007), were included. The original file contained detailed product 
information, e.g. name, active ingredients, formulation, package size, strength, ATC 
code, prices, reimbursement status and reimbursement restrictions. 
Each product, from both countries, was classified by their reimbursement status ac­
cording to the level of reimbursement (part or full) and restrictions (restricted or 
unrestricted) and any combinations of these (e.g. full subsidy with restrictions but 
part subsidy for all). For consistency, products that were reimbursed in New Zealand 
only in extemporaneous products or only when distributed by primary or secondary 
health-care providers (e.g. influenza vaccines) were classified as not reimbursed. 
Further information to determine the “global age” of medicines was retrieved from 
publicly available databases with historical registration years: the US FDA Electronic 
Orange book (FDA 2008a) and Drugs@FDA (FDA 2008b), the Canadian Patented 
Medicine Prices Review Board Annual Reviews (Patented Medicine Prices Review 
Board 2000−2007), The European Medicines Agency (EMA 2008) and the online 
product databases of national regulatory agencies in New Zealand (Medsafe 2008), 
France (AFSSPS 2008), Finland (National Agency for Medicines 2008), and Sweden 
(Medical Products Agency 2008). FDA Fast Track -listings (FDA 2008c) and above­
mentioned (Canadian) Patented Medicines Prices Review Board Annual Reviews 
were also used in forming the list of new important medicines that provide health 
gain. 
The final dataset of medicines was formed by collapsing the product-level listings 
described above based on distinct ATC level 5 code and the highest observed reim­
bursement status, after removing excluded ATC-classes (see below). Full reimburse­
ment (100%) was the highest and no reimbursement was the lowest reimbursement 
status. The dataset contained 1,046 distinct ATCs for Finland and 1,007 for New Zea­
land. After excluding combination ATCs, the final dataset contained 779 medicines 
(distinct ATC-codes) for Finland and 763 for New Zealand. 
Exclusion criteria included ATC classes A11 (vitamins), A12 (mineral supplements), 
B05 (blood substitutes and perfusion solutions), D02 (emollients and protectives), 
and V (various) because of the high percentage of combination products that pre­
vented a meaningful comparison. All combination products from other therapeu­
tic groups were excluded from the analyses, although combination products were 
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searched for reimbursed equivalents for those active ingredients only reimbursed in 
one of the countries (11 more common reimbursed active ingredients were found). 
Products registered as medicines in New Zealand, but as foods, other medical sup­
plies, or natural remedies in Finland were classified in V03, and were therefore ex­
cluded. Products listed in the Finnish Pharmaca Fennica, but not licensed as medi­
cines were excluded, although medicines with a temporary license (batch-specific 
exemption from the conditions of a marketing authorisation or registration) were 
included. From New Zealand, products listed as being available under section 29 of 
the Medicines Act 1981 (unregistered medicines approved for use by medical practi­
tioners) were included. Differing funding mechanisms and distribution channels led 
to the exclusion of medicines used in the treatment of HIV, hepatitis, and tuberculo­
sis, as well as infusions. 
Data analyses 
Similarity of range of medicines: The medicines in the final dataset were categorised 
into the following eight classes and the number of medicines in each group was de­
termined. 
i. Available and reimbursed in both countries; 
ii. Available but not reimbursed in both countries; 
iii. Available in both countries but only reimbursed in Finland; 
iv. Available in both countries but only reimbursed in New Zealand; 
v. Available and reimbursed in Finland, not available in New Zealand; 
vi. Available and reimbursed in New Zealand, not available in Finland; 
vii. Available but not reimbursed in Finland, not available in New Zealand; and 
viii. Available but not reimbursed in New Zealand, not available in Finland. 
Differences by therapeutic groups: The numbers and overlap of medicines available 
and reimbursed were determined by ATC-level 1 group (anatomical main group). 
A further qualitative within-class assessment was conducted at ATC level 4 (Chemi­
cal subgroup) for medicines in three largest ATC main groups. The largest ATC main 
groups were determined by the total number of medicines. 
Differences in reimbursing old and new medicines: All medicines only reimbursed in 
one of the countries were ranked by their “global age”, i.e. first year of registration. For 
each medicine, the “global age” was determined by a three-stage procedure based on 
first registration years in 1−4 reference countries or areas. The first reference coun­
try was Finland or New Zealand and when the registration date was prior 1970, no 
further references were sought (prior 1960 registration years were rounded to 1960). 
The second reference country was New Zealand or Finland, depending which had 
not been referenced at the first stage, and for medicines with registration dates in 
both countries between 1970−1979, the earliest of the identified years was selected. 
The third round applied to medicines with post-1980 (inclusive) registration years in 
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both Finland and New Zealand. For these medicines, further registration dates were 
searched from all of the following countries or areas, or until two years of registra­
tion were identified: United States, the European Union (EU) or France, Canada, 
and Sweden. After assigning a year of first registration to each medicine, the mean, 
median, and percentiles (25% and 75%) were determined. 
Delay in licensing and launching innovative products: A list of 57 innovative products 
was constructed, as previously published by Roughead et al. (2007), by using the 
listing of products selected for “fast-track” approval (FDA 2008c) and the products 
classified as a “breakthrough or substantial improvement” by the Canadian Patented 
Medicines Price Review Board (Patented Medicine Prices Review Board 2000−2007). 
In the present analysis, products with new chemical entities that had one active in­
gredient only were included. The proportion of innovative products registered and 
launched in Finland and New Zealand was determined. Registration status in Fin­
land and New Zealand in June 1st, 2007 was sought from national regulatory authori­
ties’ web pages (see data collection). To compare the launch status, the listing of these 
entities was searched from national desk references in 2007 (see data collection). 
The raw data were entered into MS Excel. The collapsing and merging of data sets and 
statistical analyses were performed in STATA (version 8.0) (StataCorp LP, College 
Station, TX). The between-country differences were tested for statistical significance 
by using bivariate methods. Differences at p < 0.05 level were considered as statisti­
cally significant. 
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5 Results 
5.1 Trends and income related differences in out-of-pocket costs for medicines in 
Finland (I) 
In Finland, between 1985 and 2006, the mean out-of-pocket costs for medicines in­
creased from €138 to €373 (2.7-fold, in 2006 currency value) and the share of total 
actual consumption spent on medicines from 0.8% to 1.6% (Figure 5). Household 
spending on medicines increased over time in all income quintiles for both prescrip­
tion and OTC-medicines. Lower income was associated with lower sums spent on 
medicines and less rapid growth of out-of-pocket costs. This difference was most 
distinct between the lowest income quintile when compared to the others. Between 
Figure 5. The age-adjusted marginal means estimates for out-of-pocket costs for medicines by income 
quintile (I−V) in total (A), for prescription medicines (B) and for over-the-counter medicines (C) during 
1985–2006 (Euros, 2006 currency value).a 
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a Reproduced with the kind permission of Elsevier. 
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1985 and 2006, the increase was 2.7-fold for the lowest income quintile and 3.3-fold 
for the highest quintile. 
Medicines accounted for a larger share of total actual household consumption for 
lower income than for higher income households (Figure 6). Although the share of 
consumption spent on medicines increased over time in all income quintiles, the 
increase was largest in the lowest income quintile, from 1.1% to 2.2%, and smallest 
in the highest income quintile, from 0.5% to 1.1%, which resulted in a widening gap 
between the lowest and the highest income quintiles. 
Figure 6. The age-adjusted marginal means estimates for out-of-pocket costs for medicines as a share of
household total consumption, by income quintile (I−V) during 1985−2006 (%).a 
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5.2 Distribution of out-of-pocket costs for medicines among community dwelling 
older people in New Zealand (II) 
In Gisborne, New Zealand, the top 50% spenders of older people, ranked by their out­
of-pocket costs, accounted for 86% of the total out-of-pocket expenditure (Table 11, 
p.  85). The mean annual out-of-pocket expenditure for those in the top half was 
NZ$201 and the average reimbursement rate was 86% of total costs. The bottom 50% 
accounted for 14% of the total out-of-pocket expenditure (mean out-of-pocket costs 
NZ$33/year) with 93% average reimbursement rate. The top 1% accounted for 16% 
of the total out-of-pocket costs (mean out-of-pocket costs NZ$1,863/year) and their 
average reimbursement rate was 45%. The average out-of-pocket costs in the top 1% 
were 5.9 times higher than in the top 25%. However, the higher out-of-pocket costs 
in the top 1% did not coincide with higher reimbursements or medicine use: the dif­
ference in reimbursements was 1.0-fold, the numbers of ATCs used were 14 vs. 14, 
and the difference in the number of DDDs was 1.4-fold when top 1% spenders were 
compared to top 25% spenders. Māori and females were underrepresented among 
people with high out-of-pocket costs. 
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Table 11. Distribution of the annual out-of-pocket (OOP) costs and government reimbursements ($NZ), and 
medicine use, among older people in Gisborne, New Zealand. 
Percentile 
of OOP
costs 
Characteristics Annual costs for medicines Medicine use 
N 
Mean 
age 
(years) 
Maori 
(%) 
Male 
(%) 
Total 
OOP
costs 
($NZ) 
% of
the 
OOP
costs 
Average
OOP
cost per
patient
($NZ) 
Average
reim­
burse­
ment
per
patient
($NZ)a 
Average
reim­
burse­
ment
rate 
(%)a 
Mean 
num­
ber of
medi­
cines 
Mean 
num­
ber of
DDDs 
Top 1% 53 76 15 53 98,740 16 1,863 1,388 45 14 3,816 
Top 5% 261 77 13 45 216,264 36 829 1,324 64 15 3,176 
Top 10% 522 77 12 44 287,285 47 550 1,443 74 15 2,955 
Top 25% 1,305 77 17 43 408,933 67 313 1,326 82 14 2,712 
Top 50% 2,610 76 20 41 524,165 86 201 1,133 86 13 2,472 
Bottom 50% 2,607 74 24 44 85,594 14 33 424 93 6 1,056 
All 5,217 75 22 43 609,759 100 117 779 88 9 1,771 
a E xcluding purchases from pharmacy using Galen-sof tware (0.3%). 
Abbreviation: DDD = Defined Daily Doses. 
In the study population, mean out-of-pocket costs were NZ$117 and the median 
number of medicines (distinct ATCs) was 9. Out-of-pocket costs and number of 
medicines increased with increasing age. Reimbursements and the number of DDDs 
were the highest in the middle age group (75−84 years). Māori had lower mean and 
median out-of-pocket costs and reimbursements, as well as a lower number of DDDs 
than non-Māori. The average number of distinct ATCs was similar for Māori and 
non-Māori. People living in the urban or mid deprived areas had higher mean and 
median out-of-pocket costs and reimbursements than their counterparts. 
After adjusting for age, out-of-pocket costs, reimbursements and medicine use were 
lower for Māori than for non-Māori. For all variables, the difference between Māori 
and non-Māori became larger in the top quantiles. 
In the multivariate analyses, non-Māori ethnicity (Reference: Māori OR 1.9; 95% 
Confidence intervals (CI) 1.4; 2.7), older age (85 + years vs. 65−74 years OR 1.6; 95% 
CI 1.2; 2.2) and male gender (females vs. males OR 0.7; 95% CI 0.6; 0.9) were signifi­
cantly associated with high out-of-pocket costs (Table 12, p. 86). Although significant 
in the bivariate comparisons, socioeconomic deprivation or area of residence were 
not significantly associated with high costs after adjusting for ethnicity, gender and 
age. A higher number of medicines was also significantly associated with high costs. 
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Table 12. Bivariate (%, chi-squared test) and multivariate [odds ratios (OR) with 95% confidence inter­
vals (CI), logistic regression] associations between high out-of-pocket costs (NZ$217.50/year or more) and 
independent variables (N = 4,497) among older people in Gisborne, New Zealand. 
% of people 
Model 1 with sociodemo­
graphic variables only 
Model 2 with sociodemo­
graphic variables and number
of medicines 
% p OR with 95% CI p OR with 95% CI p 
Age group 65−74 8 < 0.001 1 1 
75−84 11 1.4 (1.1;1.7) 0.004 1.1 (0.9;1.4) 0.458 
85 + 16 2.1 (1.5;2.7) < 0.001 1.6 (1.2;2.2) 0.002 
Gender Male 11 0.207 1 1 
Female 10 0.8 (0.7;1.0) 0.082 0.7 (0.6;0.9) 0.004 
Ethnicity Māori 6 < 0.001 1 1 
Non-Māori 11 1.8 (1.3;2.5) < 0.001 1.9 (1.4;2.7) < 0.001 
Socio­
economic
deprivation 
Least 10 0.002 1 1 
Mid 12 1.2 (0.9;1.6) 0.213 1.0 (0.7;1.3) 0.828 
Most 9 0.9 (0.7;1.2) 0.663 0.8 (0.6;1.1) 0.205 
Area of
residence 
Rural/mixed 8 0.023 1 1 
Urban 10 1.1 (0.8;1.5) 0.527 0.9 (0.7;1.3) 0.58 
N of distinct ATCs 1.2 (1.1;1.2) < 0.001 
Abbreviation: ATC = Anatomical Therapeutic Chemical system. 
5.3 Cost-related barriers to prescription medicines and health care in Finland (III) 
In Finland, in a survey targeted to general population households with a reference 
person aged between 18−74 years, 18% of the respondents reported at least one prob­
lem with access to health care due to cost within the past year (Table 13, p. 87). In 
total, 11% reported not filling a prescription, 8% not going to hospital and 13% going 
without some other form of treatment prescribed by a doctor due to cost during the 
previous 12 months. Of respondents who assessed their health as fair or poor, 53% 
had encountered at least one access problem, and of respondents with a diagnosed 
disabling illness or impairment, 32%. Those living alone, those with lower educa­
tion or income and those reporting worse health or disabling illness or impairment 
were all significantly more likely to encounter access problems than their counter­
parts. The bivariate associations were mostly not significant for age, gender and area 
of residence. After adjusting for age and health status, 25% of below-average income 
households and 12% of above-average income households experienced access prob­
lems (P < 0.001). 
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Table 13. Characteristics of the study population (n = 1,770) and bivariate associations with statistical sig­
nificance (p, by Chi-squared test) between the studied cost barriers and included background variables.a 
N (%) 
Respondents who reported problems with access 
because of cost (row %) 
Did not fill 
prescription 
Did not go 
to a hospital 
visit
Went with­
out other
form of care 
Had at least
one access
problem 
Total 1,770 (100%) 11% 8% 13% 18% 
Missing (n) 0 184 185 188 162 
Gender Male 877 (50%) 9% 8% 11% 16% 
Female 884 (50%) 12% 8% 14% 20% 
Missing (n) 9 189 192 193 169 
p = NS p = NS p = NS p = 0.038* 
Age, years 18−34 508 (29%) 14% 11% 13% 21% 
35−49 464 (26%) 9% 8% 12% 17% 
50−64 538 (31%) 11% 6% 13% 18% 
65−74 254 (14%) 7% 4% 11% 15% 
Missing (n) 5 185 187 189 164 
p = NS p = 0.003* p = NS p = NS 
Family
structure 
Couple with children 547 (31%) 8% 6% 9% 14% 
Couple only 657 (37%) 11% 7% 11% 17% 
Single parent 61 (3%) 13% 7% 13% 22% 
Others 498 (28%) 15% 12% 18% 25% 
Missing (n) 6 185 186 189 163 
p = 0.003* p = 0.001* p < 0.001* p < 0.001* 
Education Primary 419 (24%) 17% 11% 18% 24% 
Secondary 773 (44%) 13% 10% 15% 21% 
Tertiary 551 (32%) 5% 4% 6% 11% 
Missing (n) 28 200 201 204 178 
p < 0.001* p < 0.001* p < 0.001* p < 0.001* 
Income Low 582 (36%) 20% 16% 21% 31% 
Mid 509 (32%) 11% 5% 12% 17% 
High 523 (32%) 3% 3% 4% 7% 
Missing (n) 156 295 295 296 275 
p < 0.001* p < 0.001* p < 0.001* p < 0.001* 
Table 13 continues. 
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Table 13 continued. 
N (%) 
Respondents who reported problems with access 
because of cost (row %) 
Did not fill 
prescription 
Did not go 
to a hospital 
visit
Went with­
out other
form of care 
Had at least
one access
problem 
Area of
residence 
Urban 1,298 (74%) 12% 9% 13% 19% 
Rural 458 (26%) 9% 7% 12% 17% 
Missing (n) 14 191 192 194 169 
p = NS p = NS p = NS p = NS 
Self­
assessed 
health 
Very good/good 1,277 (73%) 7% 6% 8% 13% 
Average 315 (18%) 15% 11% 19% 26% 
Fair/Poor 153 (9%) 37% 25% 43% 53% 
Missing (n) 25 201 202 204 179 
p < 0.001* p < 0.001* p < 0.001* p < 0.001* 
Diag­
nosed 
disabling 
illness or
impair­
ment 
No 1,198 (70%) 7% 6% 8% 13% 
Yes 516 (30%) 21% 13% 25% 32% 
Missing (n) 56 222 223 223 200 
p < 0.001* p < 0.001* p < 0.001* p < 0.001* 
*Statistically significant at p < 0.05 level.
 
a Reproduced with the kind permission of Oxford Universit y Press.
 
According to multivariate analysis, low income (the lowest vs. the highest income 
tertile odds ratio (OR) 4.95 (95% confidence intervals (CI) 3.02; 8.12)) and poor 
health (Fair/poor vs. very good/good health OR 7.07 (95% CI 4.45; 11.22)) had inde­
pendent and strong associations with going without care due to cost, after adjusting 
for gender, age, education and family structure (Table 14, p. 89). Lower education 
was associated with a small (primary vs. tertiary education OR 1.63 (95% CI 1.02; 
2.61)) but significant increased likelihood of encountering cost-related access prob­
lems. Among the covariates in the model, which were mostly not significant in the bi­
variate associations, younger age had a moderately strong and increasing association 
with access problems (18−34 vs. 65−74 years OR 3.8 (95 % CI 2.06; 7.01)). According 
to the model, female gender was also associated with slightly more frequent access 
problems (OR 1.39 (95% CI 1.04; 1.87)). 
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Table 14. Odds Ratios (ORs), with 95% confidence intervals (CIs) of reporting at least one health related 
access problem, with adjusting for effects of socioeconomic and health predictors.a 
OR 95 % CI p 
Gender Male 1 
Female 1.39 (1.04−1.87) 0.028 
Age, years 18−34 3.80 (2.06−7.01) < 0.0001 
35−49 3.19 (1.69−6.02) 0.0003 
50−64 1.9 (1.06−3.40) 0.0306 
65−74 1 
Family structure Couple with children 1 
Couple only 1.02 (0.69−1.53) 0.911 
Single parent 0.77 (0.35−1.68) 0.506 
Others 0.76 (0.49−1.18) 0.228 
Education Primary 1.63 (1.02−2.61) 0.043 
Secondary 1.64 (1.13−2.38) 0.009 
Tertiary 1 
Household net income Low 4.95 (3.02−8.12) < 0.0001 
Mid 2.24 (1.40−3.57) 0.001 
High 1 
Self-assessed health Very good/Good 1 
Average 2.34 (1.61−3.40) < 0.0001 
Fair/Poor 7.07 (4.45−11.22) < 0.0001 
a Reproduced with the kind permission of Oxford Universit y Press. 
Among households that had encountered access problems in health care, 34% had 
applied for social assistance and 17% had received this benefit. Among all respond­
ent households, 5% had received social assistance. Social assistance is the last resort 
financial aid in the Finnish social security system, received by 7% of all households, 
according to the National Statistics in 2010 (National Institute for Health and Welfare 
2011). 
5.4 Range of available and reimbursed medicines in Finland and in New Zealand (IV) 
In Finland, 779 distinct medicines were available and 495 were reimbursed. In New 
Zealand 763 medicines were available and 471 were reimbursed. The overlap, i.e. the 
number of medicines that were the same in both countries, was 538 for available 
and 290 for reimbursed medicines (Figure 7, p. 90). Hence, 69−71% of the available 
medicines and 59%−62% of the reimbursed medicines were the same in Finland and 
New Zealand. In New Zealand, 86% of all reimbursed medicines were reimbursed 
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in full and in Finland, 29%. Restrictions (means-test) applied to all fully reimbursed 
medicines in Finland, however, fully reimbursed medicines were typically also partly 
reimbursed without restrictions. In New Zealand, the majority of medicines were 
fully reimbursed to all, with no restrictions. Restrictedly reimbursed medicines were 
generally not reimbursed at all for those not meeting the criteria. 
Figure 7. The number and overlap of active ingredients available (listed) and reimbursed (subsidised) in 
Finland and in New Zealand.a, b 
Subsidised in
Finland 
(8) 107 
(1) 290 
(3) 72 (4) 63 
(5) 133 (6) 118 
(2) 113 (7) 108 
Listed in 
New Zealand 
Listed in 
Subsidised in 
New Zealand 
Finland 
a The larger circles represent the medicines available and the smaller circles the medicines reimbursed. The propor tions of the
sections are not to scale. The numbers of the analysis groups are in brackets followed by the number of entities in each group. 
b Reproduced with the kind permission of Elsevier. 
The numbers of medicines available and reimbursed were similar across the main 
ATC-groups. In further examination of the ATC-level 4 chemical subgroups within 
the three largest ATC main groups – Alimentary tract and metabolism (A), Car­
diovascular system (C) and Nervous system (N) – the following general differences 
were observed: i) Within chemical groups which included several new and relatively 
commonly used similar molecules (me-too products), some of which were on-patent 
and some generic competition (e.g., SSRIs, angiotensin II antagonists, 5HT-agonists, 
statins), a larger variety was reimbursed in Finland, but at least one reimbursed op­
tion was also available in New Zealand; ii) Within chemical groups that only included 
one or a few expensive, mostly on-patent new medicines or very expensive medicines 
for rare conditions (orphan medicines), often only Finland had reimbursed options 
(e.g., antidementia medicines, anti-obesity medicines, meglitinides, indole derivates, 
nitisinone, miglustat, bosentan, hydroxybutyric acid, aripiprazole, levetiracetam); iii) 
Chemical groups that only had reimbursed options in New Zealand usually contained 
old medicines no longer marketed in Finland (e.g. tolbutamide, imipramine, phenel­
zine, pizotifen), or medicines used for treatment of milder conditions, or symptoms 
(e.g., laxatives, antacids, antipyretics, analgesics), commonly sold over the counter. 
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Figure 8. Medicines (entities) only reimbursed in Finland or New Zealand, by their first year of registration. 
N = 205 (Finland) and 181 (New Zealand).a 
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a Reproduced with the kind permission of Elsevier. 
The mean registration year for medicines only reimbursed in Finland (n = 205) was 
1990 and for medicines only reimbursed in New Zealand, 1972 (Figure 8). Fewer new 
innovative medicines that provide health gain were registered and launched in New 
Zealand than in Finland. From the list of the examined 57 innovative medicines, 47 
were registered in Finland and 33 in New Zealand, and 37 and 22, respectively, were 
launched based on being listed in the national desk references. 
5.5 Summary of the main results
In Finland, higher income households tended to spend higher sums on both pre­
scription and OTC medicines than lower income households, although the largest 
differences were observed between the lowest income quintile and quintiles II−V. 
Despite lower absolute sums, medicines accounted for a larger share of the total con­
sumption for low-income households. Almost every fifth Finnish household had en­
countered cost-related access barriers to prescription medicines, other recommend­
ed treatments or hospital visits at least once during the previous year. Low income, 
worse self-assessed health, younger age, lower level of education and female gender 
were associated with access problems. 
In Gisborne, New Zealand, a large majority of older people paid relatively little for 
their medicines while few individuals paid a lot. Medicines not reimbursed in full or 
at all contributed to the high out-of-pocket payments. High costs were not associated 
with socioeconomic deprivation, however, Māori spent less on medicines and used 
fewer medicines than non-Māori. 
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In comparison, a larger variety of older active ingredients and active ingredients com­
monly sold over the counter were reimbursed in New Zealand. In addition, a larger 
share of reimbursed medicines was reimbursed in full. In Finland, a wider range of 
newer active ingredients, as well as more options within therapeutic groups (includ­
ing me-too -products) were reimbursed and a higher share of innovative medicines 
were available. 
Affordability of medicines from the pharmaceutical system perspective 93 
 
 
  
6 Discussion 
6.1 Methodological considerations 
The methodological purpose of this study was to assess the usability of used data 
sources in examining dimensions of affordability. Below, the methodological aspects 
of each phenomenon examined in the sub-studies are discussed in this context. 
6.1.1 Distribution of out-of-pocket costs
Studies I and II assessed the distribution of out-of-pocket costs for medicines in Fin­
land and New Zealand. In Finland, the focus was on income differences, and in New 
Zealand, in ethnic differences, due to previously reported country-specific inequali­
ties in health (e.g. Bramley et al. 2005; Tarkiainen et al. 2013). The used sources of 
data were chosen because they contained information on out-of-pocket costs for non­
reimbursed medicines, which is generally lacking from comprehensive claims-based 
registers and of which limited information was thus available in the earlier literature. 
The data used in Study I derived from national Household Budget Surveys (HBS) 
conducted in Finland. Previous studies have also used household expenditure survey 
data to assess the distribution of costs for medicines and health care in e.g. Australia, 
Canada, Italy and Austria (Jones et al. 2008; McLeod et al. 2011; Sanmartin et al. 
2014; Sanwald and Theurl 2014; Terraneo et al. 2014). HBSs or other household sur­
veys are conducted in most developed countries and many developing countries (Xu 
et al. 2009; Seiter 2010). The strengths of HBS data include national representative­
ness and comparable measuring points over time. The limitations derive from the 
short collection periods and the aggregated nature of information due to which indi­
vidual level information cannot be used (Statistics Finland 2009). Further, differences 
between any two surveys are expected because of differences in e.g. the survey years, 
survey designs and recall periods (Eurostat 2003; Xu et al. 2009). A further limitation 
of the data is that no information is available on the medicines used, or the illnesses 
of included household members, and therefore examinations of specific conditions 
or therapeutic groups are out of scope. 
In the sensitivity analyses in Study I, removing age from the model decreased the dif­
ferences between income groups, since lower income groups composed a larger share 
of older households with higher costs. Using costs in relation to disposable income 
instead of total consumption resulted broadly in similar findings as the main analy­
ses. However, the results were more inconsistent when income was used as a denomi­
nator, because of the aggregated nature of the cost and consumption data. Exclud­
ing households without recorded purchases decreased differences between income 
groups to negligible levels. This finding suggests that the observed differences were 
more likely to be due to fewer low-income households reporting purchases than e.g. 
differences in the prices paid. However, this approach is also limited by the applica­
bility of aggregated data. It was also noted that the overall proportion of households 
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with purchases was also markedly higher in the two earlier time points than in the 
latter three (91−92% vs. 39−45%), possibly due to unreported differences between 
studies conducted at different time points. 
In Study II, pharmacy register data from one area of New Zealand were used. The 
strength of the data was the inclusion of out-of-pocket costs for medicines outside 
the reimbursed range as well as all patient fees related to purchasing medicines. How­
ever, since pharmacy dispensing data are not routinely pooled or collected, these 
had to be obtained separately from each pharmacy. The limitations of the current 
study included the lack of information regarding health needs apart from age and 
ethnicity, and regarding income, which meant that costs relative to income could 
not be calculated. The study was also limited to older people and one area, and they 
may not be generalisable to other age groups and parts of the country. An alternative 
source of data could have been the Pharmaceuticals Collection database (Pharms), 
maintained by the Ministry of Health and the PHARMAC (Ministry of Health 2015, 
PHARMAC 2016b). However, the national database only contains reimbursed pur­
chases of medicines (Horsburgh et al. 2010). Therefore, the share of costs deriving 
from using medicines outside the reimbursed range could not have been assessed 
with the national data. 
Overall, there is limited published information of the out-of-pocket costs and medi­
cines used in New Zealand. The Ministry of Health provides no routine reports or 
publications based on register data on medicine use and PHARMAC only publishes 
limited information in Annual Reports and Annual Reviews. The latest OECD data 
of health spending on medical goods for New Zealand is from 2007 and data on 
pharmaceutical sales is largely incomparable (OECD 2015c). Data on out-of-pocket 
health expenditure derive from Household Economic Surveys (HES) instead of reg­
isters (Ministry of Health 2012). 
Several limitations also need to be noted in regards to measuring medicine use by 
using defined daily doses (DDD). DDDs are average daily doses, estimated based on 
the main indication of the active ingredient. They allow standardising between dif­
ferent formulations and doses but only give a rough estimate of actual use. The doses 
prescribed and used by patients may differ e.g. because of patient characteristics (age, 
weight, tolerance, pharmacokinetics), when used for different indications, because 
of treatment guidelines and traditions in different countries (WHO 2003; WHO CC 
2017). It is therefore possible, that the observed differences are caused by underlying 
differences of the population subgroups. 
In summary, in assessing out-of-pocket costs, both HBS and pharmacy register data 
had the advances of including the out-of-pocket costs of non-reimbursed medicines. 
However, neither source of data alone provided sufficient information to comprehen­
sibly assess the equity of the distribution of out-of-pocket costs in relation to need. 
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The HBS data lacked the information on the share of costs that were covered, and 
the treatments that the payments represented, and thus offered limited information 
on whether differences persisted in medicine use. The pharmacy register data lacked 
information on need and on the socioeconomic characteristics, which prevented e.g. 
the assessment of out-of-pocket costs in relation to income. Nevertheless, the results 
of the studies presented here are of importance in assessing to what extent the results 
from claims-based studies are biased due to the lack of non-reimbursed purchases. 
HBS data is available for long periods of time and from a large number of countries 
and thus could best serve as a crude indicator of the level and distribution of out-of­
pocket spending in relation to income across countries and over time. It could also be 
used to assess the validity of the patterns observed in analyses based on claims-based 
registers. Pharmacy data includes purchase-level information and therefore further 
examinations of specific conditions or therapeutic groups are feasible. Several exam­
ples of studies focusing on specific therapeutic groups have already been published 
(Norris et al. 2011a; 2011b; 2014). 
6.1.2 Cost-related access barriers 
Access barriers and unmet needs are commonly used features of national and inter­
national health or health insurance related surveys (de Looper and Lafortune 2009; 
Schoen et al. 2010; Moreno-Serra et al. 2012). This self-assessment-based method 
is relatively straightforward when compared to e.g. examining access based on uti­
lisation (e.g. van Doorslaer et al. 2004; Bago d’Uva et al. 2009; Mayer and Österle 
2014), although each method has its limitations. The pros of using self-report include 
being able to separate between different reasons for forgone care and therefore be­
ing able to distinguish cost-related barriers from other reasons, e.g. waiting times or 
personal reasons. The cons include common limitations of surveys, e.g. recall bias, 
non-response, selective attrition and the comparability of results from surveys from 
different countries and at different points of time. Further, it is usually not possible to 
assess the necessity of forgone care. Individual cross-sectional surveys also provide 
no information on causalities. 
In Study III, national survey data from Finland were used. The largest limitation was 
that the survey was not designed to specifically address access barriers to medicines 
and therefore the range of independent variables was very limited, e.g. the Finnish 
data did not include variables related to psychological distress or health behaviour. 
Other factors associated with use (Piette et al. 2006), that could not be assessed, in­
cluded physician-related factors (e.g. physician knowledge, therapeutic choices), fac­
tors related to patient attitudes or experiences (e.g. physician-patient relationship, 
past experiences), treatment-related factors (essentiality, side effects, polypharmacy) 
or diagnosis-related factors (e.g. quality of life). Further, barriers to accessing doc­
tors were not assessed. There was also no distinction between people who did not 
encounter access barriers and who did not use medicines. 
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The questions used in the Finnish survey were constructed based on a previous Finn­
ish study, conducted in 2000, to produce comparative results. However, the results 
were not directly comparable to international surveys, e.g. Commonwealth Fund In­
ternational Health Policy Surveys, due to differences in questions and survey meth­
ods (postal vs. telephone). Overall, nevertheless, comparisons of results from surveys 
conducted in different countries need to be interpreted with caution. Especially at­
titudes towards unmet needs can be affected by e.g. cultural factors, public expecta­
tions and policy debates (OECD 2013). Further, there are limitations of generalis­
ability of the results. The response rate was low, 35%, and the weighting might not 
fully account for non-response, e.g. due to selective attrition. Also, people aged over 
75 years were not included in the survey. 
Inequities in access to health care have previously commonly been examined by us­
ing doctor visits as an indicator of access to care (e.g. van Doorslaer et al. 2004; 2006; 
Allin and Masseria 2009a; 2009b). However, the results related to doctor visits may 
not act as a reliable proxy of overall access. Based on EU-SILC-surveys, Finland was 
among the countries with the least cost-related access barriers to medical examina­
tion (instead, barriers related to waiting times were common) (Eurostat 2016b). The 
results from Study III indicate that although costs may not limit access to medical 
examination, they are an important factor in limiting access to treatments recom­
mended or prescribed during those visits. 
Overall, to aid policymaking, more in-detail research is needed on the necessity of 
forgone treatments and of the specific reasons behind cost-barriers, i.e. whether the 
barriers are related to the level of cost-sharing or reliance on medicines not covered 
within the basic range. In comparative analyses, more information is needed on the 
comparability of results related to cost-related access barriers across countries. Com­
paring differences between population subgroups observed within countries instead 
of directly comparing observed percentages could partly resolve the uncertainty re­
lated to country-specific response patterns. 
6.1.3 Range of available and reimbursed medicines 
In Study IV, the range of compared medicines was defined as published by Chui et al. 
(2004; 2005). In this method, available (licensed) medicines are determined based on 
being listed in the published national physician’s desk reference. Such a list represents 
the range of generally available medicines, for most patients, under normal ambula­
tory care conditions. No 100% comprehensive list of products was available from ei­
ther country, and almost any single entity could be available for an individual patient 
in hospital settings or under named-patient or Exceptional Circumstances policies. 
One limitation of this study (IV) was the lack of electronic records from New Zea­
land. The Finnish data was composed of electronic records, which have obvious ad­
vances in terms of accuracy and consistency. However, electronic records from dif­
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ferent countries may vary in completeness or they may not be available (Folino-Gallo 
et al. 2001). The standardised assignment of ATC-codes to New Zealand data was 
also challenging, especially for combination products and products with the same 
active ingredient but different administration routes and indications. Further chal­
lenges in standardisation included differences in licensing (e.g., medicines vs. foods 
vs. medical supplies vs. complementary and alternative products), funding (commu­
nicable diseases, vaccines, infusions) and distribution (hospital only, general sales, 
OTC). It was also noted that the disproportionate use of combination products in 
the compared countries might bias comparisons in several ways: including com­
bination products in the comparison may result in the multiple counting of active 
ingredients (each under separate ATC-codes) and excluding combination products 
may result in losing active ingredients only available in combinations. In this study, 
combination products were excluded from the analyses but active ingredients only 
available in combination products were included. Differences in reimbursement were 
only assessed on a general level, however, the criteria for reimbursement, reimbursed 
indications and covered population subgroups may vary (Ballem and Krause 2011; 
Blankart et al. 2011). 
The comparison of availability of innovative products in Study IV may have been 
influenced by how the compared products were chosen. In this study, a method pub­
lished by Roughead et al. (2007) was used. Alternative assessments of therapeutic 
innovation have been published by e.g. Motola et al. (2005; 2006) and the French 
medicine bulletin La Revue Prescrire / Prescrire International (e.g. Prescrire editorial 
2012). Ahlqvist-Rastad et al. (2004) found broadly similar ratings by Prescrire and 
by the Swedish national regulatory agency. Conversely, Lexchin (2015) only found 
fair agreement between Health Canada’s priority approval and ratings by PMPRB or 
Prescrire. Of note, disconcordance was also found in the ratings by PMPRB and Pre­
scrire. Lexchin (2012) also found differences in the assessments of Prescrire, the US 
FDA, Health Canada and PMPRB. According to Vitry et al. (2013), who used Motola 
et al. and Ahlqvist-Rastad et al. (based on Prescrire) classifications to examine the 
therapeutic value of medicines available in Australia, both classification systems were 
broadly consistent. It seems thus that using different classifications is likely to alter 
the compared selection, but it is unlikely that the overall results would be different. 
However, unobserved differences may persist in the approved indications (Blankart 
et al. 2011; Cheema et al. 2012). 
Nevertheless, the differences in the reimbursed and available range of medicines 
between Finland and New Zealand observed in Study IV were in line with other 
published comparative results. In comparisons where both Finland and New Zea­
land were included, New Zealand was among the countries with least launches of 
innovative medicines in a comparison of 25 countries (Danzon et al. 2005); and New 
Zealand had the lowest share of reimbursed indications for new oncology medicines 
in a comparison of 13 countries (Cheema et al. 2012). Finland, on the other hand, 
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ranked relatively high in these comparisons. In comparisons where New Zealand was 
included but Finland was not, New Zealand had a more narrow range of newer medi­
cines than Germany and the Netherlands (Danzon and Kelcham 2004); fewer avail­
able and reimbursed medicines and a narrower range of reimbursed and available in­
novative and/or new medicines than the US VANF, Australia and the UK (Ragupathy 
et al. 2012); and fewer available and reimbursed medicines and formulations suitable 
for paediatric use than Australia and the UK (Ragupathy et al. 2010). In European 
comparisons, Finland and other Nordic countries tended to have a low number of 
medicines in comparison to Central-European countries (Folino-Gallo et al. 2001); 
and a higher share of reimbursable products (Vogler 2008). 
An overall challenge in designing meaningful comparisons of product ranges is the 
lack of standardised methodology in identifying when the observed differences are 
clinically relevant. Especially when the comparison is not limited to one or a few 
conditions, assessment of available treatment alternatives, possibly across therapeu­
tic groups, becomes challenging. Differences due to reimbursement restrictions may 
also go unnoticed. If comparable sales or claims statistics were available, an alterna­
tive method would be to assess differences in actual patterns of use. Using therapeu­
tic innovations as a proxy of availability is less cumbersome, although not without 
limitations. Products ranked as innovations at the time of market entry may turn out 
to be less effective, or even harmful, in real-life settings. Fast reimbursement of new 
medicines also needs to be assessed in relation to opportunity costs. 
6.2 Discussion with comparative perspective 
6.2.1 Pharmaceutical systems in shaping affordability
In terms of protective strength, the reimbursement systems in both countries have 
strengths and weaknesses. By using modified indicators of de-commodification 
(adapted from Reibling 2010) to compare the dimensions of access in each system, the 
Finnish pharmaceutical system seemed to provide a better benefit level, in particular 
a faster access to new and innovative medicines, as well as a wider choice between 
therapeutic options. New Zealand´s system provides reimbursed options across most 
therapeutic groups, although the options within the groups are few. Cost-sharing, the 
main disincentive, is softer in New Zealand. The two countries both had universal 
coverage for prescription medicines and they also had similarities in determining the 
conditions for lower cost-sharing or exemptions. Both systems used ceiling mecha­
nisms and targeted specific groups, although on different grounds. The Finnish sys­
tem is disease-specific (needs-test) whereas the New Zealand system is population 
group-specific (means-test: low-income, age-based: children). Both countries also 
use restricted reimbursements to influence prescribing, although in Finland these 
restrictions are limited to new and the most expensive medicines. In New Zealand, 
restrictions apply to many second and third-line options. 
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Within published health system typologies, the health care system in New Zealand 
best fits the criteria of the Beveridge model (OECD 1987), the “entrenched com­
mand-and-control state” (Moran 1999; 2000; Burau and Blank 2006) or, based on the 
similarity to the UK system, the “universal coverage – controlled access” and “strong 
gatekeeping and low supply” models (Wendt 2009; Reibling 2010). Characteristics of 
these systems include a strong public role, gatekeeping and regulation, a low level of 
cost-sharing, low number of providers and high equity in access. The Finnish health 
care system has also been classified as best fitting the criteria of the Beveridge model 
(Häkkinen and Lehto 2005; Klavus et al. 2012; Lehto 2014). Moran (1999; 2000) clas­
sified all Nordic countries as “entrenched command-and-control states”. However, 
based on the cluster analyses by Wendt (2009) and Reibling (2010), Finland rep­
resented the “mixed regulation model” or “low budget – restricted access model”, 
together with Portugal, Italy and Spain. These systems were characterised by high 
gatekeeping, high cost-sharing and technology, and by very low prescriber autonomy. 
The institutional differences identified by the more recent cluster analyses reflect 
some of the differences in the pharmaceutical systems in Finland and New Zealand. 
The main routes of regulation differ between the two countries. Conventional regula­
tion, i.e. command-and-control activities, designed to override market forces (Salt­
man 2002; Blank and Burau 2014, 129), is the predominant route applied in New 
Zealand. PHARMAC has an active role in shaping the streamlined list of reimbursed 
products as an entity, with multiple supply side strategies to maximising value for 
money. On the demand side, prescriber autonomy is limited by the narrow choice 
of reimbursed medicines and detailed restrictions on the use of therapeutic options, 
which also lessens the risk of moral hazard. Prescribers and patients have limited 
choice between reimbursed options, but they may participate by initiating the reim­
bursement evaluation process (PHARMAC 2015), which is in line with the overall 
health policy goals to involve consumers and communities in decision-making. Indi­
vidual decisions are also allowed under the Exceptional Circumstances framework, 
although for clinical reasons only, not because of patient preference. 
When compared to New Zealand, the Finnish pharmaceutical system has more 
characteristics of pro-market regulation, in which the public role is to provide bal­
ance among stakeholders but maximise the autonomy of providers and consumers 
through marketplace principles (Saltman 2002; Blank and Burau 2014, 129). On the 
supply side, the reimbursement process can only be initiated by pharmaceutical com­
panies and the public focus is on price regulation. However, active control is used for 
new and expensive medicines, which are often reimbursed with restrictions. Besides 
broad determination of reimbursable products in the legislation, there is no active 
public control in determining the “benefit package” of reimbursed medicines. In­
stead, it is a selection guided by the principles of demand and supply, together with 
company marketing strategies. On the demand side, Finland relies more heavily on 
influencing patients than prescribers. 
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The reimbursement systems also have institutional differences related to funding. 
Public control is expected to be the highest in systems where the majority of funding 
derives from general taxation, which is the case for New Zealand (Blank and Burau 
2014, 87). Accordingly, in New Zealand, PHARMAC has had considerable autonomy 
in the policies and procedures it uses to control prices and reimbursements, and the 
public control over the overall budget is high. In Finland, the reimbursements for 
medicines are paid through National Health Insurance, which is funded by employee 
contributions and state funding. The reimbursement system therefore shares charac­
teristics of the social insurance model (Moran 1999; 2000). The public budget control 
is weaker and reform processes more rigid since changes in the health insurance ben­
efits, including implementation of cost containment policies, are subject to legislative 
process. The stakeholders, including labour market parties and lobbyists of interest 
groups thus also have higher possibilities in influencing decision making. (Immergut 
1992; Niemelä 2014, 239–248; Saarinen 2011.) 
Furthermore, the low prescriber autonomy associated with national health service 
systems does not seem to apply to the Finnish pharmaceutical system. Due to the 
dual funding mechanisms, doctors are not subject to financial incentives as regards 
the prescribed medicines and the expenditure on medicines has no direct budgetary 
effects (Vuorenkoski et al. 2008). Further, there are no national formularies or pre­
scription guidelines based on cost-effectiveness. In New Zealand, although the phar­
maceutical budget is de facto centralised to PHARMAC, exceeding the budgetary cap 
would lead to the DHBs having to reduce their spending in other areas (PHARMAC 
2016a). Cost-effectiveness and opportunity costs are used as criteria by PHARMAC 
in determining the Pharmaceutical Schedule, which is in fact a national formulary. 
Nevertheless, restricted reimbursements are used in both countries rather widely, as 
a form of a cost-containment measure. 
Differences have also been shaped by supranational institutions and pharmaceuti­
cal industry business strategies. The Finnish available range of medicines is shaped 
by the centralised and mutual recognition marketing authorisation processes of the 
EU, with specific favourable regulation concerning orphan medicines and paediatric 
medicines (Greer et al. 2013). The EU also imposes requirements for the national 
pricing and reimbursement process, in terms of timeframe, transparency of decision 
criteria, and appealability (Directive 2013/50/EU). Similar requirements of increased 
transparency and appealability concerning pricing and reimbursement processes, to­
gether with extended intellectual property rights, have been proposed in trade and 
investment agreement negotiations between the US and Pacific countries, includ­
ing New Zealand and Australia. The proposed measures were estimated to lead to 
increased secondary patenting and evergreening, delay access to generic medicines, 
and increase prices for pharmaceuticals in New Zealand and Australia and thus in­
crease either public or private expenditure, or lead to restricting the reimbursed range. 
(Gleeson et al. 2013; 2015.) On the other hand, lower expected profits from extensive 
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cost-containment policies in New Zealand, together with small market size, are likely 
to affect availability via market mechanisms (Kyle 2007; Kanavos et al. 2011). Accord­
ingly, New Zealand has had comparatively few submissions to reimbursement from 
pharmaceutical companies (Cheema et al. 2012). 
6.2.2 Distribution of out-of-pocket costs
Based on publicly available national statistics, the average level of out-of-pocket costs 
is lower in New Zealand than in Finland, even when adjusted to differences in price 
and income levels. However, to assess fairness, also distribution matters (WHO 2000, 
26), especially since the distribution of health care utilisation and needs is strongly 
skewed (Steinberg et al. 2000; Berk and Monheit 2001; Goulding 2005; Zuvekas and 
Cohen 2007; Saastamoinen and Verho 2013). 
In Finland, after adjusting for age, lower income households paid lower sums than 
high income households, but spent a higher share of their overall consumption on 
medicines (Study I). Out-of-pocket costs for medicines thus had some regressive ef­
fects in Finland. Similar findings, regarding costs for medicines, have been described 
in studies from Germany, Australia and Italy (Jones et al. 2008; Bock et al. 2014; 
Terraneo et al. 2014). Also in Canada, social assistance households spent a similar 
share on medicines compared to households in general, but were more likely to spend 
over 10% of consumption on medicines (McLeod et al. 2011). In Austria, higher in­
come was associated with higher likelihood of buying OTC-medicines (Sanwald and 
Theurl 2014), which was in line with the higher expenditures found in Finland. 
Previous descriptions of the distribution of out-of-pocket costs from Finland are 
scarce. In an unadjusted analysis, which only encompassed people with reimbursed 
purchases, co-payments were found to be highest in the second lowest income decile, 
which also contained a high share of older people (Martikainen et al. 2008). Similar 
unadjusted findings were reported from Canada (Sanmartin et al. 2014). Accord­
ingly, in Study I, without adjusting for age, the differences between income quintiles 
decreased. Differences also decreased when only households with purchases were 
included, since the lowest income quintile also had lowest share of households with 
purchases. 
The magnitude of the difference in the share of total consumption spent on medicines 
between the lowest and the highest income households in Finland increased over 
time and was 1.1 percentage points in 2006. Similarly, Terraneo et al. (2014) found a 
one percentage point difference between the poorest and other families in Italy. How­
ever, it is likely that the regressive effects in Finland would be even larger without the 
progressive effects of the disease-based eligibilities to higher reimbursement, since 
eligibilities to the highest reimbursements are most common among low-income 
population groups (Aaltonen 2015). Studies from the US, where cost-sharing and in­
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surance coverage varies widely, have described much larger income differences, and 
high burden resulting from out-of-pocket costs (Sambamoorthi et al. 2003; 2005). 
In New Zealand, according to Study II, high out-of-pocket costs from using medicines 
outside the reimbursed or fully reimbursed range were rare. This may indicate that, at 
least among older people, the fully reimbursed range addresses relatively adequately 
the health needs for most. On the other hand, it may also indicate that the majority of 
older people are either unwilling or unable to pay higher costs for medicines outside 
the fully reimbursed range. High out-of-pocket costs for medicines were not signifi­
cantly more or less frequent among people with higher socioeconomic position. 
Nevertheless, high costs were less frequent among Māori and they coincided with 
a lower level of medicine use. Similarly, previous research from New Zealand has 
shown that Māori tend to be less likely to purchase prescription medicines and also 
to have fewer subsequent dispensings than non-Māori, after adjusting for need (Met­
calfe et al. 2013); that Māori, also children living in rural areas, had few dispensings 
and low quantities of antibiotics, despite their higher prevalence of rheumatic fever 
(Norris et al. 2011a); and that older Māori are less likely than older non-Māori to be 
dispensed psychotropic medicines (Norris et al. 2011b). 
The lower level of utilisation is of concern, since Māori tend to have a lower life ex­
pectancy, higher mortality and poorer health outcomes, together with higher preva­
lence of risk factors (e.g. obesity) than New Zealanders of European descent (Bram­
ley et al. 2005; Elley et al. 2008; Kenealy et al. 2008; Robinson et al. 2016). Ethnic/ 
racial differences in health have also been identified in other populations (Bramley et 
al. 2004; 2005). Nevertheless, the manifold causes behind these differences are out of 
scope of this research and they are likely to vary depending on the group of popula­
tion and the health system in question, as well as the cultural, historical and political 
context (Dahlgren and Whitehead 1991, 39–40; Smedley et al. 2003; Kawachi et al. 
2005; Kenealy et al. 2008; Chen et al. 2010). 
Measurements of disparities based on overall costs and utilisation have their limita­
tions. Medicines differ in their therapeutic value, and thus higher utilisation or costs 
may also represent irrational use. This is most evident with discretionary medicines 
and to some extent, with OTC medicines. Also the tendency to use expensive treat­
ment alternatives without therapeutic reasons, e.g. “me too” products, or branded 
medicines instead of generics, could create clinically less relevant disparities. Even so, 
from the perspective of public spending, the financial consequences of irrational use 
may have consequences in terms of efficiency. It has been suggested that new medi­
cines can behave, in terms of demand and price elasticity, as luxury goods, as they 
cover a more “marginal” demand with higher price to patients and consumers (Cle­
mente et al. 2008). The price elasticity has also been show to differ between income 
groups (Terraneo et al. 2014). Further, increasing the overall insurance coverage may 
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not always decrease disparities, since those with previously the highest consumption 
patterns may increase their consumption the most (Borrell et al. 2006; Korda et al. 
2007; Mahmoudi and Jensen 2014). 
The public willingness to pay and the general attitudes towards cost-sharing also 
need to be viewed in a historical context. New Zealand has a long tradition of no or 
very low cost-sharing, dating back to the New Zealand Social Security Act of 1938, 
when all New Zealanders became eligible to free medicines and hospital services 
(Cumming et al. 2014). In comparison, Finns are used to a much higher level of 
cost-sharing since the relatively late establishment of National Health Insurance in 
1963, when the standard reimbursement rate for medicines was set to 50% (Health 
insurance Act 364/1963). Even though both countries have increased cost-sharing 
for medicines over time, New Zealand has a notably lower level of cost-sharing than 
Finland, in absolute and relative terms. 
The results from Study I thus offered support for the prior concern of the inequitable 
distribution of out-of-pocket costs in Finland. Study II showed that whether or not 
the fully reimbursed range in New Zealand was adequate, most older people relied 
on it, regardless of their incomes. The use of expensive medicines outside the reim­
bursed range did therefore not seem to have a socioeconomic gradient. However, the 
lower costs and use among Māori, who also have higher health needs, is of concern. 
Since need could not be assessed in this study, further research is needed to under­
stand whether the different use patterns derive from over or underuse, and whether 
they are caused by economic, cultural or other factors. 
Out-of-pocket costs in health care generally tend to have regressive effects, since they 
are difficult to allocate otherwise (WHO 2000, 35). However, it must be noted, that in 
both Finland and New Zealand out-of-pocket payments only represent a small part 
of the total pharmaceutical expenditure, while the public funding derives from pro­
gressive forms of prepayments (taxes and social insurance contributions). 
6.2.3 Cost-related access barriers 
Besides out-of-pocket costs in relation to income, unmet needs are a commonly 
used indicator of inequities in access (de Looper and Lafortune 2009). The Com­
monwealth Fund has conducted health policy surveys in several countries, includ­
ing New Zealand since 1998, to assess people’s experiences related to their health 
care and health insurance systems (Schoen et al. 2010; OECD 2015b; Commonwealth 
Fund 2016). Finland has not been included in these surveys, and no published direct 
comparisons of access barriers between Finland and New Zealand were found in 
the literature. Therefore, although results from different surveys and from different 
countries are not directly comparable due to multiple reasons, the results from Study 
III represented the best available information from Finland. The findings of Study 
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III are compared with findings and patterns observed in previous studies from New 
Zealand. 
Based on indirect comparison between the results from Study III and Common­
wealth Fund survey results (Schoen et al. 2010; Commonwealth Fund 2010b), Fin­
land would rank the third highest by the frequency of reported access barriers both 
to prescription medicines and to other forms of treatment, after the US and Australia. 
Cost-related barriers seem thus more frequent in Finland than in New Zealand or the 
European countries surveyed by the Commonwealth Fund: Sweden, Norway, Ger­
many, the Netherlands, Switzerland, France and the UK. Examination of reporting 
any cost-related barriers by income (Study III and Schoen et al. 2010) would place 
Finland close to Australia and Germany, and above New Zealand, in the frequency of 
barriers for both above and below average income groups. Earlier (year 2000) results 
from Finland (Lindholm 2001), in comparison to the Commonwealth Fund 2001 
study results (Commonwealth Fund 2001; Schoen et al. 2002), would place Finland 
the third highest in frequency of access barriers to prescription medicines, after the 
US and Australia, and the highest in barriers to other treatments. 
Based on indirect evidence, cost barriers seem thus to be slightly more common in 
Finland than in New Zealand. Due to the lower level of cost-sharing in New Zealand, 
this finding is expected. However, in direct comparisons, New Zealand has ranked 
high in relation to other countries with low level of cost-sharing (UK, Netherlands 
and Sweden). New Zealand does, therefore, not seem to reach the same level of equity 
than its benchmark countries. This difference is likely to be influenced by the nar­
row choice of reimbursed products, together with, at least in comparison to the UK, 
a slightly higher level of cost-sharing (Ragupathy et al. 2012). Also, a previous study 
from New Zealand has shown that for people with no or very low income, even low 
fees may have catastrophic financial effects (Norris et al. 2015). 
In Commonwealth Fund surveys to the general population conducted between 
1998−2013, New Zealand ranked higher for cost-related access barriers to care than 
to prescription medicines. Accordingly, New Zealand has traditionally had relatively 
high patient fees in primary care. New Zealanders tended to report access barriers to 
care less frequently than respondents from the US but more often than respondents 
in the UK, Netherlands (except 2013), Norway, Switzerland, Canada and Sweden. 
Ranking with Australia, France and Germany varied. In the later years, the frequen­
cy of reported barriers to medicines seemed to decrease in New Zealand, possibly 
due to the reforms in primary care that decreased co-payments for doctor services 
and medicines. (Commonwealth Fund 1998; 2001; 2010b; Schoen et al. 2002; 2007a; 
2007b; 2010; 2013.) 
The Finnish survey (Study III) did not assess cost-related access barriers to prescrib­
ers. The pro-rich inequity in doctor use, especially access to specialists, has previously 
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been found to be particularly large in Finland in relation to other developed coun­
tries (van Doorslaer et al. 2006). However, access barriers to medical examination 
in Finland derived mainly from other reasons (e.g. waiting time) than cost, accord­
ing to EU-SILC surveys (Eurostat 2016b). Patients thus seem to experience barriers 
to prescribers in both countries, although for different reasons. However, socioeco­
nomic factors are likely to play a key role in shaping inequalities in access and use 
in both countries, regardless of the specific barriers (van Doorslaer et al. 2006; Allin 
and Masseria 2009a; de Looper and Lafortune 2009). According to Commonwealth 
Health policy survey 2010, the UK was the only country where no significant differ­
ences in the frequency of cost-related access barriers to care were observed between 
above and below-average respondents (4% for both groups, after adjusting for health 
and age). In the UK, also a significant proportion of people are completely exempt 
from user charges. (Schoen et al. 2010.) 
Besides low income, other risk factors for cost-related access barriers observed in 
Finland included poor health status, lower education, younger age and female gen­
der. A parallel analysis, limited to cost-related barriers to prescription medicines, 
gave broadly similar results in terms of income, education and health. However, gen­
der was not significantly associated with cost-related access barriers to medicines, but 
a more rural area of residence was significantly associated. (Aaltonen et al. 2013.) In 
studies from other countries, lower income or socioeconomic status and poor health 
have been robust risk factors for cost-related non-adherence and unmet needs (Brie­
sacher et al. 2007; Mielck et al. 2007; 2009; Allin and Masseria 2009a; 2009b; Bryant et 
al. 2009; de Looper and Lafortune 2009; Allin et al. 2010; Israel 2016). Mixed results 
have been found for gender in regards to medicines (Briesacher et al. 2007). 
In New Zealand, Jatrana et al. (2009; 2011) assessed determinants of cost related 
access barriers to prescription medicines and primary care based on national Sur­
vey of Family, Income and Employment (SoFIE) Health add-on module results in 
2004−2005. In multivariate analyses, factors associated with deferring both doc­
tor visits and prescription medicines were socioeconomic deprivation, higher co­
morbidity, psychological distress, younger age, female gender and current smoking. 
Māori were less likely than European to defer doctor visits but more likely to defer 
prescriptions, after adjusting for other factors. Those living alone, with the highest 
level of education or with a lower level of income were more likely to defer doctor 
visits than their counterparts, but the results for prescription medicines were mixed 
or not significant. Self-assessed health was not significantly associated, after adjusting 
for co-morbidities, psychological stress, smoking and other factors. Socioeconomic 
deprivation and the presence of one or more co-morbid diseases were significant 
determinants of deferring prescriptions for all examined ethnic groups: European, 
Asian, Māori and Pacific (Jatrana et al. 2011). According to a subsequent study, peo­
ple who reported deferring buying medicines because of cost also had an increased 
risk of a decline in health (Jatrana et al. 2015). 
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Despite the differences in the level of out-of-pocket costs, cost-related access barri­
ers are reported in both Finland and New Zealand, and similar patterns have been 
observed across studies regarding the determinants of access barriers. Although the 
reimbursement systems in both countries are likely to promote equitable access, the 
used mechanisms seem not generous and extensive enough to entirely counterbal­
ance the negative effects of cost-sharing, as has been previously found in several stud­
ies from other countries (Jones et al. 2008; McLeod et al. 2011; Terraneo et al. 2014). 
The overall level of social security influences the ability to pay, especially for individ­
uals most dependent on income transfers. Countries vary in the emphasis they place 
on different types of social provision: services and cash transfers (e.g. pensions, sick­
ness benefits, unemployment benefits). Nordic countries, including Finland, have 
rated high for both types of provision. New Zealand, conversely, has rated relatively 
high in services but low in cash transfers. (Bambra 2005.) The differences in the level 
of cash transfers is out of the scope of this study but may provide one explanation for 
why the two countries rate relatively similarly in financial access barriers despite the 
differences in the level of cost-sharing. 
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7 Conclusions
Based on the present study, the following conclusions can be drawn: 
• The reimbursement systems in Finland and New Zealand both had strengths and 
weaknesses related to different dimensions of affordability. In New Zealand, the 
high control over the range of medicines limits the risk of moral hazard and prescri­
ber autonomy and thus low user charges apply to medicines across therapeutic 
groups. In Finland, supply side regulation is targeted to patients, who pay relatively 
high out-of-pocket costs for most treatments. Prescribers, on the other hand, have 
a wide choice over reimbursed therapeutic alternatives, although restrictions apply 
to new and expensive treatments. 
• Fewer new innovative medicines that provide health gain are registered and 
brought to market in New Zealand than in Finland. Since the countries are similar 
in market size, the differences are likely to be influenced by the lower potential 
profits made in New Zealand, due to cost-containment policies, and by the effects 
of the European Union on Finnish pharmaceutical policies, which are beneficial to 
pharmaceutical companies. 
• The level of out-of-pocket costs was higher in Finland than in New Zealand. In 
Finland, out-of-pocket costs had regressive effects. In New Zealand, most older 
people relied on the fully reimbursed range of medicines regardless of their inco­
mes and the use of expensive medicines outside the reimbursed range did not seem 
to have a socioeconomic gradient. However, high costs were less frequent among 
Māori and they seemed to coincide with lower level of medicine use. 
• Cost-related access barriers to medicines seem relatively high in Finland, when 
compared to results from previous studies from other European countries and 
New Zealand. Access barriers were associated with higher health needs and lower 
socioeconomic position in Finland. Similar patterns have been previously descri­
bed for New Zealand. It seems therefore that, although both countries use me­
chanisms to protect patients from high burden of costs, these are not sufficient to 
counterbalance the negative effects of user charges entirely. 
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  8 Implications for research and practice 
In the recent years, fiscal sustainability issues have led to increasing patients’ share 
of costs in both Finland and New Zealand, and thus increasing individuals’ financial 
responsibility. At the same time, new high cost therapies for small patient groups take 
up a growing share of the public pharmaceutical budget. There is often limited infor­
mation on the therapeutic value of new products, and the line between necessities 
and luxury products is not always easy to draw. These trends make decisions on the 
level and allocation of resources increasingly difficult. Public pressure, industry influ­
ence and political forces challenge the systems in their ability to justify public control 
over costs and utilisation. Social and political solutions are essential in promoting the 
rational use of medicines. In finding the solutions, policymakers should be aware of 
the trade-offs between individual choice and equitable access. Future research can 
contribute by making these trade-offs more visible. 
Addressing the financial barriers to prescription medicines is important in both 
Finland and New Zealand, although similar measures may not be effective in both 
countries and for all population groups. Clinicians and pharmacists could mitigate 
the negative effects of increased cost-sharing to patients by rational prescribing and 
promoting the rational use of medicines. 
In Finland, shifting the focus of cost containment policies from influencing patients 
to influencing prescribers could better serve the aims of increasing equity in access 
and promoting the rational use of medicines. By definition, rational use of medicines 
requires that appropriate medication is received at the lowest cost to patients, not 
only to their community. In New Zealand, patients and society are both likely to 
have financially benefitted from the complex arrangements between PHARMAC and 
pharmaceutical companies. However, the confidential nature of these arrangements 
have an impact on transparency. Comparable data, even on system level, on medicine 
use and costs is scarce and largely outdated. 
A number of questions remain unanswered and should be addressed in further stud­
ies. First, the processes, causes and consequences of socioeconomic and ethnic differ­
ences in medicine use require further assessment. The multiple factors that influence 
the different steps of the process of care – seeking care, accessing care, care received, 
adherence to care, and the relative impact that the different barriers in the course of 
the process have on health outcomes, need to be better understood. Second, further 
studies should focus on understanding the necessity of care to distinguish patterns 
related to underuse of necessary treatments, and on the other hand, patterns related 
to using discretionary or unnecessarily expensive treatments. 
Third, to be able to better understand and compare pharmaceutical systems across 
countries, standardised methods and outcomes are needed. Instead of focusing on 
differences in system characteristics, relative performance should be assessed. In re­
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gards fairness in financing, the distribution of out-of-pocket spending is of inter­
est. Assessing policies and utilisation patterns together, within specific therapeutic 
groups, could serve in estimating the joint effects of conditions and disincentives on 
use in different countries. Further, little is known of how well the different reimburse­
ment systems respond to patient and prescriber expectations. 
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Appendix 
Key facts and statistical indicators of society, health care and pharmaceutical sector in Finland 
and New Zealand 
Year Finland New Zealand Source of data 
General Surface area, km2 2014 338,420 267,710 World Bank, WDI 
Population, total 2014 5.5 Million 4.5 Million World Bank, WDI 
Population growth, 
annual % 
2000−2014 0.2−0.5% 0.5−1.5% World Bank, WDI 
Population density, 
people per km2 
2014 18 17 World Bank, WDI 
Urban population, % 
of total 
2014 84% 86% World Bank, WDI 
People Population, female (% 
of total) 
2000 / 2014 51% / 51% 51% / 51% World Bank, WDI 
Population, ages
0−14 (% of total) 
2000 / 2014 18% / 16% 23% / 20% World Bank, WDI 
Population, ages
15−64 (% of total) 
2000 / 2014 67% / 64% 65 % / 65% World Bank, WDI 
Population, ages 65 
and above (% of total) 
2000 / 2014 15% / 20% 12% / 14% World Bank, WDI 
Ethnic groups FI: 2006 
NZ: 2013 
Finn 93%, Swede 
6%, Russian 0.5%, 
Estonian 0.3%, 
Roma 0.1%, Sami 
0.1% 
European 71%, Maori 
14%, Asian 11%, 
Pacific peoples 8%, 
Middle Eastern, Latin 
American, African 
1%, other 2%, not
stated/unidentified 
5% (people may
belong to more than 
one ethnic group) 
CIA World 
Factbook 
Income GDP per capita, USD
PPP 
2000 / 2014 26,470 / 40,200 21,570 / 37,510 OECD Health 
Statistics 
Annual median equiv­
alised disposable 
household income, 
USD PPP (current 
prices, current PPP) 
2010 23,700 (rank
13. among OECD
countries) 
21,900 (rank 18. 
among OECD coun­
tries) 
OECD Society at
a glance 2014 
Gini coefficient of
household dispos­
able income 
2010 0.26 (rank 6. 
among OECD
countries) 
0.32 (rank 20. among 
OECD countries) 
OECD Society at
a glance 2014 
People living with less
than 50% of median 
equivalised house­
hold income (%) 
2010 7.3 (rank 6. among 
OECD countries) 
10.3 (rank 19. among 
OECD countries) 
OECD Society at
a glance 2014 
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Year Finland New Zealand Source of data 
Health Life expectancy at
birth, years, total 
(male; female) 
2000 / 2013 78 (M 74; F 81) / 
81 (M 78; F 84) 
78 (M 76; F 81) /  
81 (M 80, F 83) 
OECD Health 
Statistics 
Infant mortality, 
deaths per 1,000 live 
births 
2000 / 2011 3.8 / 2.4 (rank 4. 
among OECD in 
2011) 
6.3 / 5.2 (Rank 30. 
among OECD in 2011) 
OECD Health 
Statistics 
Maternal mortality, 
deaths per 100,000 
live births 
2000 / 2011 5.3 / 0 (rank 1. 
among OECD in 
2011) 
8.8 / 11.3 (rank 27. 
among OECD in 2011) 
OECD Health 
Statistics 
Potential years of life 
lost / 100,000 popu­
lation aged 0–69 
years old:  
  - all causes of death 
2005 / 2011 4,028 / 3,395 3,675 / 3,378 OECD Health 
Statistics
  - neoplasms 2005 / 2011 849 / 728 1,030 / 916 OECD Health 
Statistics
 - endocrine, nutri­
tional and metabolic
diseases 
2005 / 2011 87 / 70 135 / 115 OECD Health 
Statistics
  - mental and behav­
ioural diseases 
2005 / 2011 67 / 50 18 / 11 OECD Health 
Statistics
  - diseases of circula­
tory system 
2005 / 2011 719 / 599 601 / 492 OECD Health 
Statistics
  - diseases of respira­
tory system 
2005 / 2011 83 / 81 112 / 109 OECD Health 
Statistics 
Health 
care 
utilisa­
tion 
Number of doctor
consultations per
person 
2012 2.7 (rank 33. 
among the OECD) 
3.7 (rank 39. among 
the OECD) 
OECD Health at a 
glance 2015 
Inpatient care dis­
charges per 100,000 
population 
2005 / 2013 19,680 / 16,950 13,270 / 13,960 OECD Health 
Statistics 
Inpatient care aver­
age length of stay, 
days (all hospitals) 
2005 / 2013 12.7 / 10.8 9.0 / 7.9 OECD Health 
Statistics 
Waiting times, me­
dian days
  - cataract surgery 
2005 / 2013 174 / 87 57 / 75 OECD Health 
Statistics
  - hip replacement 2005 / 2013 145 / 103 42 / 98 OECD Health 
Statistics
  - coronary bypass 2005 / 2013 50 / 21 34 / 27 OECD Health 
Statistics
  - Percutaneous
transluminal coronary
angioplasty (PTCA) 
2005 / 2013 22 / 17 53 / 41 OECD Health 
Statistics 
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Year Finland New Zealand Source of data 
Financ­
ing 
Health expenditure 
per capita, USD PPP 
2013 3,442 (rank 17. 
among OECD
countries) 
3,328 (rank 18. 
among OECD coun­
tries) 
OECD Health 
Statistics 
Annual average 
growth in expenditure 
on health, in real 
terms, % 
2005−2009 / 
2009−2013 
1.7% / 1.3% 4.1% / 0.6% OECD Health 
Statistics 
Public share of total 
health expenditure, 
% of total 
2013 75% 80% OECD Health 
Statistics 2015 
Health expenditure 
by type of financing, 
% of total (General 
government / social 
security / private OOP
/ Private insurance / 
other) 
2013 61% / 14% / 19% 
/ 2% / 4% 
72% / 8% / 13% / 5% 
/ 3% 
OECD Health at a 
glance 2015 
Pharma­
ceutical 
market 
Health expenditure 
per capita on medical 
goods, USD PPP (total 
expenditure/private 
OOP) 
  - prescribed medi­
cines 
2007 365 / 133 217 / 51 OECD Health 
Statistics
  - OTC-medicines 2007  55 / 55 28 / 28 OECD Health 
Statistics 
Pharmaceutical sales
(NZ: paid reimburse­
ments only, FI: all 
pharmaceutical sales)
  - total, Million USD
PPP 
2000 / 2013 1.122 / 2.183 366 / 629 OECD Health 
Statistics
  -per capita, USD
PPP (current prices, 
current PPPs) 
2000 / 2013 217 / 401 95 / 141 OECD Health 
Statistics 
Generic share of
total pharmaceutical 
market, % 
(FI: community
pharmacy market; NZ: 
reimbursed pharma­
ceuticals) 
2008 / 2013 12% / 18% (value)  
36% / 40% (vol­
ume). 
27% / 34% (value) 
64% / 77% (volume) 
OECD Health 
Statistics 
References: World Bank 2016; CIA 2016; OECD 2014c; 2015a; 2015b. 
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Medicines are among the most common and important health 
care interventions. Most high income countries have 
implemented reimbursement systems, to ensure economic
access to necessary medicines. This study aimed to examine the 
features of pharmaceutical systems in Finland and New Zealand, 
and how they translate into affordability-related outcomes. 
The study found that the Finnish system provides a wider choice 
between reimbursed therapeutic options, and faster availability
of new innovative medicines. However, medicines were subject
to higher patient payments, which had inequitable effects. 
Within the New Zealand system, patient payments are generally
low for most health needs, but the choice between therapeutic
options is narrower and the availability of new innovative 
medicines lower. Despite the narrow range, the utilisation of
non-reimbursed medicines was rare among older people and 
did not seem to have a socioeconomic gradient. 
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